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“Life is pleasant. Death is peaceful. It’s the transition that’s troublesome.” 
Isaac Asimov, American science fiction novelist & scholar (1920 – 1992)
Death comes to us all
At the beginning of the 20th century, death was often a sudden event, with infectious dis-
eases, accidents and death in relation to childbirth as leading causes. Nowadays, sudden 
deaths are less common, especially in Western societies, where most people can anticipate 
death at an advanced age from a progressive illness which is preceded by a period of gradual 
decline1 2. Each year, 1.6 million patients in Europe will die from cancer and around 5.7 million 
from non-malignant chronic diseases3. In The Netherlands the total number of deaths in 
2016 was approximately 149.000, of which 89.000 were non-sudden deaths4 5. Half of the 
patients (53%) die at home, 19% die in hospital and 28% in a nursing home5.
Palliative care
As a chronic disease progresses, the emphasis in treatment goals shifts from prolonging 
life to preservation of quality of life3. This transition from curative care to palliative care is 
often a gradual process. The World Health Organization (WHO) defined palliative care in 
2002 as “an approach that improves the quality of life of patients and their families facing 
the problem associated with life-threatening illness, through the prevention and relief of 
suffering by means of early identification and impeccable assessment and treatment of pain 
and other problems, physical, psychosocial and spiritual”6. It has been estimated that in high 
income countries, up to 82% of people who are approaching the end of life may benefit from 
palliative care7.
Palliative care is mostly provided to patients suffering from advanced cancer, despite the 
fact that patients with a non-cancer diagnosis, like organ failure, neurological disease or 
dementia, may have the same palliative care needs as cancer patients3 8. Several studies have 
shown that early provision of palliative care can improve the quality of life of people with 
cancer or other life-threatening illnesses9-11. However, the start of palliative care is often 
delayed until the last weeks or days of life, when the disease is far advanced and disease 
focused treatments are no longer effective12. Three distinct trajectories of functional decline 
in patients with progressive chronic illness (see Figure 113) have been described by Lunney 
et al, illustrating the characteristic dynamic patterns of patients with different underlying 
diseases14. The first trajectory, typically associated with cancer, involves a reasonably pre-
dictable decline in physical health over a period of weeks, months, or, in some cases, years, 
followed by a fast deterioration in the last few weeks. The second trajectory, typically as-
sociated with organ failure, features a gradual decline with intermittent severe symptomatic 
crises. Each exacerbation may result in death, but the patient may also survive several of 
such episodes. The third trajectory, typically associated with dementia or frailty, shows a 
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progressive erratic decline from an already low baseline of cognitive or physical function-
ing13 14. Insight into these trajectories can assist healthcare professionals in estimating when 
palliative care should commence. However, with multimorbidity, which has become the 
norm at the end of life, patients may present with a combination of one or more trajectories, 
making this estimation more complex15.
symptoms
In order to deliver good palliative care it is important to know which symptoms may oc-
cur during a specific disease trajectory or disease phase and what their impact on daily 
Trajectory 2: long term limitations with
intermittent serious episodes
With conditions such as heart failure and chronic
obstructive pulmonary disease, patients ar usually ill
for many months or years with occasional acute, often
severe, exacerbations. Deteriorations are generally
associated with admission to hospital and intensive
treatment. This clinically intuitive trajectory has
sharper dips than are revealed by pooling quantitative
data concerning activities of daily living.4 Each exacer-
bation may result in death, and although the patient
timing of death, however, remains uncertain. In one
large study, most patients with advanced heart failure
died when expected to live for at least a further six
months.8 Many people with end stage heart failure and
chronic obstructive pulmonary disease follow this
trajectory, but this may not be the case for some other
organ system failures. Box 2 illustrates this trajectory.
Trajectory 3: prolonged dwindling
People who escape cancer and organ system failure are
likely to die at an older age of either brain failure (such
as Alzheimer’s or other dementia) or generalised frailty
of multiple body systems.7
This third trajectory is of progressive disability
from an already low baseline of cognitive or physical
functioning. Such patients may lose weight and
functional capacity and then succumb to minor physi-
cal events or daily social “hassles” that may in
themselves seem trivial but, occurring in combination
with declining reserves, can prove fatal.9 10 This
trajectory may be cut short by death after an acute
event such as a fractured neck of femur or pneumonia.
Box 3 illustrates this trajectory.
Clinical implications
Trajectories allow us to appreciate that “doing
everything that can be done for a possible cure” may be
misdirected.
Optimising quality of life before a timely, dignified,
and peaceful death are the primary aims of palliative
care. Understanding and considering trajectories may
help professionals take on board, at an earlier stage
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Onset could be deficits in functional
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Fig 1 Typical illness trajectories for people with progressive chronic illness. Adapted from
Lynn and Adamson, 2003.7 With permission from RAND Corporation, Santa Monica,
California, USA.
Box 1: Example of a cancer trajectory
CC, a 51 year old male shop assistant, complained of
night sweats, weight loss, and a cough. An x ray initially
suggested a diagnosis of tuberculosis, but
bronchoscopy and a computed tomography scan
revealed an inoperable, non-small cell lung cancer.
He was offered and accepted palliative chemotherapy
when he had already lost considerable weight (too
much to allow him to enter a trial). The chemotherapy
may have helped control his breathlessness, but he was
subsequently admitted owing to vomiting. Looking
back, CC (like several other patients in our study)
expressed regret that he had received chemotherapy:
“If I had known I was going to be like this . . . .”
His wife felt they had lost valuable time together when
he had been relatively well.
CC feared a lingering death:
“I’d love to be able to have a wee turn-off switch,
because the way I’ve felt, there’s some poor souls go on
for years and years like this, and they never get cured, I
wouldn’t like to do that.”
CC’s wife, in contrast, worried that her husband might
die suddenly: “When he’s sleeping, I keep waking him
up, I am so stupid. He’ll say, ‘Will you leave me alone,
I’m sleeping.’ . . . He’s not just going to go there and
then, I know, but I’ve got to reassure myself.”
CC died at home three months after diagnosis, cared
for by the primary care team, night nurses, and
specialist palliative care services. His death had been
discussed openly. He and his wife were confident that
Clin cal review
Figure 1, Typical illness trajectories for 
people with progressive chronic dis-
ease. From Murray et al., 2005
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functioning is. The New Oxford Dictionary provides the following defi nition of a symptom: 
“A physical or mental phenomenon, circumstance or change of condition arising from and 
accompanying a disorder and constituting evidence for it.” Symptom expression varies from 
patient to patient, depending on the individual patient’s perception and on other factors, 
such as psychosocial issues. While symptoms are often addressed separately, patients fre-
quently have multiple coexisting symptoms16-18. Moreover, when evaluating symptoms, it is 
important to be aware of their multidimensional nature. Evaluation of a symptom should not 
be limited to its mere presence but also includes its severity and/or impact. The mere pres-
ence of a symptom does not imply that it is distressing or that there is a need for action16.
symptoms in patients with advanced disease
The last 25 years, the number of studies focusing on symptoms in patients with advanced 
diseases has increased steadily (see fi gure 2). Symptom related aspects that are covered in 
these studies are the prevalence, burden (i.e. impact or distress) or management (i.e. symp-
tom control or interventions) of symptoms; the development, validation or translation of 
tools for screening or assessment of symptoms; a focus on specifi c symptoms or specifi c di-
agnoses; symptom aspects in relation to specifi c locations of care, care providers, (palliative) 
care teams, countries or regions of the world; and comparisons between diff erent symptom 
assessors (e.g. patients or proxies such as family members or healthcare professionals).
A number of systematic reviews on symptoms in patients with advanced diseases (i.e. 
cancer, chronic organ failure, dementia) have been published this last decade19-21. Teunissen 
et al. performed a review on symptom prevalence in patients with cancer which showed 
that during the palliative phase fatigue, pain, lack of energy, weakness and appetite loss 
were all highly prevalent symptoms, being present in more than 50% of patients20. Janssen et 
al. reviewed studies on the prevalence of symptoms in patients with advanced chronic organ 
failure and found that fatigue, dyspnoea, insomnia and pain were frequently reported in all 
patient groups19. Lastly, van der Steen showed that patients with advanced dementia are 
often reported as having pain, shortness of breath, discomfort, restlessness, and diffi  culty 
with swallowing21. There seems to be a certain degree of concordance when looking at 





* The following search string was used: symptom AND (advanced OR end-stage OR palliative OR terminal)  Figure 2 Number of published studies on sympt s in advanc dis ases b tween 1990 and 2015 in English
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Although the number of studies on symptoms in patients with advanced diseases in-
creases, evidence remains scarce or lacking for some subgroups. Of the approximately 9000 
studies published between 1990 and 2015 on symptoms in patients with advanced diseases, 
around 56% focused on symptoms in relation to cancer compared to 9% that focused on 
chronic organ failure (i.e. chronic heart failure, chronic obstructive pulmonary disease or 
chronic renal failure) and 2% that focused on dementia22. Furthermore, also in the studies in 
cancer, various cancer types were not evenly represented. Especially, patients with specific 
cancer types, as for example head and neck cancer, were barely studied. Moreover, almost 
all research has focused on patients in high-income countries19 20 23 24, whether patients in 
developing parts of the world experience the same symptoms and functional limitations 
remains unclear.
Diagnosing dying and awareness of dying
Recognition of the dying phase (i.e. the phase when death is expected to occur within hours 
or days25 26) is an important prerequisite to enable patients and their families to prepare for 
their impending death and saying goodbye27. Being aware that death is imminent is often 
seen as one of the features of a good death in modern Western culture28-31. Awareness 
that a patient’s death is imminent allows healthcare professionals to appropriately reset the 
goals of care to prevent possible harmful treatment. Diagnosing dying has been described 
as being partly ‘art’ and partly science32. On the one hand, it has been repeatedly shown 
that physicians are inaccurate in their prognoses for terminally ill patients. Mostly they 
overestimate patients’ life expectancy, although more experienced physicians have shown 
to have greater prognostic accuracy33 34. On the other hand, nurses have been described as 
perceiving signs and symptoms of dying earlier than physicians do35. This seems to be related 
to the intensity, frequency and duration of their contact with patients. Besides spending 
more time with a patient, intuition or a ‘sixth sense’ have also been suggested to be part of 
nurses’ assessment of imminent death36 37. Hence, a diagnosis of dying should preferably 
be established by physicians together with nurses, i.e. by an interdisciplinary team. It is not 
clear to what extent patients recognize their own dying.
symptoms in the dying phase
Several studies have focused on the relation between symptoms and patients’ impending 
death38-41. Rigorous scientific evidence on which signs or symptoms could indicate immi-
nence of death is still lacking. Benedetti et al. performed a Delphi study to establish expert 
consensus on clinical phenomena indicating that a person will die within the next hours or 
days42. Death rattle, no food or fluid intake and changed breathing rhythm were judged by 
these experts as having the highest relevance.
A reduced oral intake is a common phenomenon at the end of life. This may be due to 
illness- or treatment-related symptoms or complications, such as dysphagia, nausea or vom-
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iting, mechanical of functional obstruction in the digestive tract, generalized weakness, and 
in the last days of life by a decreased level of consciousness or a loss of desire to drink43 44. 
The evidence that artificial hydration may be beneficial when patients have a reduced oral 
intake at the end of life is limited and inconclusive45-47. Common arguments against artificial 
hydration are that it may increase the risk of complications such as oedema, ascites, and 
death rattle43 48 49. On the other side, artificial hydration has been suggested to reduce the 
risk of delirium or terminal restlessness47 50 51. To be able to provide good quality of care at 
the end of life it is important to know which symptoms or phenomena can occur, but also 
how symptoms or interventions interact.
Patients with an advanced disease (cancer or non-cancer) have been reported to experi-
ence many symptoms in their last week or days of life52-62. Pain (reported prevalence between 
30%-60%)20 52 56 58 60 62, shortness of breath (22%-62%)20 52 56 58 60, restlessness (42%-51%)52 62, 
dysphagia (16%-46%)20 58, confusion (30%-68%)56 57 60 62 and death rattle (39%-56%) 52 58 have 
all been reported to be common in the last week or days of life. Insight into commonly 
occurring symptoms in the dying phase enables healthcare professionals to be proactive in 
the care they provide and enables them to explain to patients and family members what 
they can expect during the dying phase.
Aim And overview of the thesis
In this thesis, we focus on the impact of symptoms in the last phase of life. The studies 
described in this thesis were aimed at providing insight into various aspects of symptoms 
and symptom relief during the last phase of life. The following research questions will be 
addressed:
Research question 1  What is the prevalence and impact of symptoms in two understudied 
patient groups: patients with incurable head and neck cancer and 
patients in a developing country with advanced heart failure?
To answer this research question data were used from two survey studies.
To explore the prevalence and impact of symptoms in patients with incurable head and 
neck cancer, a cross-sectional descriptive study was performed at Erasmus MC. This study 
consisted of two parts. First, data from questionnaires filled in by patients between October 
2006 and October 2008 as part of normal care were used to establish symptom prevalence 
for 30 symptoms, of which 9 psychosocial. Second, data were prospectively gathered from 
February 2009 up to May 2009 to establish the impact of those 30 symptoms for patients 
and potential discrepancies between the ratings from patients and their family caregivers 
(see chapter 2).
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To explore the prevalence and burden of symptoms in patients with advanced heart failure 
in a developing region of the world, a cross-sectional observational study was performed at 
Groote Schuur Hospital in Cape Town, South Africa. Patients were recruited for this study 
between August and November 2012 from several inpatient facilities (i.e., an emergency 
unit, emergency ward, cardiology ward, and general medicine wards) and the outpatient 
cardiology clinic. Patients provided information on symptom prevalence of 28 physical and 
4 psychological symptoms and the associated burden (see chapter 3).
Research question 2  What is the prevalence and impact of death rattle and terminal 
restlessness and does fluid intake influence their occurrence?
To answer this research question, first a systematic review focused on death rattle was 
performed in 2012. Several databases were searched for empirical studies on death rattle. 
We investigated which labels and definitions of death rattle were used, the prevalence of 
death rattle, the impact of death rattle on patients, relatives, and professional caregivers, 
and effects of medical and nonmedical interventions (see chapter 4).
As fluid intake is suggested to be related to the occurrence of death rattle and terminal 
restlessness, a multicentre prospective observational study was performed. Data were col-
lected in 8 hospitals (one to three wards per hospital) and five hospices, including three 
palliative care units in nursing homes (PCUs), in the Netherlands. Data collection took 
place between November 2012 and November 2013 in patients who were, according to the 
multidisciplinary care team, likely to die within a few days. Data were collected using a 
digital version of the Care Program for the Dying (CPD), which was supplemented for this 
study with questions about death rattle, terminal restlessness, use of opioids and patients’ 
fluid intake (see chapter 5). The CPD, a Dutch instrument for multidisciplinary care can 
be used to support care and symptom management during the last days of life. The CPD 
was originally based on the Liverpool Care Pathway for the dying patient63 and adapted to 
the Dutch language and healthcare system. The CPD is started when the multidisciplinary 
team agrees that the patient is likely to die within a few days. The CPD is a template for 
multidisciplinary care in the last few days to hours of life and consists of three parts in which 
different data are recorded by doctors and nurses64. The care program assesses the physical, 
psychological, social, spiritual/religious and information needs of patients and relatives at 4 
hourly intervals59 64. Between 2010 and 2012 a digital version of the CPD was developed in 
the Netherlands to comply with the need for digitalization in healthcare
Research question 3  To what extent are patients aware of the imminence of their death?
To answer this research question, we performed a secondary analysis of data that were 
collected in a study that investigated the effect of using the CPD on the care and quality of 
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life during the last 3 days of life. Patients were recruited from hospitals, nursing homes and 
home care services and data collection took place between November 2003 and February 
2006. Nurses and family caregivers were requested to fill out a questionnaire with questions 
about the last 3 days of life. Both groups were asked whether a patient had been aware of 
the imminence of death. Also, medical records were screened for statements indicating that 
the patient had been informed of the imminence of death (see chapter 6).
Research question 4  Do nurses experience moral distress in relation to the practice of 
palliative sedation?
Patients who are nearing death sometimes experience symptoms that cannot be relieved 
with conventional therapeutic interventions, such as intractable pain, dyspnoea, and 
delirium65 66. Palliative sedation is a medical intervention used to alleviate unbearable and 
refractory suffering in the last phase of life by the deliberate lowering of a patient’s level 
of consciousness to induce decreased awareness of symptoms67-69. Palliative sedation is a 
practice of last resort and is therefore often used in complicated cases, under stressful con-
ditions and with time constraints, it has been linked to (emotional) burden for nurses68 70-74. 
To answer this research question, a secondary analyses of qualitative interview data was per-
formed. Qualitative interviews with nurses were collected as part of a larger project about 
the practice of palliative sedation in the Netherlands after the introduction of a national 
guideline on palliative sedation. Nurses were interviewed between October 2008 and April 
2009. Analyses were performed with the constant comparative method. (see chapter 7).
16 Chapter 1
referencelist
 1. Lynn J, Harrell FE, Cohn F, et al. Defining the “terminally ill”: insights from SUPPORT. Duquesne Law 
Rev 1996;35(1):311-36.
 2. Boyd K, Murray SA. Recognising and managing key transitions in end of life care. BMJ 2010;341:c4863.
 3. Radbruch LP, Payne S. White Paper on standards and norms for hospice and palliative care in Europe: 
part 1. Recommendations from the European Association for Palliative Care. European Journal of Pal-
liative Care 2009;16
 4. Centraal Bureau voor de Statistiek (CBS). Nu ook bij vrouwen meeste sterfgevallen door kanker 2017 
[Available from: https://www.cbs.nl/nl-nl/nieuws/2017/52/nu-ook-bij-vrouwen-meeste-sterfgeval-
len-door-kanker.
 5. Blinderman CD, Homel P, Billings JA, et al. Symptom distress and quality of life in patients with 
advanced congestive heart failure. J Pain Symptom Manage 2008;35(6):594-603.
 6. World Health Organization. WHO Definition of Palliative Care [Available from: http://www.who.int/
cancer/palliative/definition/en/2018.
 7. Murtagh FE, Bausewein C, Verne J, et al. How many people need palliative care? A study developing 
and comparing methods for population-based estimates. Palliat Med 2014;28(1):49-58.
 8. British Medical Association. End-of-life care and physician-assisted dying, 2016.
 9. Higginson IJ, Bausewein C, Reilly CC, et al. An integrated palliative and respiratory care service for 
patients with advanced disease and refractory breathlessness: a randomised controlled trial. Lancet 
Respir Med 2014;2(12):979-87.
 10. Tassinari D, Drudi F, Monterubbianesi MC, et al. Early Palliative Care in Advanced Oncologic and Non-
Oncologic Chronic Diseases: A Systematic Review of Literature. Rev Recent Clin Trials 2016;11(1):63-71.
 11. Temel JS, Greer JA, El-Jawahri A, et al. Effects of Early Integrated Palliative Care in Patients With Lung 
and GI Cancer: A Randomized Clinical Trial. J Clin Oncol 2017;35(8):834-41.
 12. Murray SA, Kendall M, Mitchell G, et al. Palliative care from diagnosis to death. BMJ 2017;356:j878.
 13. Murray SA, Kendall M, Boyd K, et al. Illness trajectories and palliative care. BMJ 2005;330(7498):1007-11.
 14. Lunney JR, Lynn J, Foley DJ, et al. Patterns of functional decline at the end of life. JAMA 
2003;289(18):2387-92. doi: 10.1001/jama.289.18.2387
 15. Tinetti ME, Fried TR, Boyd CM. Designing health care for the most common chronic condition--
multimorbidity. JAMA 2012;307(23):2493-4.
 16. Ingham JM, Portenoy RK. Symptom assessment. Hematol Oncol Clin North Am 1996;10(1):21-39.
 17. Chang VT, Hwang SS, Feuerman M, et al. Symptom and quality of life survey of medical oncology 
patients at a veterans affairs medical center: a role for symptom assessment. Cancer 2000;88(5):1175-
83.
 18. Lidstone V, Butters E, Seed PT, et al. Symptoms and concerns amongst cancer outpatients: identify-
ing the need for specialist palliative care. Palliat Med 2003;17(7):588-95.
 19. Janssen DJ, Spruit MA, Wouters EF, et al. Daily symptom burden in end-stage chronic organ failure: a 
systematic review. Palliat Med 2008;22(8):938-48.
 20. Teunissen SC, Wesker W, Kruitwagen C, et al. Symptom prevalence in patients with incurable cancer: 
a systematic review. J Pain Symptom Manage 2007;34(1):94-104.
 21. van der Steen JT. Dying with dementia: what we know after more than a decade of research. J 
Alzheimers Dis 2010;22(1):37-55.
 22. Pubmed was searched with the following search string (symptom AND (palliative OR advanced OR 
end-stage OR terminal) AND ((“1990/01/01”[PDat] : “2014/12/31”[PDat]) AND English[lang]) Diag-
General introduction 17
nose specific we added (cancer OR neoplasms), ((heart OR organ OR kidney OR renal OR lung) AND 
failure) OR (CHF OR Copd OR CRF)) OR (Dementia).
 23. Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, 
heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manage 
2006;31(1):58-69.
 24. Kavalieratos D, Corbelli J, Zhang D, et al. Association Between Palliative Care and Patient and Care-
giver Outcomes: A Systematic Review and Meta-analysis. JAMA 2016;316(20):2104-14.
 25. Hui D, Nooruddin Z, Didwaniya N, et al. Concepts and definitions for “actively dying,” “end of life,” 
“terminally ill,” “terminal care,” and “transition of care”: a systematic review. J Pain Symptom Manage 
2014;47(1):77-89.
 26. Ellershaw J, Ward C. Care of the dying patient: the last hours or days of life. Bmj 2003;326(7379):30-4.
 27. van Esch HJ, Lokker ME, Geijteman EC, et al. Can the Dying Phase Be Masked by the Use of Dexa-
methasone? A Case Report. J Pain Palliat Care Pharmacother 2016;30(1):41-3.
 28. Clark D. Between hope and acceptance: the medicalisation of dying. BMJ (Clinical research ed 
2002;324(7342):905-7.
 29. Field D, Copp G. Communication and awareness about dying in the 1990s. Palliat Med 1999;13(6):459-
68.
 30. Goldsteen M, Houtepen R, Proot IM, et al. What is a good death? Terminally ill patients dealing with 
normative expectations around death and dying. Patient education and counseling 2006;64(1-3):378-86.
 31. Smith R. A good death. An important aim for health services and for us all. BMJ (Clinical research ed 
2000;320(7228):129-30.
 32. Kennedy C, Brooks-Young P, Brunton Gray C, et al. Diagnosing dying: an integrative literature review. 
BMJ Support Palliat Care 2014;4(3):263-70.
 33. White N, Reid F, Harris A, et al. A Systematic Review of Predictions of Survival in Palliative Care: How 
Accurate Are Clinicians and Who Are the Experts? PLoS One 2016;11(8):e0161407.
 34. Christakis NA, Lamont EB. Extent and determinants of error in doctors’ prognoses in terminally ill 
patients: prospective cohort study. BMJ 2000;320(7233):469-72.
 35. van der Werff GF, Paans W, Nieweg RM. Hospital nurses’ views of the signs and symptoms that herald 
the onset of the dying phase in oncology patients. Int J Palliat Nurs 2012;18(3):143-9.
 36. Taylor P, Dowding D, Johnson M. Clinical decision making in the recognition of dying: a qualitative 
interview study. BMC palliative care 2017;16(1):11.
 37. Price A, Zulkosky K, White K, et al. Accuracy of intuition in clinical decision-making among novice 
clinicians. J Adv Nurs 2017;73(5):1147-57.
 38. Liu Y, Zhang PY, Na J, et al. Prevalence, intensity, and prognostic significance of common symptoms 
in terminally ill cancer patients. J Palliat Med 2013;16(7):752-7.
 39. Teunissen SC, de Graeff A, de Haes HC, et al. Prognostic significance of symptoms of hospitalised 
advanced cancer patients. Eur J Cancer 2006;42(15):2510-6.
 40. Kehl KA, Kowalkowski JA. A systematic review of the prevalence of signs of impending death and 
symptoms in the last 2 weeks of life. Am J Hosp Palliat Care 2013;30(6):601-16
 41. Toscani P, Brunelli C, Miccinesi G, et al. Predicting survival in terminal cancer patients: clinical obser-
vation or quality-of-life evaluation? Palliat Med 2005;19(3):220-7.
 42. Domeisen Benedetti F, Ostgathe C, Clark J, et al. International palliative care experts’ view on phe-
nomena indicating the last hours and days of life. Support Care Cancer 2013;21(6):1509-17.
 43. Hui D, Dev R, Bruera E. The last days of life: symptom burden and impact on nutrition and hydration 
in cancer patients. Curr Opin Support Palliat Care 2015;9(4):346-54.
 44. Plonk WM, Jr., Arnold RM. Terminal care: the last weeks of life. J Palliat Med 2005;8(5):1042-54.
18 Chapter 1
 45. Good P, Richard R, Syrmis W, et al. Medically assisted hydration for adult palliative care patients. 
Cochrane Database Syst Rev 2014(4):CD006273.
 46. Nwosu AC, Mayland CR, Mason S, et al. The Association of Hydration Status with Physical Signs, 
Symptoms and Survival in Advanced Cancer-The Use of Bioelectrical Impedance Vector Analysis 
(BIVA) Technology to Evaluate Fluid Volume in Palliative Care: An Observational Study. PLoS One 
2016;11(9):e0163114.
 47. Dev R, Dalal S, Bruera E. Is there a role for parenteral nutrition or hydration at the end of life? Curr 
Opin Support Palliat Care 2012;6(3):365-70.
 48. Dalal S, Bruera E. Dehydration in cancer patients: to treat or not to treat. J Support Oncol 2004;2(6):467-
79, 83.
 49. Fritzson A, Tavelin B, Axelsson B. Association between parenteral fluids and symptoms in hospital 
end-of-life care: an observational study of 280 patients. BMJ Support Palliat Care 2015;5(2):160-8.
 50. Bruera E, Franco JJ, Maltoni M, et al. Changing pattern of agitated impaired mental status in patients 
with advanced cancer: association with cognitive monitoring, hydration, and opioid rotation. J Pain 
Symptom Manage 1995;10(4):287-91.
 51. Yamaguchi T, Morita T, Shinjo T, et al. Effect of parenteral hydration therapy based on the Japanese 
national clinical guideline on quality of life, discomfort, and symptom intensity in patients with 
advanced cancer. J Pain Symptom Manage 2012;43(6):1001-12.
 52. Lichter I, Hunt E. The last 48 hours of life. J Palliat Care 1990;6(4):7-15.
 53. Ventafridda V, Ripamonti C, De Conno F, et al. Symptom prevalence and control during cancer 
patients’ last days of life. J Palliat Care 1990;6(3):7-11.
 54. Lokker ME, van Zuylen L, Veerbeek L, et al. Awareness of dying: it needs words. Support Care Cancer 
2012;20(6):1227-33.
 55. Brandt HE, Ooms ME, Deliens L, et al. The last two days of life of nursing home patients--a nationwide 
study on causes of death and burdensome symptoms in The Netherlands. Palliat Med 2006;20(5):533-
40.
 56. Pinzon LC, Claus M, Zepf KI, et al. Symptom prevalence in the last days of life in Germany: the role of 
place of death. Am J Hosp Palliat Care 2012;29(6):431-7.
 57. Conill C, Verger E, Henriquez I, et al. Symptom prevalence in the last week of life. J Pain Symptom 
Manage 1997;14(6):328-31.
 58. Hall P, Schroder C, Weaver L. The last 48 hours of life in long-term care: a focused chart audit. Journal 
of the American Geriatrics Society 2002;50(3):501-6.
 59. Ellershaw J, Smith C, Overill S, et al. Care of the dying: setting standards for symptom control in the 
last 48 hours of life. J Pain Symptom Manage 2001;21(1):12-7.
 60. Klinkenberg M, Willems DL, van der Wal G, et al. Symptom burden in the last week of life. J Pain 
Symptom Manage 2004;27(1):5-13.
 61. Twycross R, Lichter, I. The terminal phase. In: D. Doyle H, G., Cherny, N.I., Calman, K., ed. Oxford 
Textbook of Palliative Medicine. Oxford: Oxford University Press 2004:977-94.
 62. Goodlin SJ, Winzelberg GS, Teno JM, et al. Death in the hospital. Arch Intern Med 1998;158(14):1570-2.
 63. Ellershaw JE, Foster A, Murphy D, et al. Developing an integrated care pathway for the dying patient. 
Eur J Palliat Care 1997;4:203-07.
 64. Ellershaw J, Wilkinson S. Care of the dying - A pathway to excellence. Oxford: Oxford University Press 
2003.
 65. Cherny NI, Portenoy RK. Sedation in the management of refractory symptoms: guidelines for evalu-
ation and treatment. J Palliat Care 1994;10(2):31-8.
General introduction 19
 66. Quill TE, Byock IR. Responding to intractable terminal suffering: the role of terminal sedation and 
voluntary refusal of food and fluids. ACP-ASIM End-of-Life Care Consensus Panel. American College 
of Physicians-American Society of Internal Medicine. Ann Intern Med 2000;132(5):408-14.
 67. Cherny N. The use of sedation to relieve cancer patients’ suffering at the end of life: addressing 
critical issues. Ann Oncol 2009;20(7):1153-5.
 68. de Graeff A, Dean M. Palliative sedation therapy in the last weeks of life: a literature review and 
recommendations for standards. J Palliat Med 2007;10(1):67-85.
 69. KNMG. KNMG-richtlijn palliatieve sedatie 2009 [http://www.knmg.nl/Publicaties/KNMGpublicatie-
levenseinde/61575/KNMGrichtlijn-palliatieve-sedatie-2009.htm]. 2009 [cited 2015 December].
 70. Anquinet L, Rietjens JA, Mathers N, et al. Descriptions by general practitioners and nurses of their 
collaboration in continuous sedation until death at home: in-depth qualitative interviews in three 
European countries. J Pain Symptom Manage 2015;49(1):98-109.
 71. Morita T, Miyashita M, Kimura R, et al. Emotional burden of nurses in palliative sedation therapy. 
Palliat Med 2004;18(6):550-7.
 72. Hasselaar JG, Verhagen SC, Vissers KC. When cancer symptoms cannot be controlled: the role of 
palliative sedation. Curr Opin Support Palliat Care 2009;3(1):14-23.
 73. Swart SJ, van der Heide A, van Zuylen L, et al. Continuous palliative sedation: not only a response to 
physical suffering. J Palliat Med 2014;17(1):27-36.




symptoms of patients with incurable 
head and neck cancer: prevalence and 
impact on daily functioning
M.E. Lokker*, M.P. Off erman*, L.A. van der Velden, M.F. de Boer, J.F.A. Pruyn, 
S.C.C.M. Teunissen




Background. There is lack of research on symptoms in patients with head and neck cancer 
in the palliative phase. The aim of this study was to explore symptom prevalence and the 
impact of these symptoms on daily functioning in patients with incurable head and neck 
cancer. Also, discrepancies between patients and family caregivers are described.
Methods. Questionnaires were used to collect data about symptom prevalence (N=124) and 
symptom impact (N=24).
results. We discovered that the symptoms with a high prevalence were fatigue, pain, weak-
ness, trouble with short walks outside, and dysphagia. The symptoms with the greatest 
impact on daily functioning were dyspnoea, voice changes, trouble with short walks outside, 
anger and weakness.
conclusions. Patients with incurable head and neck cancer experience a great number of 
different symptoms. Focus on these symptoms by healthcare professionals could further 
optimize symptom management. In future research, we recommend further validation of 
the used questionnaires.
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introduction
Head and neck cancer is known as a psychological highly traumatic cancer type1. This is due 
to potential negative effects of the tumour itself and its treatment on various functions, 
such as swallowing, speaking, tasting, and smelling, as well as on the appearance of a pa-
tient. Head and neck cancer is the fifth most common cancer type worldwide and the most 
common neoplasm in central Asia2. In the United States, head and neck cancer accounts 
for 3% of malignancies; in The Netherlands, it accounts for nearly 5%3 4. The average age of 
patients affected with head and neck cancer is 63 years. More than two thirds of this patient 
group is men4. Significant risk factors for the occurrence of head and neck cancer are the 
use of tobacco and alcohol5.
Approximately 25 to 30% of patients with head and neck cancer will at a certain moment 
reach the palliative phase3 6. Knowledge about experiences in the palliative phase of head 
and neck cancer is limited7. The palliative phase begins when cure is no longer possible 
or when curative treatment is refused and ends with the patient dying8. Earlier research 
among palliative patients with head and neck cancer showed a mean duration for the pal-
liative phase of approximately 6 months7. During this phase, the number and intensity of 
symptoms can influence the quality of life of a patient negatively. Palliative care aims to 
improve the quality of life of patients and their family caregivers by adequately dealing with 
occurring symptoms, known as “symptom management”9. In this research, symptoms are 
defined as all complaints expressed by a patient as a result of a progressing disease or the 
consequences of the treatment for that disease. Patients with cancer in the palliative phase 
are frequently confronted with multiple and simultaneously occurring symptoms10-15. A sys-
tematic review of the literature (2007)16 about symptom prevalence in patients with cancer 
in general during the palliative phase, revealed 5 somatic symptoms occurring in more than 
50% of patients during the palliative phase. These somatic symptoms were: fatigue, pain, 
lack of energy, weakness and appetite loss. However, this research only included a very small 
group of patients (5%) suffering from a head and neck tumour Therefore, the possibility to 
generalize the results from this review to the entire population of patients with head and 
neck cancer patients is limited.
In another article (1997) 13 on symptom prevalence, patients with head and neck cancer 
were included, however, this research focused on somatic symptoms only in the terminal 
phase. The 5 most frequently reported symptoms were: weight loss, pain, feeding dif-
ficulties, dysphagia and cough. Symptoms in the very last part of the palliative phase (the 
terminal phase), however, are not fully representative for the entire palliative phase. This is 
confirmed by a review of patients with cancer in general16, showing a difference between 
the prevalence of symptoms occurring in the last 2 weeks of living and symptoms that occur 
during the period prior to those weeks Research among patient with head and neck cancer 
in general also indicates that, besides somatic issues, more than one third of patients are 
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also confronted with psychological problems17. In a recent study of surviving relatives of 
patients with head and neck cancer, two thirds of the relatives claimed that the patient was 
depressed and had a need for better psychosocial support during the palliative phase6. When 
it comes to symptom report, earlier research suggests that family caregivers in comparison 
with patients often over-estimate patient symptoms18-21. These studies, however, did not 
include patients with head and neck cancer.
In order to deliver good healthcare, it is important to know which symptoms occur during 
a specific disease or disease phase, as well as the extent of their impact on daily function-
ing. In this article, “symptom impact” refers to: “the impact that symptoms have on daily 
functioning of an individual patient.” The premise is that such an impact is either neutral or 
negative.
The current study focused on: (1) the prevalence of symptoms in patients with head and 
neck cancer during the palliative phase; (2) the impact of those symptoms on daily function-
ing of patients; and (3) discrepancies between patients and family caregivers with reference 
to how they individually score the occurrence of symptoms as well as their evaluation of the 
impact on daily functioning.
mAteriAls And methods
Design
This cross-sectional descriptive study consists of a retrospective and a prospective element. 
The first research question was answered by making use of retrospectively collected data. 
The other 2 questions were answered by examining prospective data. This study was ap-
proved by the Medical Ethics Committee of the Erasmus Medical Centre Rotterdam.
setting
At the Erasmus Medical Centre Rotterdam, a university medical centre in The Netherlands 
treating around 600 patients newly diagnosed with head and neck cancer every year, pallia-
tive care is given by a specialist palliative team for patients with head and neck cancer. This 
team consists of head and neck surgeons, specialized nurses, speech therapists, pain special-
ists, dietitians, social workers, and clergymen. Each year, approximately 130 new patients 
are registered by the palliative team. Since October 2006, as part of the standard working 
procedure, data is structurally gathered from patients with an head and neck tumour in the 
palliative phase. Since that date, all new patients are being requested by the specialized 
nurses to fill out a questionnaire, the Palliative Checklist (Pal-C), once during their palliative 
phase. In most cases, this happens shortly after receiving the diagnosis of their palliative 
status.
Follow-up of patients by the palliative team is done regularly, both in the outpatient clinic 
as well as by telephone. During about half of these medical telephone contacts, the family 
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caregiver speaks on the patient’s behalf. This occurs because of issues such as difficulties 
with speech, pain and physical weakness of the patient.
Participants and procedure
Patients with a primary head and neck tumour in the palliative phase treated in the Erasmus 
Medical Centre Rotterdam were included. Patients who were younger than 18 years, unable 
to speak or write in Dutch, mentally incompetent or participating in another study at the 
same time were excluded. Participants were divided into 2 groups: the prevalence group and 
the symptom impact group.
The prevalence group
This group consists of all patients who completed a Pal-C (instrument described in detail 
below) between October 2006 and October 2008.
The symptom impact group
For this prospective part of our study, patient’s main family caregivers were also included. 
Because of the limited number of available patients and the limited average life expectancy, 
a convenience sample was chosen. From February 2009 up to May 2009, patients were 
approached by the specialized nurses of the palliative team. After they had given written 
informed consent, participants were requested to separately fill out a questionnaire which is 
called the Palliative Symptom Impact list (Pal-SI), as mentioned below.
Data collection
The prevalence group
Sociodemographic data was gathered from the electronic patient file. Prevalence of symp-
toms was measured using the Pal-C. This questionnaire provides insight into the prevalence 
of 30 separate symptoms. The Pal-C was developed in 2006 by the Expert Centre of Palliative 
Care for Head and Neck Cancer of the department of Otorhinolaryngology and Head and 
Neck surgery of the Erasmus Medical Centre in Rotterdam. The instrument consists of 53 
questions, of which the first 15 questions are from the European Organisation for Research 
and Treatment of Cancer Quality of Life Questionnaire-Core 15- Palliative (EORTC QLQ-
C15-PAL)22 23. The remaining 38 questions of the Pal-C are based on the Integral Checklist24. 
The Integral Checklist is a questionnaire that was developed as an instrument for systematic 
screening of psychosocial and physical problems in ambulatory patients with cancer. The 
Pal-C is meant to obtain an impression of the situation as experienced by the patient during 
the past week. The Integral Checklist has been used previously in a study with patients with 
cancer in all phases of disease, including patients with head and neck cancer 24. Completion 
of the questionnaire requires approximately 20 minutes The Pal-C, in its current form, has 
not been tested on validity and/or reliability. However, the Pal-C was primarily used to 
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support the gathering of information about the patient’s health in a nonburdensome way 
and turned out to be a very practical instrument for that purpose and for referral to other 
specialists.
The symptom impact group
Sociodemographic data of patients was gathered from the electronic patient file. Caregivers 
sociodemographic data; sex, relationship to the patient, and age, were gathered by making 
use of questionnaires. Impact of symptoms was measured using the Pal-SI. This instrument 
was developed, for this study, by the Expert Centre of Palliative Care for Head and Neck 
Cancer of the department of Otorhinolaryngology and Head and Neck surgery of the 
Erasmus Medical Centre in Rotterdam. To enable comparison of data, the Pal-SI covers the 
same symptoms and uses equal formulation as in the Pal-C. The Pal-SI consists of 2 parts. 
Part A contains the 30 symptoms from the Pal-C. By answering “yes” or “no”, the patient can 
indicate whether or not the specific symptom occurred in the previous week. In part B, the 
patient is asked to rate all symptoms present on an 11 point numeric scale (NMS), indicating 
the impact of a specific symptom on daily functioning. (0= “no impact”, 10= “unbearable 
impact”).
Specifically for family caregiver’s, a family caregiver’s version of the Pal-SI was available. 
This version differs from the original Pal-SI on 2 aspects: (1) to prevent missing values, the 
answer option “do not know” was added; and (2) all questions were formulated from the 
perspective of the family caregiver (i.e. instead of asking: “Have you had pain?”, the fam-
ily caregiver’s version states “Do you think the patient had pain?”. It took approximately 15 
minutes to complete the Pal-SI.
statistical analysis
The sociodemographic data, the prevalence of symptoms, and the impact of those symp-
toms were described by way of descriptive statistics. The sociodemographic data of patients 
from the prevalence group were statistically tested using the independent samples t test 
(age), chi-square test (sex, tumour location, and treatment) and the Mann-Whitney test 
(duration of palliative phase).
The sociodemographic data with reference to the patients from the symptom impact 
group were statistically tested using the Mann-Whitney test. In order to compare the preva-
lence and the symptom impact data of the patients and their family caregivers per pair, the 
Wilcoxon matched pairs test was performed.
Nonparametric tests were used when data was not normally distributed. With reference 
to the symptom impact group, this was the result of the limited number of cases. The 
significance level was set at 5%. For the analysis of the data, the statistics program SPSS 
version 14.0 was used.
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results
Description of “prevalence group”
Between October 2006 and October 2008, 310 new patients were registered with the spe-
cialized nurses for palliative care. After exclusion, 220 patients were approached, of which 
124 (56%) completed the Pal-C. Two percent of questions were not filled in. The reasons for 
exclusion and nonresponse are indicated in Figure 1.
Refer to Table 1 for sociodemographic data. Patients who completed a Pal-C (Pal-C+) 
were significantly different from those who did not complete a Pal-C (Pal-CΘ) on 3 aspects. 
The Pal-C+ group (1) consisted of more men; (2) were subjected to more extensive palliative 
treatment; (3) their duration of the palliative phase was longer, with a median discrepancy 
of more than 100 days.
Description of “symptom impact group”
Between February 2009 and May 2009, 116 new patients were registered with the special-
ized nurses. Of the total of 56 patients who met all the inclusion criteria, 24 patients (43%) 
Figure 1. Prevalence Group
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and 24 family caregivers completed a Pal-SI. For 3% of the questions, no answer was given. 
The reasons for exclusion and nonresponse are indicated in Figure 2.
Refer to Table 2 for sociodemographic data. Patients from the Pal-SI+ group were not 
significantly different from the patients of the Pal-SIΘ group. Family caregivers were, on 
average, 60 years old (32-77 years). Their relation to the patient was that of the husband/
wife (17), daughter/son (5), friend (1) and brother (1).
table 1. Socio-demographic data Prevalence Group
Characteristic
% (no. of patients) by group*
P value
Pal-C+ group (n=124) Pal-CΘ group (n=137)
Age, average (interval) 68 (39-90 y) 66 (28-98 y) .203
Sex
Male 73 (91) 61 (83) .019
Female 27 (33) 39 (54)
Location of Tumour
Oral cavity 24 (30) 20 (28) .724
Oropharynx 26 (32) 30 (41)
Larynx 11 (14) 13 (18)
Hypopharynx 13 (16) 14 (19)
Nasopharynx 2 (3) 2 (3)
Nasal fossa 11 (14) 6 (8)








No treatment 8 (10) 50 (62) 17 (23) 70 (96) .067 .017
Surgery 2 (3) 2 (2) 3 (4) 0 (0)
Radiotherapy (RT) 32 (39) 35 (43) 19 (26) 22 (30)
Chemotherapy (CT) 0 (0) 7 (8) 0 (0) 6 (8)
Surgery + RT 35 (43) 2 (2) 33 (45) 0 (0)
Surgery + CT 1 (1) 0 (0) 0 (0) 1 (1)
Surgery + RT + CT 7 (9) 1 (1) 15 (21) 0 (0)
CT + RT 15 (19) 5 (6) 13 (18) 2 (2)
Time interval between start 
of pall phase and Pal-C 
median (interval)
61 days (0-1682) X
Duration palliative phase 169 days (9-2621) ‡ 62 days (1-652)§ .000
Abbreviation: Pal-C, Palliative Checklist; CT, chemotherapy; RT, radiotherapy.
* Except as otherwise stated.
† Tumours of the skin, salivary glands, ear, and trachea.
‡ Based on 109 patients.
§ Based on 128 patients.
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Prevalence of symptoms in “prevalence group”
All results obtained from the Pal-C are described in Table 3. Patients reported an average 
of 14 different symptoms (interval 0-26), of which there were 10 somatic symptoms and 4 
psychosocial symptoms. Fatigue had the highest prevalence (81%), followed by pain (75%), 
weakness (75%), trouble with short walks outside (65%) and dysphagia (59%). Frequently 
reported psychosocial symptoms were worrying (61%), sadness (57%), tenseness (52%), 
depressed mood (52%) and powerlessness (50%).
Prevalence of symptoms in “symptom impact group”
All results obtained from the Pal-SI are described in Table 4. The patient and his/her family 
caregiver differed significantly from one another for the occurrence of 4 symptoms: dif-
ficulty sleeping (patient 29% vs caregiver 13%; p= .046), dyspnoea (21% vs 42%; p= .025), 
powerlessness (75% vs 46%; p= .046) and anxiety (29% vs 50%; p= .034).
Figure 2. Symptom Impact Group
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impact on daily functioning from “symptom impact group”
According to the patients, dyspnoea, voice changes, trouble with short walks outside, anger, 
and weakness, all had, in decreasing order, a large impact on daily functioning. The score for 
the symptom impact on daily functioning of the patient differed significantly between the 
patients and their family caregivers on 5 symptoms: trouble with short walks outside (patient 
NMS 5,5 vs caregiver NMS 6,7 p= .047), difficulty sleeping (4,7 vs 5,3; p= .042), powerlessness 
(4,4 vs 3,8; p= .031), trouble expressing oneself (3,3 vs 4,9; p= .014) and anxiety (5,1 vs 4,5; p= 
.015).
table 2. Socio-demographic data Symptom Impact Group
Characteristic
% (no. of patients) by group
P value
Pal-SI + group (n=24) Pal-SIΘ group (n=42)
Age, average (interval) 66 (29-90 y) 67 (38-98 y) .957
Sex
Male 50 (12) 64 (27) .260
Female 50 (12) 36 (15)
Tumour location
Oral cavity 33 (8) 21 (9) .823
Oropharynx 17 (4) 19 (8)
Larynx 8 (2) 14 (6)
Hypopharynx 4 (1) 12 (5)
Nasopharynx 0 (0) 5 (2)
Nasal fossa 17 (4) 12 (5)








No treatment 4 (1) 38 (9) 10 (4) 45 (19) .797 .615
Surgery 4 (1) 4 (1) 2 (1) 2 (1)
Radiotherapy (RT) 21 (5) 42 (10) 21 (9) 38 (16)
Chemotherapy (CT) 0 (0) 13 (3) 0 (0) 10 (4)
Surgery + RT 42 (10) 0 (0) 41 (17) 0 (0)
Surgery + CT 0 (0) 0 (0) 2 (1) 0 (0)
Surgery + RT + CT 17 (4) 4 (1) 12 (5) 0 (0)
CT + RT 13 (3) 0 (0) 12 (5) 5 (2)
Time interval between start 
of pall phase and Pal-SI, 
average (interval)
270 days (17-1024) ) X
Abbreviation: Pal-SI, Palliative Symptom impact list; CT, chemotherapy; RT, radiotherapy.
* Tumours of the skin, salivary glands, ear, and trachea
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discussion
In the first part of this research, we explored symptom prevalence in 124 patients with 
incurable head and neck cancer. Within this sample, “fatigue” was the somatic symptom 
most prevalent (81%), followed by pain (75%), weakness (75%), trouble with short walks 
outside (65%) and dysphagia (59%). To our knowledge, no comparative figures are known for 
symptom prevalence in patients with incurable head and neck cancer. Prior studies among 
head and neck cancer survivors, a few years after their curative treatment, indicate diverging 
percentages for the prevalence of fatigue (33 to 48%)25 26, pain (10 to 43%)25-28, and dysphagia 
(17 to 76%)25-28. For the prevalence of weakness and trouble with short walks outside, no 
comparative figures were found. We hypothesize that symptoms experienced by patients in 
the palliative phase are not consistent with those experienced by cancer survivors because of 
the difference of disease phase, location/ presence of the tumour, and tumour treatments.
The 4 most prevalent symptoms experienced by patients with head and neck cancer in 
the palliative phase are consistent with the results of a systematic review in 25,074 patients 
with cancer in general, during the palliative phase.16. Despite a probable difference in aetiol-









(no./total no. of 
patients)
Fatigue 81 (101/124) Dyspnoea 41 (51/123)
Pain 75 (93/123) Coughing after eating/
drinking
38 (47/122)
Weakness 75 (93/123) Need for help with 
everyday functioning
30 (37/123)
Trouble with short walks 
outside
65 (81/123) Nausea 29 (36/121)
Dysphagia 59 (73/123) Wound in neck or face 22 (27/124)
Difficulty speaking 57 (71/123) Unpleasant smell/ 
stench
19 (24/123)
Difficulty sleeping 56 (70/124) Worrying* 61 (75/118)
Head and Neck oedema 56 (69/122) Sadness* 57 (71/118)
Daily activities restricted 
as result of pain
53 (66/121) Depressed mood* 52 (65/123)
Weight loss 53 (66/124) Tenseness* 52 (65/122)
Voice changes 52 (64/123) Powerlessness* 50 (62/117)
Constipation 48 (60/123) Anger* 39 (48/116)
Shortness of breath 48 (59/123) Anxiety* 32 (39/117)
Need to stay in bed/
chair during day
48 (59/123) Trouble expressing 
oneself*
24 (30/118)
Appetite loss 53 (66/119) Feelings of shame* 12 (15/118)
Abbreviation: Pal-C, Palliative Checklist. * Psychosocial symptoms.
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table 4. Results Symptom Impact Group n=24 from the Pal-SI
Symptoms
Prevalence,
% (n) P value
Symptom impact, 
average (interval) P value
Patients Close relatives Patients Close relatives
somatic
Trouble with short walks 
outside
25 (6/24) 38 (9/24) .083 5,5 (2-9) 6,7 (3-9) .047
Need to stay in bed/chair 
during day
21 (5/24) 25 (6/24) .317 3,8 (1-6) 4,8 (1-8) .102
Need for help with everyday 
functioning
13 (3/24) 13 (3/24) 1.00 4,0 (3-5) 5,0 (5) .180
Shortness of breath 38 (9/24) 33 (8/24) .705 3,4 (1-7) 4,5 (2-8) .561
Pain 54 (13/24) 58 (14/23) .317 4,9 (2-10) 5,5 (1-10) .109
Difficulty sleeping 29 (7/24) 13 (3/24) .046 4,7 (1-10) 5,3 (2-10) .042
Weakness 42 (10/23) 50 (12/22) .705 5,2 (1-1-0) 4,6 (1-10) .476
Appetite loss 21 (5/23) 13 (3/23) .059 5,0 (1-8) 6,0 (2-8) .414
Nausea 25 (6/24) 17 (4/22) .317 3,4 (1-5) 2,0 (1-3) .223
Constipation 21 (5/24) 25 (6/22) .564 4,8 (2-10) 4,8 (2-10) .102
Fatigue 92 (22/24) 79 (19/23) .317 4,5 (1-10) 4,8 (1-10) .796
Daily activities restricted as 
result of pain
33 (8/24) 25 (6/23) .317 5,0 (1-10) 4,5 (2-6) .313
Head and Neck oedema 25 (6/23) 29 (7/22) .655 4,3 (1-7) 4,9 (1-10) .465
Wound in neck or face 13 (3/24) 17 (4/23) .564 5,0 (5) 5,3 (3-9) .102
Unpleasant smell/ stench 4 (1/24) 17 (4/24) .083 5,0 (5) 4,3 (2-6) .068
Dyspnoea 21 (5/24) 42 (10/24) .025 7,0 (3-10) 4,6 (1-8) .234
Difficulty speaking 54 (13/24) 54 (13/24) 1.00 4,9 (2-10) 4,7 (1-9) .648
Dysphagia 54 (13/23) 42 (10/22) .405 5,0 (1-10) 6,2 (3-10) .813
Coughing after eating/drinking 33 (8/23) 42 (10/24) .666 4,1 (1-7) 5,0 (1-10) .055
Voice changes 38 (9/24) 50 (12/24) .257 5,9 (1-10) 4,8 (1-10) .698
Weight loss 25 (6/24) 29 (7/23) .317 3,8 (1-8) 4,9 (1-8) .131
Psychosocial
Tenseness * 38 (9/24) 33 (8/23) 1.00 3,9 (1-10) 4,1 (2-6) .858
Depressed mood * 46 (11/24) 38 (9/21) .317 3,9 (2-7) 3,1 (2-5) .088
Powerlessness * 75 (18/24) 46 (11/21) .046 4,4 (1-10) 3,8 (2-7) .031
Worrying * 63 (15/24) 63 (15/21) .083 4,4 (1-8) 4,4 (1-8) .368
Trouble expressing oneself* 25 (6/24) 42 (10/23) .157 3,3 (2-7) 4,9 (2-8) .014
Feelings of shame* 13 (3/24) 4 (1/24) .317 2,3 (1-5) 2,0 (2) .461
Anxiety * 29 (7/24) 50 (12/21) .034 5,1 (2-8) 4,5 (2-8) .015
Anger * 29 (7/24) 42 (10/23) .180 5,3 (3-7) 4,2 (1-8) .609
Sadness 71 (17/24) 54 (13/24) .102 4,6 (1-9) 6,0 (2-9) .338
Abbreviations: Pal-SI, Palliative Symptom impact list.
* Psychosocial symptoms.
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ogy of various symptoms as a result of different primary diagnoses, it seems that the most 
prevalent symptoms during the palliative phase are independent of the primary diagnosis.
In this study, a distinction was made between somatic and psychosocial symptoms. De-
spite the assumption that psychosocial symptoms occur less frequently in palliative patients 
with cancer in general17, it has been shown that these symptoms play an important role in 
the assessment of quality of life in patients with head and neck cancer29-33. The 5 most fre-
quently reported psychosocial symptoms in our study were: worrying (61%), sadness (57%), 
tenseness (52%), depressed mood (52%) and powerlessness (50%). The prevalence figures for 
psychosocial symptoms found in our study are higher for the symptoms: worrying, sadness, 
tenseness, and anxiety compared to the findings of 2 other studies. The article by van den 
Beuken et al.34 studied a subpopulation of 25 patients with incurable head and neck cancer 
during their treatment and found a prevalence of 25% for worrying, 17% for tenseness, and 
8% for anxiety. In the overall incurable oncological population, Teunissen et al.16 found a 
prevalence of 36% for worrying, 39% for sadness, and 30% for anxiety. These discrepancies 
between our findings compared with other studies could be explained by the use of different 
terminology, measuring instruments and sample selection. For example, van den Beuken 
(2009) included patients who were all still receiving some form of (palliative) treatment 
aimed at symptom control, such as surgery, radiotherapy, or chemotherapy during the pal-
liative phase of their illness. Whereas we studied a group of patients of which only a small 
portion was receiving such treatment and the larger portion was not. Receiving treatment, 
even if this treatment is of a palliative nature, can place patients more in a fighting mode 
and less open to feelings and negative emotions such as worrying. Teunissen et al.16 used a 
brought population of patients in the palliative phase, which could also lower the prevalence 
of these results because we know that patients with head and neck cancer psychologically 
suffer more1 and have been associated with higher levels of depression and anxiety.
The least occurring psychosocial symptom (12%) was “feelings of shame”. We find this 
remarkable because head and neck cancer and its treatment can lead to mutilations and 
disfigurement, and therefore one would expect a higher prevalence for this specific symp-
tom. It could be possible that patients already coped with these consequences when they 
occurred earlier on during the curative phase. Another reason for the low prevalence of 
feelings of shame may be related to the specific characteristics of the majority of patients 
with head and neck cancer; men over 60 years of age, generally with a lower socioeconomic 
background. Especially sex and age might influence the importance of appearance. Our find-
ings are consistent with a study of patients after a laryngectomy, in which 14% of patients 
reported experiencing feelings of shame35.
In the second part of this research we explored the impact of symptoms on daily func-
tioning of patients with incurable head and neck cancer. We also looked at discrepancies 
between patients and their family caregivers with respect to how they score symptom 
occurrence and symptom impact on daily functioning. The symptoms dyspnoea, voice 
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changes, trouble with short walks outside, anger, and weakness, all have, according to the 
patients in the symptom impact group, a significant impact on daily functioning.
Furthermore, we found that family caregivers of patients with head and neck cancer dur-
ing the palliative phase frequently overestimate the occurrence of somatic symptoms as well 
as the impact from those symptoms on daily functioning of patients. In two thirds of cases, 
although not always significant, the prevalence and the symptom impact score for somatic 
symptoms were systematically estimated higher by the family caregivers compared to pa-
tients. However, when it comes to psychosocial symptoms, we see a reverse trend. Both 
symptom prevalence as well as symptom impact are underestimated by family caregivers. 
Approximately 50% of the symptom prevalence and the symptom impact score are indicated 
higher by the patients compared with family caregivers. These findings are not consistent 
with studies in patients receiving oncology treatment during the palliative phase, in which 
family caregivers more frequently overestimated psychosocial symptoms compared to 
somatic symptoms 19-21. Research indicates that the degree of consistency between patients 
and their caregivers depends on the health condition of the patient in question. Just a 
slight consistency can be found when the health of the patient is very good or very bad36. A 
potential explanation for the discrepancy between patients and family caregivers could be 
underreporting of symptoms by patients. Patients do not wish to worry their caregivers and 
hence are very careful when communicating about their symptoms and/or the intensity of 
those symptoms18 20 21 37. Whether or not the discrepancy between patients and their family 
caregivers in our study can be explained by this is unclear and requires further investigation. 
It is remarkable that family caregivers indicated that dyspnoea was present, twice as often 
as the patients did. In case of a head and neck tumour, dyspnoea is a potentially realistic 
threat. It is likely that fear of suffocation makes the family caregivers more aware of possible 
signs of dyspnoea. In addition, a lot of patients with head and neck cancer trivialize their 
dyspnoea because the progression happens gradually. Our result is consistent with prior 
research among patients with lung cancer during the palliative phase18.
Limitations
The cross-sectional method of current study is inapt to obtain a definite conclusion about 
the entire palliative phase. Practical achievability of a longitudinal approach within a pal-
liative population, however, is limited, and hence very difficult to realize38 39. Despite the 
fact that the Pal-C and the Pal-SI are well used and practical instruments for gathering 
information in the least possible intrusive way, the lack of validation is a limitation. Another 
limitation was the 44% nonresponse within the prevalence group. Nonresponding patients 
had a significant shorter life expectancy and seemed to have a much worse condition than 
responding patients. Generalization of the results from the prevalence group should there-
fore be done carefully. The large number of nonresponse (more specifically, patients that 
dropped out because of their weak condition) within this group, however, also confirms 
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how vulnerable this specific cancer population group is. Finally, the option to work with an 
occasional random sample for investigating the symptom impact group means that patients 
were selected. The number of patients and caregivers is too limited to generalize results to 
the entire population. However, the gained insight has resulted in a number of discrepancies 
between patients with head and neck cancer and their caregivers, and patients suffering 
from other malignant dysfunctions.
conclusion
implications for clinical practice
This is the first study investigating the prevalence of symptoms in patients with head and 
neck cancer and their impact on daily functioning during the palliative phase reported by 
patients themselves and their family caregivers. These patients experience a large number 
of different symptoms. We found that most frequently reported somatic symptoms were: 
fatigue, pain, weakness, trouble with short walks outside, and dysphagia, which is consistent 
with research involving a wide palliative cancer population. In the psychosocial area, these 
are worrying, sadness, tenseness, depressed mood, and powerlessness. For these symptoms, 
there are no comparative prevalence figures yet available. The symptom with the greatest 
impact on daily functioning, according to patients, is dyspnoea. According to the caregivers, 
this is the symptom “trouble with short walks outside”. For a number of symptoms, the 
mutual discrepancies between patients and their caregivers are significant.
These results were limited due to several aspects such as a relatively low accrual rate, 
mainly because of the condition of patients and the use of a non-validated questionnaire. 
Future research should, therefore, be focused on replication of our results with further 
validation of the used questionnaire. We do, however, believe that the results give valuable 
insight into symptoms experienced by patients with head and neck cancer in the pallia-
tive phase and their impact on daily functioning of those patients, a subject that is clearly 
underexposed in research.
Furthermore, we suggest that care for patients with head and neck cancer in the palliative 
phase should include targeted screening. This screening should focus on highly prevalent 
symptoms as fatigue and psychosocial symptoms which, because they are less visible, may 
now receive less attention. We also suggest that in the relationship between healthcare 
workers and patients and their caregivers, attention should be paid to the discrepancies 
between patients and caregivers found in this study. By making this difference in perception 
open for discussion, patients and caregivers can become more aware of this within their 
relationship. Insight regarding possible discrepancies may contribute to better and targeted 
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AbstrAct
Background. Despite the high prevalence of heart failure in low- and middle-income coun-
tries, evidence concerning patient-reported burden of disease in advanced heart failure is 
lacking.
objective. The aim of this study is to measure patient-reported symptom prevalence and 
correlates of symptom burden in patients with advanced heart failure.
Methods. Adult patients diagnosed with New York Heart Association (NYHA) stage III 
or IV heart failure were recruited from the emergency unit, emergency ward, cardiology 
ward, general medicine wards and outpatient cardiology clinic of a public hospital in South 
Africa. Patients were interviewed by researchers using the Memorial Symptom Assessment 
Scale-Short Form, a well-validated multidimensional instrument that assesses presence and 
distress of 32 symptoms.
results. A total of 230 patients (response, 99.1%) 90% NYHA III and 10% NYHA IV (12% 
newly diagnosed), with a mean age of 58 years, were included. Forty-five percent were 
women, 14% had completed high school, and 26% reported having no income. Mean 
Karnofsky Performance Status Score was 50%. Patients reported a mean of 19 symptoms. 
Physical symptoms with a high prevalence were shortness of breath (95.2%), feeling drowsy/
tired (93.0%), and pain (91.3%). Psychological symptoms with a high prevalence were wor-
rying (94.3%), feeling irritable (93.5%), and feeling sad (93.0%). Multivariate linear regression 
analyses, with total number of symptoms as dependent variable, showed no association 
between number of symptoms and gender, education, number of healthcare contacts in the 
last 3 months, years since diagnosis, or co-morbidities. Increased number of symptoms was 
significantly associated with higher age (b=0.054, p=0.042), no income (b=-2.457, p=0.013) 
and fewer hospitalizations in the last 12 months (b=1.032, p=0.017).
conclusions. Patients with advanced heart failure attending a medical centre in South 
Africa experience high prevalence of symptoms and report high levels of burden associated 
with these symptoms. Improved compliance with national and global treatment recom-
mendations could contribute to reduced symptom burden. Healthcare professionals should 
consider incorporating palliative care into the care for these patients.
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introduction
Heart failure is a chronic progressive syndrome associated with high morbidity and mor-
tality1-3. The prognosis of heart failure is as poor as, or even worse than, that of many 
cancers4-10. Community-based studies have reported mortality rates of 30% to 40% within 
1 year of diagnosis and 60% to 70% within 5 years1 11-13. Progressive decrease in functional 
capacity and an increasing frequency of hospitalizations are common in patients who have 
advanced heart failure14-16. Among patients who are hospitalized, mortality rates are even 
higher9. However, when patients are optimized using evidence-based medication, mortality 
can be reduced3 17-19.
Multiple investigators have shown that heart failure has a great impact on the health 
status and quality of life of patients, which can be directly attributed to their symptom 
burden (e.g., fatigue, shortness of breath, fluid retention) and functional limitations4 9 20-28. 
Unlike most cardiovascular conditions, heart failure is becoming more common6 7 29 30. At 
this moment, cardiovascular diseases account for about 30% of deaths worldwide, with 80% 
of deaths occurring in the developing world31. Heart failure has emerged as a dominant 
type of cardiovascular disease in Africa31, and it is a leading cause of death in South Africa32. 
Common causes of heart failure in Africa, such as rheumatic heart disease, peripartum 
cardiomyopathy, and hypertensive heart disease, are most prevalent in the young31 33-35. This 
is in contrast with developed countries, where heart failure is a condition of the elderly, with 
a mean age of 76 years31.
Despite the great burden of heart failure being present in low- and middle-income coun-
tries where formal health resources are limited, almost all research concerning advanced 
heart failure has focused on patients in high-income countries. It remains unclear whether 
patients with heart failure in developing parts of the world experience the same symptoms 
and functional limitations. The aims of this study are to measure the prevalence and associ-
ated burden of physical and psychological symptoms among patients with New York Heart 
Association (NYHA) stage III/IV heart failure attending a South African medical centre and 
to determine which characteristics are associated with the level of symptom burden.
method
Design and population
This cross-sectional observational study is part of a longitudinal study investigating symp-
toms and care needs in patients with advanced heart failure. The Human Research Ethics 
Committee of the University of Cape Town reviewed and approved this study (HREC REF: 
208/2012).
Patients were recruited for this study between August and November 2012 from several 
inpatient facilities (i.e. emergency unit, emergency ward, cardiology ward, general medicine 
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wards) and the outpatient cardiology clinic of a 900-bed tertiary academic medical cen-
tre in South Africa. Patients 18 years or older; able to communicate in English, Afrikaans 
or isiXhosa; and diagnosed with NYHA stage III/IV heart failure were included. Patients 
were recruited consecutively by the researcher (M.E.L.) after the attending physicians had 
indicated that a specific patient met the inclusion criteria. Informed consent was obtained 
from all participants. The questionnaires used in this study and the information and consent 
forms were translated from English (forward and back) into Afrikaans and isiXhosa (the main 
languages of the Western Cape of South Africa).
Data collection
The following patient demographic and clinical data were collected from the patient: age, 
gender, education level (primary school, some high school, high school completed, higher 
education), income (employed with/without payment, unemployed, disability grant, pension, 
living from private means), number of healthcare contacts during the last 3 months (outpa-
tient visits, telephone contacts, other) and number of previous hospital admission within 
the past 12 months. The reason for the hospital visit, years since diagnosis, NYHA stage at 
the time of the interview, aetiology/ comorbidity, current medication, and presence of an 
implantable cardioverter defibrillator were collected from the medical record.
To describe the functional limitations of the population, functional status was measured 
with the Karnofsky Performance Status (KPS) scale36. The KPS consists of 11 percentage 
categories denoted in deciles from 100% (asymptomatic, normal function) to 0% (death), 
which combine information on the patient’s ability to function at work and at home, the 
severity of symptoms, and the need for personal and medical care37. The KPS is regarded 
as the gold standard performance scale for patients with cancer, but use of the instrument 
has been reported in 3 studies in patients with advanced heart failure and 1 study in patients 
with acute myocardial infarction38 39. Recently, the KPS was described as adding clarification 
to the description of the heart failure population when used in studies together with the 
NYHA classification39. Interobserver reliability of the KPS varies between 0.66 and 0.9740-42.
For a 2-dimensional assessment of symptom prevalence and associated burden, we used 
the Memorial Symptom Assessment Scale-Short Form (MSAS-SF)43. The MSAS-SF is a 
patient-rated instrument in which patients rate the presence of 28 physical symptoms and 
the frequency of 4 psychological symptoms during the past 7 days. In addition to the 7-day 
period prevalence, the MSAS-SF also measures the associated burden for each symptom 
recorded as prevalent. Distress of physical symptoms is rated on a 5-point (0–4) Likert scale 
(not at all, 0.8; a little bit, 1.6; somewhat, 2.4; quite a bit, 3.2; very much, 4.0). Frequency of 
psychological symptoms is rated on a 4-point (0-4) Likert scale (rarely, 1; occasionally, 2; fre-
quently, 3; almost constantly, 4). If the symptom is not present, a value of 0 is assigned for the 
burden index. The MSAS-SF consists of 3 subscales: the global distress index (4 psychological 
symptoms: feeling sad, worrying, feeling irritable, and feeling nervous, and 6 physical symp-
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toms: lack of energy, pain, lack of appetite, feeling drowsy, constipation, and dry mouth); 
the physical symptom distress score (12 prevalent physical symptoms: lack of energy, pain, 
lack of appetite, feeling drowsy, constipation, dry mouth, nausea, vomiting, change in taste, 
weight loss, feeling bloated, and dizziness), and the psychological symptom distress score (6 
prevalent psychological symptoms: worrying, feeling sad, feeling nervous, difficulty sleeping, 
feeling irritable, and difficulty concentrating). The MSAS-SF has good psychometric proper-
ties, with subscale Cronbach’s α coefficients of 0.76 to 0.87, and 1-day test-retest reliability 
correlation coefficients of 0.86 to 0.9443. Use of the MSAS-SF has been well reported among 
patients with heart failure and patients from sub-Saharan Africa with HIV and cancer20 21 44-46.
Questionnaire items of the MSAS-SF were read aloud by researcher (M.E.L.), and patient’s 
self-report response entered on their behalf. All patients were interviewed in the language 
of their choice (English, Afrikaans, or isiXhosa). Self-completion was not used because of 
potential limited literacy in this population. All data were then entered into LimeSurvey 
(online survey software that was used as data entry tool in this study) and subsequently 
imported into SPSS version 20.0 for analysis.
Analysis and statistics
The patient demographic and medical characteristics were described with descriptive 
statistics. When data were nonnormally distributed, median scores were presented. For 
each item within the MSAS-SF, prevalence and associated burden were calculated. Scores 
for the global, physical, and psychological subscales were calculated47. The total number of 
prevalent symptoms for each respondent and the mean number of prevalent symptoms for 
the sample were also calculated. A high level of symptom burden was defined as the sum of 
‘‘quite a bit’’ and ‘‘very much’’ of distress associated with physical symptoms and the sum of 
‘‘frequently’’ and ‘‘almost constantly’’ for the frequency of psychological symptoms. Educa-
tion was measured using 4 groups (primary school, some high school, high school completed, 
and higher education). The high school completed and the higher education group both 
contained a very low number of patients, making a 3-group division (ie, lower, middle, and 
higher education) not possible. Therefore, education was divided into 2 groups of primary 
school versus more than primary school (including some high school, high school completed, 
and higher education). Income was measured using 6 groups (employed with payment, 
employed without payment, unemployed, disability grant, pension, living on own private 
means), but could not be categorized into levels of income (low, middle, and high); therefore, 
income was divided into no income (employed without payment and unemployed) versus 
income (employed with payment, disability grant, pension, and living on own private means).
Linear regression analyses were used to identify associations with symptom burden. Five 
models were constructed, with the following dependent variables: global distress (model 1), 
physical distress (model 2), psychological distress (model 3), total MSAS (model 4) and total 
number of symptoms (model 5). Univariate linear regression analyses were performed to test 
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the association of different patient characteristics with the dependent variables: age (con-
tinuous), gender (two levels of male/female), education (two levels of primary high school 
/ > primary high school), income (two levels of yes/no), years since diagnosis (two levels of 
0 / > 0 years), number of prior hospital admission within the past 12 months (continuous), 
number of healthcare contacts during the last three months (two levels of 0/>0) and number 
of co morbidities (continuous). Following each univariate regression, multivariate regression 
models were constructed. Independent variables were entered stepwise into the multivari-
ate model if they were significant in univariate analyses at the conservative 25% level.45 For 
each model, the 95% confidence interval of the unstandardized b coefficient was calculated.
results
sample characteristics
A total of 232 patients met the inclusion criteria for this study, and of these, 2 patients 
declined participation. Therefore, a total of 230 patients (response 99.1%) were included in 
the study (Table 1). The mean (SD) age was 58 (16.7) years (median, 60 years; min-max, 18-90 
years); 45% were women, 14% completed high school, and 26% reported having no income. 
Most patients included in this study had been admitted to the hospital because of an exac-
erbation of their illness. Eighty-eight percent had been diagnosed with heart failure before 
their hospital visit. The most prevalent stage of heart failure in this population was NYHA 
stage III (90%). Comorbidity was common; only 19 patients were reported having no other 
illnesses. The most prevalent comorbidities were hypertension (70%) and diabetes (38%). 
Mean KPS was 50% (“requires considerable assistance and frequent medical care”). On aver-
age, patients had been previously admitted to hospital on 1 occasion during the past year. 
Sixty-eight percent of all patients had not had any contact with a healthcare professional 
during the previous 3 months. According to the medical records, angiotensin-converting en-
zyme (ACE) inhibitors, were used by 57% of patients with an existing diagnosis; β-blockers, 
by 47%; angiotensin receptor blockers by 4%; mineralocorticoid receptor antagonists(MRA), 
by 12%; diuretics other than MRA, by 92%; and digoxin, by 11%. Five percent of patients had 
an implantable cardioverter-defibrillator (ICD).
symptom prevalence and burden
The 7-day period symptom prevalence and associated burden are reported in Table 2. Pa-
tients reported a mean of 19 symptoms (not in table). Eighteen symptoms were reported by 
more than 50% of all patients. Physical symptoms with highest prevalence were shortness of 
breath (95.2%), feeling drowsy/tired (93.0%) and pain (91.3%). Psychological symptoms with 
highest prevalence were worrying (94.3%), feeling irritable (93.5%) and feeling sad (93.0%). 
Symptoms associated with highest burden were shortness of breath (93.1%), numbness/ 
tingling in hands or feet (90.5%) and “I do not look like myself” (89.9%).
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table 1. Sample Characteristics (n=230)
Patient demographic characteristics Patient medical characteristics
Age median ± SD, y 60 ± 16.7 Aetiology/ comorbidity cardiovascular diseases
Gender Hypertension 70% 161
Male 45% 103 Ischemic Heart disease 13% 30
Female 55% 127 Valvular heart disease 3% 7
Education level Rheumatic heart disease 3% 6
Primary school 49% 112 Post-partum cardiomyopathy 1% 2
Some high school 37% 86 Congenital heart disease 1% 2
High school completed 11% 25 Hypertrophic obstructive 
cardiomyopathy
0,4% 1
Higher education 3% 7 Aetiology/ comorbidity other diseases
Income Diabetes type 2 24% 55
Employed with payment 22% 50 Diabetes type 1 14% 31
Employed without payment 2% 5 Renal Failure 12% 28
Unemployed 24% 55 COPD 8% 19
Disability grant 10% 24 Asthma 7% 16
Pension 41% 94 HIV 7% 15
Living on own private means 1% 2 Tuberculosis 4% 8
Patient medical characteristics Cancer 1% 2
Heart failure diagnosis Comorbidity per patient, mean (interval) 2 0-4
Years since diagnosisa median/
interval
1 0-18 Karnofsky Performance Score, mean 
(interval)
50% (90%-20%)
Newly diagnosed 12% 27 Reason for hospital visit
NYHA stage at time of interview Acute admission 86% 197
III 90% 207 Outpatient clinicb 13% 29
IV 10% 23 Planned admission 2% 4
Contact with healthcare professionals Medication use (patients with an existing diagnosis n=201)
Prior hospital admissions last year 
(mean/interval)
1 0-4 ACE-inhibitors 57% 115
Prior healthcare contacts last 3 months β-blockers 47% 94
0 63% 144 Angiotensin receptor blockers 4% 7
1 28% 64 Digoxin 11% 22
≥ 2 10% 22 MRA 12% 25
Implantable Cardioverter Defibrillator 
(ICD)
5% 11 Diuretics other than MRA 92% 184
Data are presented as percentage and number, unless otherwise indicated. Abbreviations: ACE, angiotensin-
converting enzyme; COPD, chronic obstructive pulmonary disease; MRA, mineralocorticoid receptor antago-
nist; NYHA, New York Heart Association.
aNumber of years since diagnosis missing for 2 patients.


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































correlates of symptom burden
Univariate and multivariate regression analyses to determine associations with symptom 
burden are presented in Table 3. Age, income, and prior hospital admission were found to be 
consistent correlates for the multivariate models. In the multivariate analyses, age, income 
and prior hospital admission were correlated to global distress (model 1: ƅ=0.007, P=0.030; 
ƅ=-0.270, P=0.029 and ƅ=-0.168, P<0.001 respectively), physical distress(model 2: ƅ=0.007, 
P=0.037; ƅ=-0.298, P=0.013 and ƅ=-0.211, P<0.000 respectively), number of symptoms (model 
5: ƅ=0.053, P=0.038; ƅ=-2.233, P=0.021 and ƅ=-1.498, P<0.001 respectively), psychological dis-
tress (model 3: prior hospital admission only, ƅ=-0.116, P=0.023) and total distress (model 4: 
prior hospital admission only, ƅ=-0.168, P<0.001). In these models, a higher symptom burden 
was associated with having a higher age, having no income (dichotomous variable; having 
no income compared to income) and having fewer hospital admissions within the past 12 
months. Multivariate analyses showed no association between the different models and the 
independent variables of gender, education, healthcare contacts, years since diagnosis, or 
comorbidities.
table 3. Associations With symptom Burden
independent variables
Univariate analysis Multivariate analysis
ƅ P 95% CI for ƅ ƅ P 95% CI for ƅ
Model 1: Global distress Subscale, r2 =9,0%
Age 0.002 0.449 -0.003, 0.008 0.007 0.030 0.001, 0.014
Gender -0.102 0.280 -0.287, 0.083
Education -0.060 0.525 -0.244, 0.125
Income -0.157 0.140 -0.366, 0.052 -0.270 0.029 -0.512, -0.028
Years since diagnosis -0.042 0.772 -0.326, 0.242
Prior hospitalizations -0.172 <0.000 -0.264, 0.080 -0.168 <0.000 -0.260, -0.076
Healthcare contacts 0.137 0.156 -0.053, 0.327 0.160 0.091 -0.026, 0.347
Co-morbidity 0.022 0.661 -0.077, 0.122
Model 2: Physical distress Subscale, r2 = 13,0%
Age 0.001 0.729 -0.005, 0.006 0.007 0.037 0.000, 0.013
Gender -0.140 0.132 -0.322, 0.043 -0.112 0.204 -0.285, 0.061
Education -0.021 0.823 -0.203, 0.161
Income -0.221 0.035 -0.426, -0.016 -0.298 0.013 -0.532, -0.064
Years since diagnosis -0.088 0.534 -0.368, 0.191
Prior hospitalizations -0.216 <0.000 -0.305, -0.128 -0.211 <0.000 -0.300, -0.122
Healthcare contacts 0.074 0.438 -0.114, 0.262 0.106 0.247 -0.074, 0.286
Co-morbidity -0.024 0.625 -0.123, 0.074
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table 3. Associations With symptom Burden (continued)
independent variables
Univariate analysis Multivariate analysis
ƅ P 95% CI for ƅ ƅ P 95% CI for ƅ
Model 3: Psychological distress Subscale r2 = 2,8%
Age 0.001 0.762 -0.005, 0.007
Gender -0.115 0.251 -0.311, 0.082 -0.116 0.247 -0.312, 0.081
Education 0.045 0.653 -0.151, 0.241
Income -0.121 0.284 -0.344, 0.101
Years since diagnosis -0.027 0.859 -0.332, 0.277
Prior hospitalizations -0.114 0.024 -0.214, -0.015 -0.116 0.023 -0.215, -0.016
Healthcare contacts 0.038 0.711 -0.164, 0.241
Co-morbidity 0.008 0.885 -0.098, 0.144
Model 4: Total MSAS Score, r2 =8,8%
Age 0.001 0.749 -0.004, 0.005
Gender -0.122 0.119 -0.275, 0.032 -.0124 0.100 -0.271, 0.024
Education -0.029 0.709 -0.182, 0.124
Income -0.159 0.072 -0.333, 0.014
Years since diagnosis -0.072 0.547 -0.308, 0.164
Prior hospitalizations -0.171 <0.000 -0.246 -0.095 -0.168 <0.000 -.0243, -0.093
Healthcare contacts 0.055 0.492 -0.103, 0.213
Co-morbidity -0.016 0.695 -0.099, 0.066
Model 5: Number of symptoms, r2 =10,7%
Age 0.010 0.666 -0.034, 0.054 0.053 0.038 0.003, 0.104
Gender -1.391 0.061 -2.847, 0.066 -1.177 0.101 -2.584, 0.229
Education -0.446 0.548 -1.91, 1.013
Income -1.669 0.047 -3.316, -0.021 -2.233 0.021 -4.124, -0.341
Years since diagnosis -0.415 0.716 -2.661, 1.832
Prior hospitalizations -1.530 <0.000 -2.250 -0.809 -1.498 <0.000 -2.218, -0.778
Healthcare contacts 0.238 0.756 -1.270, 1.746
Co-morbidity -0.268 0.503 -1.056, 0.520
Bold values correspond with significant outcomes (P = .05).
Abbreviations: CI, confidence interval; MSAS, Memorial Symptom Assessment Scale.
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discussion
This study is the first to assess the prevalence, burden, and correlates of physical and psy-
chological symptoms in patients with NYHA stage III and IV heart failure in a developing 
country. We found that these patients report a high prevalence of symptoms and high levels 
of burden associated with these symptoms. Higher symptom burden is associated with a 
higher age, having no income and fewer hospital within the past 12 months.
The prevalence figures reported in this study are high compared with findings of several 
other studies who used the MSAS9 20 27 48. Focussing on the most prevalent physical and 
psychological symptoms in this study, varying percentages have been reported for the 
prevalence of shortness of breath (95.2% vs 56.3%-85.0%9 20 27 48), feeling drowsy/tired (93.0% 
vs 52.0%-90.0%9 20 27 48), pain (91.3% vs 52,0%-56,0%20 27), worrying (94.3% vs 43.7%-61.5%9 27), 
feeling irritable(93.5% vs 33.0%-53.7%9 27) and feeling sad(93.0% vs 42.7%-54.7%9 27). The high 
prevalence figures found in the current study are striking, especially in this group, with a high 
rate of patients being diagnosed with NYHA stage III. The discrepancies in symptom preva-
lence between our findings and previous studies could be explained by several factors: Not 
all studies restricted their inclusion to NYHA stage III or IV but also included NYHA stage 
I and II, measurements were done at different locations (i.e. at home, during an outpatient 
clinic visit, during an hospital admission) and at different points in the course of the illness 
(during an exacerbation, during a chronic period), studies reported on patients with a higher 
average age (having a younger age has been associated with a higher symptom burden in 
patients with cancer49 50), and studies were carried out in developed parts of the world (i.e. 
Europe and North America). It is possible that the prevalence figures in the current study 
are higher compared with earlier findings because most patients in the current study were 
interviewed at the time of an exacerbation of their illness (86% of patients were at the hos-
pital for an acute admission). Also, the KPS in our study was quite low compared with that 
in 3 other studies in patients with advanced heart failure (50% vs 69%-76%), which seems 
to confirm this hypothesis. Another possible explanation for the difference in prevalence 
figures is related to the prescription rates of recommended treatment. Treatment guidelines 
in South Africa51 52 are in line with those for Europe and North America53 54 in their recom-
mendation for the use of ACE inhibitors, ß-blockers, and spironolactone as an important 
part of heart failure treatment. The reported levels of medication in our study are, however, 
lower than recommended and also low compared to other studies, in which ACE-inhibitors 
were used by 47% to 82% of patients27 44 48 55-58 (vs 57% in our study); ß-blockers, by 34% to 
88%27 44 48 55-58 (vs. 47%); and MRAs, by 18% to 72%44 48 56-58 (vs. 12%). Under-treatment has 
been reported as a problem in heart failure treatment and does not seem to be limited to 
developing counties30 56.
The symptoms shortness of breath, numbness/ tingling in hands or feet and “I do not look 
like myself were considered most distressing by our study group. We found 2 previous studies 
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that reported on distress of symptoms in an advanced heart failure population. Blinderman 
et al.9 studied a sample of 103 community-dwelling patients with NYHA stage III/IV heart 
failure in the United States. According to this sample, the most distressing symptoms were 
other pain (in this study, pain was differentiated into cardiac pain and other pain), problems 
with sexual interest/activity and lack of energy. Zambroski et al.27 studied a sample of 53 pa-
tients with NYHA stage II to IV heart failure visiting a heart failure clinic in the United States. 
Patients in this study judged lack of energy, difficulty sleeping and shortness of breath to be 
the most distressing symptoms. Patients in the studies of Blinderman et al. and Zambroski 
et al. and the current study seem to disagree about which symptoms are most distress-
ing to them. This discrepancy could be related to the differences in symptom prevalence 
and ranking of most prevalent symptoms. Numbness or tingling in hands or feet can be 
caused by swelling of the arms or legs or associated with peripheral neuropathy secondary 
to diabetes. Prevalences of the symptom swelling of the arms or legs and of diabetes were 
higher in the current study compared with the studies of Blinderman et al. and Zambroski 
et al (81.3% vs 32.0-47.2% and 38% vs 33-32%, respectively9 27). It could by hypothesized that 
patients who report feeling that they do not look like themselves do so because of the 
presence of disfiguring symptoms such as swelling of arms or legs and weight loss (84.8% 
vs 19.4%-32.1%9 27), which were both more prevalent in our study. To be able to focus care 
on the most distressing symptoms, communication about symptom-related distress is key.
Having a higher age, having no income, and having fewer hospital admissions within the 
past 12 months were associated with higher symptom burden. The association with age is 
in accordance with previous studies that have shown an increased risk of heart failure hos-
pitalization with increasing age15 59. The association with income is in line with studies that 
have looked at the relationship between socioeconomic status (SES) and the risk of heart 
failure hospitalizations59-61. A lower SES is associated with a higher risk for heart failure and 
heart failure-related hospital admissions. Hospitalizations are usually due to an exacerbation 
of heart failure. The association of higher symptom burden with fewer hospital admissions is 
therefore rather surprising. It could be that patients who have been admitted have been well 
cared for, including receiving the recommended treatment, leading to lower symptom bur-
den in the group with previous hospital admissions. Another explanation could be related to 
the association with no income. In South Africa, healthcare access for all is constitutionally 
enshrined, but great inequities in access to and the subsequent use of healthcare remain62. 
Studies have indicated that low-income groups in South Africa cannot ‘‘afford’’ to be ill and 
therefore underreport or ‘‘ignore’’ illness62 63. Also, no money for transport, out-of-pocket 
payments, delays due to a belief that the illness was not serious enough to warrant immedi-
ate care, or that care would be ineffective have been reported as access barriers for the 
low-SES group62. It is startling that the number of healthcare contacts was not associated 
with symptom burden; therefore, we can presume that pain and symptom burden are not 
adequately addressed in routine existing care.
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Many of the symptoms that are being reported by patients with advanced heart failure 
are not generally thought of as being caused by heart failure4 20. Some symptoms may be 
related to medication used to treat heart failure, such as dry mouth or constipation, or 
with comorbidities, which are highly prevalent in this population20 64 65. Although the causes 
of various symptoms, such as pain5 8 66, remain unclear, these diverse symptoms together 
are responsible for a major portion of the decrease in quality of life associated with heart 
failure20. Advanced heart failure has been described as having one of the largest effects on 
quality of life of any advanced disease20 28. To optimally treat patients with heart failure, 
attention needs to be paid to all symptoms that are present , irrespective of their aetiology. 
Several authors have emphasized the need for incorporating palliative care in advanced 
heart failure care4 8 53 67-69. Palliative care is care tailored to the needs of patients; it is a 
holistic approach to the care for patients and their families who are facing the problems 
associated with a life-threatening illness.
There are some limitations to this study. First, concerning generalizability of the results, 
the patients were recruited from 1 medical centre and may therefore not be representative 
for the total population with heart failure residing in community settings; although patients 
were recruited consecutively during an inclusion period of 3 months, most patients who 
were included in the study were diagnosed with stage III heart failure. It is therefore possible 
that our results are not completely generalizable to patients with stage IV heart failure. We 
hypothesize that patients with stage IV heart failure are often too ill to visit the hospital 
and are taken care of at home. Second, concerning reliability and completeness of data 
collected from the medical record, it is not clear to what extent these medical records were 
complete and thus completely reflected the medical history and current health status of the 
patient. We did not collect data on ejection fraction, and therefore, we cannot fully reflect 
on the reported levels of medication in this study. Third, the cross-sectional design provides 
us with a ‘‘snapshot’’ of the symptom burden experienced by patients with advanced heart 
failure. Symptom burden is expected to change during the course of the disease. A longi-
tudinal follow-up is needed to know how symptom burden changes over time in patients 
with advanced heart failure, and these longitudinal data will follow in subsequent reporting. 
The strength of this study lies in the use of patient-reported data, instruments with good 
psychometric properties and multiple language options, the high response rate, and multiple 
recruitment points throughout the medical centre.
In conclusion, patients with advanced heart failure attending an academic medical centre 
in South Africa experience a high prevalence of symptoms and report high levels of burden 
associated with these symptoms. Current treatment seems not to be in accordance with 
national and global recommendations. Improved compliance with national and global treat-
ment recommendations could contribute to reduced symptom burden. Attention should be 
paid to high prevalent symptoms, symptoms associated with high distress, and symptoms 
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that are not generally thought of as being caused by heart failure. Incorporating palliative 
care into the care for these patients could contribute to the provision of tailored care.
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AbstrAct
context. Death rattle, or respiratory tract secretion in the dying patient, is a common and 
potentially distressing symptom in dying patients. Healthcare professionals often struggle 
with this symptom because of the uncertainty about management.
objectives. To give an overview of the current evidence on the prevalence of death rattle 
in dying patients, its impact on patients, relatives, and professional caregivers, and the ef-
fectiveness of interventions.
Methods. We systematically searched the databases PubMed, Embase, CINAHL, PsychIN-
FO and Web of Science. English-language articles containing original data on the prevalence 
or impact of death rattle or on the effects of interventions were included.
results. We included 39 articles, of which 29 reported on the prevalence of death rattle, 
eight on its impact, and 11 on the effectiveness of interventions. There is a wide variation 
in reported prevalence rates (12-92%; weighted mean, 35%). Death rattle leads to distress 
in both relatives and professional caregivers, but its impact on patients is unclear. Differ-
ent medication regimes have been studied, that is, scopolamine, glycopyrronium, hyoscine 
butylbromide, atropine and/or octreotide. Only one study used a placebo group. There is no 
evidence that the use of any antimuscarinic drug is superior to no treatment.
conclusions. Death rattle is a rather common symptom in dying patients, but it is doubtful 
if patients suffer from this symptom. Current literature does not support the standard use of 
antimuscarinic drugs in the treatment of death rattle.
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introduction
Care for the dying has received growing attention over the past decade, in both healthcare 
research and practice. Although several challenges of performing research in end-of-life care 
have been reported1-5, the demand for evidence-based guidelines is increasing. Until now, 
for many symptoms associated with the dying phase, research has been scarce, as is the 
case for death rattle. Death rattle or respiratory tract secretion in the dying patient, is a 
common symptom in dying patients, although reported prevalences vary considerably6-10. 
Death rattle is thought to be caused by an accumulation of secretions in the airways11. It 
is unclear whether or to what extent it represents discomfort for the patient, and whether 
nursing and medical interventions to reduce its prevalence are needed or effective. Even 
when the patient does not appear to be disturbed by the symptom, treatment is often initi-
ated because of distress in the attending relatives12-14. Treatment modalities include nurs-
ing interventions, for example, repositioning of the patient and suction of secretions and 
pharmacologic interventions. The use of antimuscarinic drugs is recommended in several 
palliative care textbooks11, 15-18.
A recent Cochrane review focusing on interventions for death rattle concluded that there 
is no evidence that any intervention, pharmacologic or nonpharmacologic, was superior 
to placebo in the treatment of noisy breathing in dying patients19. This Cochrane review 
was based on four articles (two English, two German) and only included level A evidence 
studies, that is, randomized controlled trials and high-quality prospective controlled studies. 
Randomized controlled trials among patients who are in the dying phase are rare, mainly 
because of ethical and practical considerations related to randomization, informed consent, 
the use of placebo, and follow-up1-5. Studies with a lower level of evidence can also provide 
useful information on care for dying patients. We performed a systematic search of the 
scientific literature with the aim of giving a comprehensive overview of empirical studies on 
the prevalence of death rattle, its impact on patients, relatives and professional caregivers, 
and the effectiveness of interventions.
methods
We conducted a systematic search of the databases PubMed, Embase, CINAHL, Web of 
Science and PsychINFO. All the databases were searched for articles published up to August 
2012 in English on the prevalence, impact and treatment of death rattle. Fig. 1 presents a 
detailed overview of the search strategy. The search strategy was not restricted to recent 
publications to retrieve all the relevant literature. In addition, we hand-searched reference 
lists of included articles and relevant literature reviews.
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study selection
Studies were included when they met the following inclusion criteria: the study described 
original empirical research about death rattle in the dying phase of human adults and the 
study included data about the prevalence of death rattle, experiences of patients, relatives, 
or professional caregivers with death rattle, or the effectiveness of interventions. Studies 
on the prevalence of death rattle had to include at least 50 subjects. Reviews, comments, 
case studies, letters, and conference abstracts were excluded. All duplicates were removed. 
Articles were selected in a stepwise procedure. First, all titles were assessed as possibly 
relevant or not relevant; titles that were not relevant were excluded. In the second step, the 
abstracts of the remaining articles were screened on the selection criteria. If the abstracts 




Search strategy  
(Death [mesh] OR death*[tw] OR asphyx*[tw] OR dying [tw] OR terminal*[tw] OR end-of-life [tw]) AND (rattl*[tw] OR 
respiratory sound*[tw] OR respiratory nois*[tw] OR noisy breath*[tw] OR breathing nois*[tw] OR lung sound*[tw] OR pleural 
rub*[tw] OR rhonch*[tw] OR bronchial secret*[tw] OR respiratory secret*[tw] OR respiratory tract secret*[tw]) NOT 
(snake*[tw] OR rattlesnake*[tw] OR rna[tw] OR tobacco rattl*[tw] OR rattle virus[tw]) 
 
 
Full texts (n=154) 
Abstracts (n=218) 
Articles included (n=36) 
Studies added after hand 
search of reference (n=3) 
 
Articles excluded (n=824) 
- Not about death rattle in dying phase (n=777) 
- Not about adults/ Article about children (n=3) 
- Not about humans / Article about animals (n=5) 
- No original empirical research* (n=4) 
- Language other than English (n=35) 
 
*Including reviews, comments, case studies, 
letters, conference abstracts 
 
Abstracts excluded (n=84) 
- Not about death rattle in dying phase (n=80) 
- No original empirical research* (n=3) 




Full text excluded (n=118) 
- Not about death rattle in dying phase (n=30) 
- Not about humans / Article about animals (n=3) 
- Study population not sufficient <5/50 (n=1)  
- No original empirical research* (n=73) 
- Language other than English (n=10) 




Articles included (n=39) 
Unique articles (n=1062) 
Fig 1. Search strategy and selection of articles 
Figure 1. Search strategy and selection of articles
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Titles of 10% of the articles were independently assessed by two reviewers (M.E.L. and 
A.v.d.H.). Cohen’s Kappa was calculated to determine the level of agreement: κ=0.78, indi-
cating a substantial agreement20. Differences in scoring were discussed until consensus was 
reached. The remaining titles were assessed by M.E.L. This procedure was repeated for the 
assessment of abstracts (κ=0.77) and full texts (κ=0.90). For all the studies that did not pass 
the selection process, the reasons for non-inclusion were registered.
Data extraction
We collected information on general characteristics of the studies and results related to 
our research questions, using a standardized extraction form. Extracted data included the 
number of patients studied, study setting, study design, source of information, frequency of 
measurements, measurement method, primary diagnosis (cancer or noncancer), and general 
patient characteristics. We also extracted data on the prevalence of death rattle, assess-
ments of the impact of death rattle on patients, relatives, and professional caregivers, and 
effects of medical and nonmedical interventions.
Quality assessment
The quality of the selected studies was assessed using the multimethod assessment tool 
devised by Hawker et al21. This tool can be used to evaluate studies with quantitative and 
qualitative designs. All studies were assessed on nine different aspects: abstract and title; 
introduction and aims; methods and data; sampling; data analysis; ethics and bias; results; 
transferability or generalizability; and implications and usefulness. For each aspect, a score 
was given on a four-point scale, from 1, very poor, to 4, good. Summing the different area 
scores results in a total score, from 9, very poor, to 36, good.
results
selection of articles
Our search yielded 1062 unique articles. In the first step, 824 articles were excluded because 
the articles’ titles were assessed as not relevant. In the second step, 84 articles were excluded 
because their abstracts did not meet the selection criteria. This resulted in 154 remaining 
articles, of which 36 articles could be included after assessment of the full texts (Figure 1). A 
manual search of references identified three other studies, for a total of 39 studies (Table 1).
The studies were published between 1988 and 2012. Eight studies were performed in Asia, of 
which seven were done in Japan; two in Australia; one in New Zealand; 24 in Europe, of which 
16 were done in the U.K.; and four in North America. The 39 studies included three randomized 
controlled trails22-24, two prospective comparative studies25-26, eight prospective observational 
studies7-8, 10, 27-31, two cross-sectional surveys32-33, two retrospective surveys34-35, 18 medical record 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The total scores for quality of the included articles are presented in Table 1. One article was 
rated between ‘‘very poor’’ and ‘‘poor;’’ 20 articles were rated between ‘‘poor’’ and ‘‘fair;’’ 
and 18 articles were rated between ‘‘fair’’ and ‘‘good.’’
Labels and definitions of death rattle
Various labels were used to describe death rattle: bronchial secretion, (troubling/noisy/ter-
minal) respiratory (tract) secretions, increasing secretions, noisy-retained secretions, terminal 
secretions, pulmonary rattles, noisy (rattling/moist) breathing (at the end of life), or respiratory 
symptoms. In addition, definitions of death rattle varied between studies. Twenty-two articles 
provided a definition of death rattle. Elements included in these definitions were the noise or 
sound associated with death rattle6-9, 12-14, 22-26, 28-31, 33, 41, 43, 50-52, the movement of (accumulated) 
secretions7-9, 22-23, 28-31, 41, 43, 50-51, location in the hypopharynx, bronchial tree7-8, 25, 28-31, 41, 43, 51 or 
upper airways9, 23, 50, the relation with respiration6-9, 12-14, 22-23, 25, 28-31, 33, 41, 43, 50, 52, its occurrence 
in the terminal phase of an illness6, 9, 12, 14, 22-23, 25, 41, its relation with weakness and/or inability 
to cough or clear the airways6, 9, 22-23, 25, 51, and the idea that it can be distressing for those 
involved6, 8, 22, 25, 41, 50-51.
Prevalence of death rattle
Data on the prevalence of death rattle were reported in 29 articles (Table 2). Sample sizes 
ranged between 68 and 2382 patients. Studies were performed in hospitals (34%), palliative 
care units (45%), home care (28%), hospices (34%), or long term care facilities (7%); some 
studies concerned more than one type of setting. Sixteen studies were performed in a popu-
lation of patients with a diagnosis of primary cancer, eight in a mixed population (cancer and 
noncancer combined) and in five studies, the diagnosis of patients were not specified.
The prevalence of death rattle varied between studies. The lowest and highest percent-
ages reported were 12%, in a retrospective study of 169 patients with a brain tumors45, and 
92%, in a prospective study of 82 patients with various forms of cancer7. The weighted mean 
for these 29 studies was 35% The reported median time from the onset of death rattle until 
death was between 11 and 28 hours23-25, 30, 41, 43, 51.
Six studies23-25, 27-29 used a scoring scale as proposed by Back et al.25 to assess the severity 
of death rattle. This scoring scale records the volume of noise associated with death rattle: 
0, inaudible; 1, audible only very close to the patient; 2, clearly audible at the end of the bed, 
in a quiet room; 3, clearly audible at about 20 ft (9.5 m) (at the door of the room), in a quiet 
room. Of these six studies, four presented data about the severity of death rattle: 6-17% of 
all patients had death rattle score 1, 19-26% had score 2 and 5-11% had a score 323-25, 28.
Patient characteristics that were found to be significantly associated with the presence of 
death rattle were disoriented cognitive function42, male gender43, lung cancer8, 28, 43, a tumor 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































located in bone, liver, intestinal tract8 or brain6, 8 , pneumonia28 and a duration of stay in a 
hospice of more than nine days6 (see appendix).
impact of death rattle
Data on the impact of death rattle on patients, relatives and professional caregivers were 
reported in eight studies: four quantitative studies32-34, 44 and four qualitative studies12-14, 52 
(table 3). Sample sizes in the four quantitative studies ranged between 11 and 65 respondents. 
Respondents were nurses32-33, 44 or bereaved relatives34. Sample sizes in the four qualitative 
studies ranged between 12 and 41 respondents. Respondents were professional or informal 
caregivers (nurses, physicians and volunteers)13, 52 or bereaved relatives12, 14.
Impact on patients
In a study among nurses, 87% indicated that they felt that death rattle does not distress the 
dying patient32. A qualitative study among physicians, nurses and volunteers suggested that 
patients may feel distressed because of the sound of death rattle of other patients in the 
same ward13.
Impact on relatives
Eight studies provided information on the impact of death rattle on relatives. According to 
one study, relatives perceived death rattle as ‘not so distressing’ in 5%, as ‘slightly distress-
ing’ in 15%, as ‘distressing’ in 26%, and as ‘very distressing’ in 52%34. In two studies among 
nurses, 100% of them indicated that death rattle causes distress for all those involved, but 
particularly for relatives32-33. Such distress is, according to one study among nurses, related 
to relatives experiencing that patients were ‘gagging’ and ‘drowning’ in secretions (no per-
centage mentioned)44.
The qualitative studies suggested that, although death rattle was regarded as distressing 
for most relatives12-14, 52, some relatives found it reassuring to hear the patient breathe, or 
regarded death rattle as a helpful warning sign of impending death12, 14, 52.
Impact on professional caregivers
One quantitative and two qualitative studies reported on the impact of death rattle on 
professional caregivers. In a cross-sectional survey, 79% of nurses regarded death rattle as 
distressing32. Focus groups with hospice staff and volunteers and interviews with physicians 
and nurses showed that for them, death rattle may be distressing13, 52. Interviewed nurses 
and physicians mentioned that they themselves possibly benefited from interventions to 
diminish death rattle. This benefit is related to being able to do something for the patient 
and family52.
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interventions for death rattle
Eleven studies reported on the effectiveness of interventions for death rattle (table 4). 
Sample sizes ranged between 5 and 167 respondents per study group. Nine studies described 
medical interventions and two studies described the association between the hydration 
level and death rattle. No studies were found on the effectiveness of other interventions, for 
example, repositioning of the patient, explanation of the symptom to relatives, or suctioning 
of secretions. Eight studies had a comparative design, comparing two or three interven-
tions22-27, 29, 41. Three studies were not controlled9, 43, 51.
Six studies compared two or three medication regimes. Medications studied included 
scopolamine22-23, 25-26, 41, glycopyrronium25-26, 41, hyoscine butylbromide23, 26, atropine23-24 
and octreotide22. Three studies found no differences in the effectiveness of the different 
v regimes22-23, 26. One randomized controlled trail found no differences in the prevalence 
of death rattle between patients receiving atropine and patients receiving a placebo24. 
One comparative but uncontrolled study found that scopolamine was significantly more 
effective than glycopyrronium in reducing the severity of death rattle as recorded by nurses 
30 minutes after administration of the medication, but no difference was found one hour 
after administration and at the final measurement before death25. A retrospective study 
using medical records found contrasting results: patients who received glycopyrronium were 
significantly more often reported as having a response to treatment than patients receiving 
scopolamine41.Two studies compared two groups with different hydration regimes (<1 liter/ 
day versus ≥1 liter/day)27, 29. A reduced level of hydration was found not to change death 
rattle prevalence.
discussion
The prevalence of death rattle was found to vary widely. Several characteristics of studies 
that assessed prevalences may explain this variance. First, there is a wide variety of labels 
and definitions used to describe death rattle, with the noise or sound as a constant element 
in all definitions. Whether the various labels all represent the exact same phenomenon is, 
however, not clear. Second, different study designs were used: 34% were prospective stud-
ies, 64% were retrospective studies. The weighted mean for the prevalence of death rattle 
in the prospective studies was 45%, compared to 30% in the retrospective studies. Third, few 
studies reported the exact point in time during the dying process at which the presence of 
death rattle was assessed. The natural course of death rattle is not clear. Kass and Ellershaw 
suggest that the prevalence of death rattle typically increases when death approaches43. 
However, Heisler et al. performed a placebo controlled trial and found an decrease of death 
rattle scores over time in the placebo group24. Fourth, studies reporting on prevalences 
were often restricted to patients with cancer, but some studies also included noncancer 
patients. Whether specific diseases are associated with the prevalence of death rattle is 
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unclear. Only patients with cerebral or lung malignancies were found to have a higher risk 
of death rattle6, 8, 28, 43. More studies are needed to give insight into specific relationships 
between underlying disease and death rattle prevalence rate. Fifth, measurement methods 
to determine death rattle prevalence varied between the different studies. Validated instru-
ments, such as the death rattle scoring scale25 were not used by most studies.
The impact of death rattle on patients remains unclear and can only be based on sub-
jective reports of others. It is often assumed by healthcare professional that patients are 
not distressed by this symptom, because they are generally unconscious when death rattle 
develops. Many professional caregivers assume that death rattle is distressing for relatives13. 
Whether relatives experience distress seems to be related to their judgment whether 
a patient is comfortable. For some relatives the symptom can also be helpful because it 
either demonstrates that the patient is still alive or is seen as a sign of impending death. 
Professional caregivers themselves may also be distressed by the noise of death rattle, which 
often results in a medical intervention. Wee et al.13 and Heisler et al.24 suggest that the 
way in which professional caregivers interpret the symptom can influence their response 
and actions, which could also affect relatives’ perceptions. Professional caregivers should be 
aware of this effect.
A number of different interventions for the treatment of death rattle are included in guide-
lines and palliative care textbooks: repositioning of the patient, explanation of the symptom 
to relatives, suctioning of secretions, reduction of artificial hydration, administration of 
antimuscarinic drugs and sedation. Only reducing the level of hydration and treatment with 
antimuscarinic drugs have been studied for their effectiveness. Two studies among patients 
with abdominal cancer found no relation between the level of hydration and the prevalence 
of death rattle. There is no evidence that the use of any antimuscarinic drug is superior to 
no treatment. This finding is in line with the previous Cochrane review focusing on interven-
tions for death rattle19. However, studies on the effect of pharmacologic interventions are 
limited by their lack of a placebo group. Well-designed studies to assess the relation between 
hydration and death rattle, and studies on the effects of non-pharmacologic interventions 
for death rattle, are still lacking. More prospective randomized controlled studies on the 
effectiveness of medical therapy and other interventions are urgently needed to confirm 
these findings.
We conclude that death rattle is a common symptom in dying patients. Approximately 
one-third of dying patients will present with this symptom. Current evidence does not 
support the standard use of antimuscarinic drugs in the treatment of death rattle. More 
high-quality studies are needed to give insight into the effects of interventions, both phar-
macologic and non-pharmacologic. Until then, care should focus on communication about 
the symptom with relatives and others involved in the care of these patients. Regarding 
the symptom as being part of the normal dying process could contribute to the lowering of 
distress levels of those involved.
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•	 Adl-independent	 28% 
•	 Adl-dependent	 32% (p > 0·05) 
cognitive function  
•	 Oriented	 25% 
•	 Disoriented	 41% (p = 0·022) 








Prevalence of secretion score ≥ 1b  
•	 Hydration	+	(c)  44%
•	 Hydration	–	(d) 46% (p > 0·05)
Prevalence of secretion score ≥ 2b 
•	 Hydration	+	  19%
•	 Hydration	–	 17% (p > 0·05)





Cancer (lung + 
abdominal)
310 Primary tumor site
•	 Abdominal	 67% 
•	 Lung	 46% (p = 0·001) 
Brain metastases  
•	 Present	 56% 
•	 Absent	 51% (p > 0·05) 
Lung metastases  
•	 Present	 58% 
•	 Absent	 47% (p > 0·05) 
Pneumonia  
•	 Present	 68% 
•	 Absent	 46% (p = 0·002) 
Dysphagia  
•	 Present	  
•	 Absent	 75% 
No correlation with age and gender 49% (p > 0·05) 
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Kass et al43., 
UK, 2003
PCU Cancer (various 
tumors)
202 Tumor locations
•	 Lung cancer 68% 
•	 GI	cancer	 42% 
•	 Hepatobiliary	&	pancreatic	ca	 40% 
•	 Breast	 46% 
•	 Gynecological	cancer	-	breast	 35% 
•	 Urological,	renal	&	prostatic	ca	 29% 
•	 Musculoskeletal	&	skin	cancer	 43% 
•	 Brain	cancer	 75% 
•	 Other	ca	or	unknown	primary	 50% 
•	 non-cancer	 50% 
Risk factors for development  
•	 Age	 (p > 0·05) 
•	 Male gender (p = 0·034) RR 1,35 
•	 Lung cancer (p = 0·003) RR 1·58 
Morita et al8., 
Japan, 2000
Hospital Cancer (various 
tumors)
245 tumor in brain
•	 Present	 21% 
•	 Absent	 9% (p <0·01) 
tumor in lung  
•	 Present	 63% 
•	 Absent	 34% (p < 0·01) 
tumor in bone  
•	 Present	 46% 
•	 Absent	 29% (p < 0·01) 
tumor in liver  
•	 Present	 32% 
•	 Absent	 51% (p<0·01) 
tumor in intestinal tract  
•	 Present	 27% 
•	 Absent	 40% (p <0·05) 
Pautex et al46., 
Switserland, 
1997




•	 Yes	 46% 
•	 No	 30% (p > 0·05) 
Bennett et 
a6l., UK, 1996




96 Duration of stay > 9 days
cerebral malignancy
No correlation with pulmonary 





PCU = palliative care unit; GI = gastrointestinal; RR = relative risk; COPD = chronic obstructive pulmonary 
disease; ADL = activities of daily living.
aNumber of patients in the study on which prevalence was based. bDeath rattle score25: ‘inaudible’ (score 0), 
‘audible only very close to the patient’ (score 1), ‘clearly audible at the end of the bed in a quiet room’ (score 
2) and ‘clearly audible at about 6m or at the door of the room’ (score 3).
cArtificial hydration ≥ 1 l/day. dArtificial hydration < 1 l/day.

chapter 5 
Hydration and symptoms in the 
last days of life





Background. At the end of life oral fluid intake is often reduced. Consensus about the most 
appropriate management for terminally ill patients with limited oral fluid intake is lacking. 
The debate about (artificial) hydration has mostly focused on two distinct symptoms in par-
ticular; death rattle, which has been linked to over-hydration at the end of life, and terminal 
restlessness, which has been linked to under-hydration at the end of life. The aim of this 
study is to investigate to what extent the amount of fluid intake, preceding and during the 
dying phase, is related to the occurrence of death rattle and terminal restlessness.
Methods. We performed a multicentre prospective observational study in eight hospitals 
and five hospices/palliative care units (PCU’s). We collected data on the occurrence of death 
rattle and terminal restlessness, fluid intake and opioid use of patients who were expected 
to die within a few days or hours.
results In total, 371 patients were included (59% of all deaths during the study period). 
Death rattle was reported at least once in 40% (n=149) of patients during the dying phase, 
and in 35% (n=130) of patients during the last 24 hours of life. The prevalence of death rattle 
increased with death coming nearer and was not associated with the amount of fluid intake 
during the days before dying. Terminal restlessness was reported in 26% of patients (n=96) 
during the dying phase and in 13% (n=49) of patients during the last 24 hours of life. Terminal 
restlessness occurred almost evenly throughout the dying phase and was not associated 
with a lower amount of fluid intake during the days before dying. Terminal restlessness 
during the last 24 hours of life was associated with a higher amount of fluid (i.e. > 250ml/
day) during 48-25 hours before death.
conclusions. Caution with fluid intake to prevent development of death rattle does not 
seem to be necessary. Our study suggests that a higher amount of fluid intake during 48-25 
hours before death may be associated with the occurrence of terminal restlessness during 
the last 24 hours of life. Actively providing dying patients with artificial fluid therefore does 
not seem to be beneficial.
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introduction
Most patients with a deteriorating chronic illness have a reduced oral intake at the end 
of life. This may be due to illness- or treatment-related symptoms or complications, such 
as dysphagia, nausea or vomiting, generalized weakness, and, in the last days of life, to a 
decreased level of consciousness or a loss of desire to drink1 2. The evidence that artificial 
hydration (AH) may be beneficial when patients have a reduced oral intake in the last days 
of life is limited and inconclusive3-5. Common arguments against AH are that it may increase 
the risk of complications such as oedema, ascites, and death rattle1 6 7. On the other side, 
the most commonly mentioned benefits of AH are that hydration may alleviate patients’ 
feelings of thirst and reduce the risk of delirium or terminal restlessness1 5 6 8-10. Opinions 
vary on whether or not AH prolongs the dying process1 5 11 12. As a result of these opposing 
arguments, attitudes whether or not AH should be used at the end of life vary among pro-
fessional caregivers5-7 13. Professional caregivers working in palliative care tend to be more 
reserved about the benefits of AH than other professionals: most of them do not believe 
that hydration contributes to the alleviation of symptoms or prolongs survival10 13. Moreover, 
many of them are concerned about the additional burden of AH in the last week of life10 13.
The debate about possible benefits of AH has focused especially on two distinct symp-
toms in particular; death rattle and terminal restlessness. Death rattle due to respiratory 
tract secretion is a common symptom with a prevalence of 35% among dying patients and 
has been linked to over-hydration at the end of life5 14 15. Terminal restlessness, an agitated 
delirium at the end of life, is a common indication for palliative sedation and has been linked 
to under-hydration at the end of life5 7 8 16-18. The aim of this study is to investigate to what 
extent the amount of fluid intake, preceding and during the dying phase, is related to the 
occurrence of death rattle and terminal restlessness. The dying phase is defined as the phase 
when death is expected to occur within hours or days19 20.
method
study design and population
We performed a multicentre prospective observational study in patients, 18 years or older, 
who were, according to the multidisciplinary care team, likely to die within a few days. Data 
were collected in 8 hospitals (one to three wards per hospital) and five hospices, including 
three palliative care units in nursing homes (PCUs), in the Netherlands. Data collection took 
place between November 2012 and November 2013. The study was approved by the Medical 
Ethics Research Committee of the Erasmus MC, University Medical Centre Rotterdam.
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Data collection
Anonymous data were collected using a digital version of the Care Program for the Dying 
(CPD), a Dutch instrument for multidisciplinary care for patients in the dying phase that was 
originally based on the Liverpool Care Pathway for the dying patient21. It was adapted to 
the Dutch language and healthcare system. The CPD is started when the multidisciplinary 
team agrees that the patient is likely to die within a few days and consists of three parts 
in which different data are recorded by nurses and physicians. For this study, the CPD was 
supplemented with questions about death rattle, terminal restlessness, patients’ fluid intake 
and use of opioids. We used the following data from the first part of the CPD, reflecting 
patient characteristics and the patient’s situation at the start of the CPD: diagnosis (cancer, 
non-cancer), gender, date of birth, date and time of the start of the CPD, level of conscious-
ness (conscious, semi-conscious, unconscious) and prevalence of restlessness, confusion and 
respiratory tract secretions. Further, we used data from questions that were added to part 
1, about patients’ opioid use during the last day before the start of the CPD, and their total 
fluid intake (oral, intravenous (IV) and via feeding tube) during the last week and during the 
last day before the start of the CPD. Questions that were added to the second part of the 
CPD, reflecting the patient’s situation from the start of the CPD until death, concerned total 
fluid intake, opioid use, occurrence of death rattle and terminal restlessness, all per 4 hourly 
intervals. From the third part of the CPD, reflecting the situation after the patient’s death, 
we used data about the date and time of the patient’s death and the provision of sedation 
during the dying phase. See the appendix for a detailed description of the variables that 
were used for this study.
Analysis and statistics
Patients were excluded from the study if data were missing on the date and time of the 
start of the CPD, the date and time of death or for more than 6 consecutive measurements 
(CPD, part 2).
Duration of the dying phase was calculated using the start date and time of the CPD and 
the date and time of the patient’s death. Total fluid intake was based on the intake of oral 
fluid, IV fluid as well as fluid intake via a feeding tube. Nurses estimated patient’s oral intake 
during the week before the start of the CPD; during the last day before the start of the CPD, 
and during the dying phase. The fluid intake by different routes was added per period of 
time and scored into 3 categories: 0-499 millilitres (ml) per day, 500-999ml per day, ≥1000ml 
per day for the periods preceding the start of the CPD; and 0-249ml per day, 250-499ml per 
day, ≥500ml per day during the dying phase. Opioid doses were recalculated to the morphine 
equivalent daily dose (MEDD) (mg/d) according to published equianalgesic dose tables22 23: 
oral morphine 60 mg/day = parental morphine 20 mg/day = transdermal/parenteral fentanyl 
25 μg/hour = oral oxycodone 40 mg/day = parental hydromorphone 4 mg/day = transdermal 
buprenorphine 26 μg/ hour.
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In case the dying phase had a duration longer than 48 hours, fluid intake and opioid dose 
during 48-25 hours before death (i.e. the last day preceding the last 24 hours of life) were 
calculated using the 4 hourly consecutive measurements from part 2 of the CPD. In case 
the dying phase had a duration between 24 and 48 hours, fluid intake and opioid dose were 
calculated using data concerning the intake/dose during the last day before the start of the 
CPD and the 4 hourly information from the consecutive measurements from part 2 of the 
CPD. In case the dying phase had a duration shorter than 24 hours, fluid intake and opioid 
dose were based on the data concerning the intake/dose during the last day before the start 
of the CPD (figure 1). Death rattle occurrence was assessed by the attending nurse using the 
scoring scale as proposed by Back et al.24. This scoring scale records the experienced volume 
of death rattle: 0. inaudible; 1. audible only very close to the patient; 2. clearly audible at 












1. Week before the start of the CPD 
2. Day before the start of the CPD 
3. Dying phase  
Three study periods at the end of life (consecutive) 
1. Week before the start of the CPD 
2. Day before the start of the CPD 
3. Dying phase  
Four study periods at the end of life (not consecutive) 
Last 24 hours 
Total study period 
Data 48-25 hours before death based on data from the  
4 hourly measurements from part 2 of the CPD 
Data 48-25 hours before death based on data from the day 
before the start of the CPD & 4 hourly measurements from part 2  
Last 24 hours 
Scenario 1 (n=105 / 28%):  
Duration dying phase > 48 hours 
Scenario 2 (n=104 / 28%) :  
Duration dying phase 24-48 hours 
Last 24 hours 
Data 48-24 hours before death based on data from the 
day before the start of the CPD 
Scenario 3 (n=162/ 44%)):  







Figure 1. Data collection in relation to the moment of dying
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feet/ 10 meter), in a quiet room. In this study a patient was considered to have death rattle 
when there was a score of ≥2 on at least one 4 hourly measurement during the dying phase. 
Terminal restlessness occurrence was assessed by the attending nurse using the calmness 
scale of the Vancouver Interaction and Calmness Scale (VICS)25. The calmness scale consists 
of five items: 1. patient appears calm; 2. patient appears restless; 3. patient appears dis-
tressed; 4. patient is moving around uneasily in bed; 5. patient is pulling at lines/tubes. Each 
item is scored on a 6-point Likert-scale (strongly agree, agree, mildly agree, mildly disagree, 
disagree, strongly disagree). In this study, a patient was considered to experience terminal 
restless when, focusing on statements 2-5, two statements were scored with ‘strongly agree’ 
or ‘agree’ on at least one 4 hourly measurement, or when at least one statement was scored 
with ‘strongly agree’ or ‘agree’ on at least two consecutive measurements.
Associations between the occurrence of symptoms and patients’ fluid intake (i.e. during 
the week and day before the start of the CPD and during 48-25 hours before death) and 
other characteristics, including patients’ gender, age at death, diagnosis, place of death, 
duration of the dying phase, level of consciousness at the recognition of the dying phase 
and opioid use (i.e. during the day before the start of the CPD and during 48-25 hours 
before death) were analysed using Chi-Square or Mann-Whitney tests, where appropriate. 
All analyses were performed using SPSS for Windows version 22.0 (SPSS, Inc. Chicago, IL).
results
Patient characteristics
During the study period 631 patients died in the participating care settings. The CPD was 
initiated for 476 patients (75% of all deaths), 371 of whom were included in this study (59% 
of all deaths). One hundred and five patients could not be included; 49 due to missing data 
about the date and time of the start of the CPD and/or death and 56 due to missing data for 
more than 6 consecutive 4 hourly measurements (part 2 of the CPD).
The included patients had a mean age of 72 years, almost half of them were male and 79% 
had been diagnosed with cancer (table 1). Forty-four percent of patients died in the hospital, 
56% in the hospice. The median duration of the dying phase was 25 hours for all patients, 23 
hours for patients dying in a hospital and 29 hours for patients dying in a hospice. Twenty-
eight percent of patients had a duration of the dying phase longer than 48 hours, 28% had 
a duration between 24-48 hours and 44% had a duration shorter than 24 hours. At the start 
of the CPD, 22% of the patients were unconscious, 36% were restless, 24% were confused 
and 19% presented with respiratory tract secretions. Seventy-six percent of the patients 
used opioids during the last day before the start of the CDP and 93% during the dying phase.
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Duration of the dying phase (hours: median, range) 25, 0-279
symptoms at the start of the cPD
Level of consciousness
Conscious 112 (30%)




Respiratory tract secretions 68 (19%)
treatment
Opioid use during the last day before the start of the CPD 282 (76%)
Morphine equivalent daily dose (mg/24h) (median, range) 75 (2-4200)
Opioid use during the dying phase 345 (93%)
Morphine equivalent daily dose (mg/24h) (median, range) 108 (0-10790)
Use of palliative sedation during the dying phase 162 (44%)
Fluid intake
Total daily fluid intake last week before start of the CPD (ml) (median, range) 625 (125-3375)
0-499ml per day 74 (22%)
500-999ml per day 117 (35%)
≥1000ml per day 144 (43%)
Total daily fluid intake last day before start of the CPD (ml) (median, range) 625 (125-2875)
0-499ml per day 187 (55%)
500-999ml per day 70 (21%)
≥1000ml per day 81 (24%)
Total daily fluid intake during the dying phase (ml) (median, range) 250 (6-2250)
0-249ml per day 257 (69%)
250-499ml per day 61 (16%)
≥500ml per day 53 (15%)
Total daily fluid intake 48-25 hours before death (ml) (median, range) 334 (42-2500)
0-249ml per day 190 (51%)
250-499ml per day 44 (12%)
≥500ml per day 121 (33%)
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Fluid intake
Patients’ total fluid intake decreased during the last phase of life (table 1). During the week 
before the start of the CPD, 78% of patients had a total fluid intake of ≥ 500 ml/day, which 
decreased to 45% of patients during the last day before the start of the CPD and 15% during 
the dying phase. Fluid intake mainly involved oral intake, which decreased during the last 
days of life. During the week before the start of the CPD, 81% of patients had an oral intake 
of fluid, which decreased to 69% of patients during the last day before the start of the CPD 
table 2. Detailed information concerning fluid intake during the last period of life
Total (n=371) Hospital (n=164) Hospice (n=207)
Week before the start of the cPD
Orally
N (%) Yes 302 (81%) 121 (74%) 181 (87%)
median-range 625ml (125-1000ml) 625ml (125-1000ml) 625ml (125-1000ml)
IV
N (%) Yes 90 (24%) 85 (52%) 5 (2%)
median-range 1250ml (250-1500mlL) 1250ml (250-1500mlL) 750ml (750-750ml)
Tube
N (%) Yes 23 (6%) 18 (11%) 5 (2%)
median-range 750ml (250-1500ml) 750ml (250-1500ml) 750ml (250-1500ml)
Day before the start of the cPD
Orally
N (%) Yes 255 (69%) 106 (65%) 149 (72%)
median-range 125ml (125-1000ml) 625ml (125-1000ml) 125ml (125-1000ml )
IV
N (%) Yes 94 (25%) 90 (55% ) 4 (2%)
median-range 750ml (250-1500ml) 750ml (250-1500ml) 750ml (250-750ml)
Tube
N (%) Yes 19 (5%) 17 (10%) 2 (1%)
median-range 750ml (250-1500ml) 750ml (250-1500ml) 500ml (250-750ml)
During the dying phase
Orally
N (%) Yes 152 (41%) 66 (40% ) 86 (42%)
median-range 250ml (25-1650ml) 250ml (25-1650ml) 220ml (27-1038m)
IV
N (%) Yes 125 (34%) 121 (74%) 4 (2%)
median-range 179ml (6-1500ml) 179ml (6-1500ml) 297ml (31-719ml)
Tube
N (%) Yes 12 (3%) 9 (6% ) 3 (1%)
median-range 21ml (4-107ml) 31ml (5-107ml) 9ml (4-11ml)
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and 41% during the dying phase. Twenty-four percent of patients had IV hydration during 
the week before the start of the CPD, 25% during the last day before the start and 34% dur-
ing the dying phase. IV hydration was predominantly prescribed in the hospital. Intake via a 
feeding tube involved 6% of patients during the week before the start of the CPD, 5% during 
the last day before the dying phase, and 3% during the dying phase. Detailed information 
concerning fl uid intake per care setting is described in table 2.
Prevalence of death rattle and terminal restlessness
Figure 1 shows the percentages of patients with death rattle or terminal restlessness per 
period of 4 hours before death. Overall, death rattle was reported at least once in 40% 
(n=149) of patients during the dying phase, and in 35% (n=130) of patients during the last 24 
hours of life. Death rattle scores of ≥2 were often reported more than once; 62% of patients 
with death rattle had 2 or more death rattle scores of ≥2 and 35% of these patients had 3 or 
more of such episodes. The prevalence of death rattle increased with death coming nearer. 
Terminal restlessness was reported at least once in 26% of patients (n=96) during the dying 
phase and in 13% (n=49) of patients during the last 24 hours of life. For most patients with 
terminal restlessness (61%), terminal restlessness was only reported once; 19% had terminal 
restlessness at ≥3 measurements. Terminal restlessness occurred almost evenly throughout 
the dying phase.
 
Figure 2. Percentage of patients with death rattle or terminal restlessness score per four-hourly measurement 
during the last 72 hours of life 
Figure 2. Percentage of patients with death rattle or terminal restlessness score per four-hourly measurement 
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Associations between death rattle or terminal restlessness with fluid intake and 
other patient characteristics
No significant association between death rattle and the amount of fluid intake was found 
(Table 3). A higher amount of fluid intake during the week and day before the start of the 
CPD tended to be associated with an increased occurrence of death rattle. Terminal restless-
ness was not associated with a lower amount of fluid intake during the days before dying. 
Terminal restlessness during the last 24 hours of life was statistically significant associated 
with a higher amount of fluid during the time period 48-25 hours before death (p=0.049). 
Patients’ level of consciousness at the start of the dying phase and the duration of the dying 
phase were also associated with terminal restlessness. Being conscious or semi-conscious at 
the start of the dying phase was associated with a higher occurrence of terminal restlessness 
during the dying phase (p=0.004). A longer duration of the dying phase was also associated 
with a higher occurrence of terminal restlessness (p=0.003).
discussion
We found no significant association between the amount of fluid intake and the occurrence 
of death rattle. We did not find an association between a lower amount of fluid intake 
and terminal restlessness either. Terminal restlessness during the last 24 hours of life was 
however associated with a higher amount of fluid intake during the time period 48-25 hours 
before death.
Three previous studies have assessed death rattle occurrence and its association with AH7 
9 14. Morita et al.14 performed a multicentre, prospective, observational study of patients 
dying from cancer. Patients were divided in two groups: those who received 1 liter or more 
of AH per day both 1 week and 3 weeks before death (hydration group n=59) and those who 
did not (non-hydration group n = 167). During the last 3 weeks of life, 44% of patients in the 
hydration group and 46% of patients in the non-hydration group were recorded as present-
ing with death rattle (p=0.79). Yamaguchi et al.9 also performed a prospective observational 
study of patients dying from cancer. A comparison was made between patients who received 
more than 1liter of AH a day (large-volume hydration group n=76) and patients who received 
less than 1 liter a day (small-volume hydration group n=75). However, this classification was 
made on the basis of their intake of AH at inclusion in the study, not taking into account any 
change in fluid intake closer to death. In total, 43% of patients were recorded as presenting 
with death rattle during 48 hours before death, 51% in the large-volume group and 35% in the 
small-volume group (p=0.07). Fritzson et al.7 performed a medical record review in which he 
studied patients who died in hospital and compared patients who had received parenteral 
fluid (PF group) to matched control patients who had not received parenteral fluid (non-PF 
group). During the last week of life 60% of all patients presented with death rattle, 63% in 
the PF group and 50% in the non-PF group (p=0.07). During the last 24 hours of life 46% of 
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all patients presented with death rattle, 50% in the PF group and 33% in the non-PF-group 
(p=0.02). Morita14 and Fritzson7 both reported on an AH intake of 1liter during the last 24 
hours before death, not taking into account any oral intake. These intakes of AH are high 
compared to the median fluid intake in our study; 334 ml during the day preceding the last 
24 hours.
We did not find an association between a lower amount of fluid intake during the days 
before dying and the occurrence of terminal restlessness. Terminal restlessness during the 
last 24 hours of life was however associated with a higher amount of fluid during the time 
period 48-25 hours before death. Previous studies on the relation between fluid intake and 
occurrence of terminal restlessness or delirium showed diverse results. Morita et al.14 failed 
to show a difference in delirium occurrence between hydrated and non-hydrated patients 
with a prevalence of 12% in the hydration group and 13% in the non-hydration group (= 
0.80). Bruera et al.11 performed a randomized controlled trial in 129 patients with advanced 
cancer. Patients were divided in two groups: those who received 1 liter of AH per day for the 
duration of a week (hydration group), and those who received 110 ml of AH per day (placebo 
group). No differences were found between the two groups in the occurrence of delirium. 
Yamaguchi et al.9 found a higher occurrence of delirium in patients who received less than 
1 liter of fluid a day compared to patients who received more than 1 liter (17% vs 5%, p=0.01) 
and proposed hydration as an intervention to treat delirium. Our finding of an association 
between more fluid intake and more terminal restlessness is in line with the study by Fritszon 
et al.7 who also found a higher occurrence of terminal restlessness in patients receiving AH 
during the last 24 hours of life as compared to patients without AH.
This study has some limitations. Firstly, the optimal design to study the effects of fluid in-
take would be a randomized controlled trial, which would however pose ethical challenges. 
We conducted a prospective observational study to explore variations in fluid intake in daily 
practice. Secondly, the patient’s oral intake was based on nurses’ estimation. It would have 
been more reliable if we had used a fluid balance measure. However a fluid balance measure 
would lead to medicalizing the dying phase and is therefore not a common practice at the 
end of life. Thirdly, at the start of this study no instrument to measure terminal restlessness 
was available. Because of the close connection between restlessness and calmness, we 
decided to use the calmness scale of the Vancouver Interaction and Calmness Scale. We did 
not use any other instrument to validate the calmness scale and it is possible that patients 
were misclassified. However, the prevalence reported in this study is in line with other stud-
ies focusing on terminal restlessness and delirium at the end of life. Fourthly, we collected 
information on fluid intake at three moments in time; the week before the start of the CPD, 
the day before the start of the CPD and, 4 hourly, during the dying phase. Information on 
symptom occurrence was measured, 4 hourly, during the dying phase. Relating the total 
fluid intake during the dying phase to symptom occurrence during the dying phase could 
mean relating a symptom occurring at the start of the dying phase to an average level of 
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fluid intake based on the entire dying phase. Therefore we calculated a separate variable 
concerning the fluid intake during the time period 48-25 hours before death. Whereas ter-
minal restlessness occurred almost evenly throughout the dying phase and often only once, 
it is possible that patients in the non-symptom group during the last 24 hours of life actually 
presented with terminal restlessness before the last 24 hours of life but were successfully 
treated (i.e. sedated). We found no evidence that patients with terminal restlessness were 
more often sedated compared to patients who were not terminal restless (p=0.23, not in 
table). Fifthly, the high percentage of missings for the measurement period 4-0 hours before 
death could mean that we over- or underestimated the occurrence of death rattle and ter-
minal restlessness during that 4 hourly period. From daily practice we know that completing 
the measurement for this time period is often forgotten by nurses because completion is 
required after the patient has died. However, the terminal restlessness percentage is in line 
with what we would expect based on the other measurements and daily practice. Looking 
at the increase in death rattle occurrence during the 4 previous measurements, it is pos-
sible that the actual percentage for death rattle would have been higher. Consensus about 
the natural course of death rattle, whether it increases or decreases closer to death, is still 
lacking. Kass and Ellershaw suggest that the prevalence of death rattle typically increases 
when death approaches26. Yet, Heisler et al.27 performed a placebo controlled trial and 
found an decrease of death rattle scores over time in the placebo group. Sixthly, we did 
not make a distinction between types of opioids and added up opioids with different opioid 
metabolisms. It is possible that by combining opioids we lost the ability to show associations 
between specific opioid use and occurrence of symptoms on the one hand and/or specific 
opioid use and level of hydration of the other hand.
In conclusion, we found that a higher amount of fluid intake (i.e. possible over-hydration), 
preceding and during the dying phase, was not associated with the occurrence of death 
rattle. Further, a lower amount of fluid intake (i.e. possible under-hydration), preceding and 
during the dying phase, was not associated with the occurrence of terminal restlessness. 
Caution with fluid intake to prevent development of death rattle does not seem to be neces-
sary. Our study suggests that a higher amount of fluid intake during the period 48-25 hours 
before death may be related to occurrence of terminal restlessness during the last 24 hours 
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Appendix
Variables used in this study









Questions added to part 1 of the CPD specifically for this study
•	 Has	the	patient	used	opioids	in	the	last	24	hours?	(yes/no)
 o  Indicate route (transdermal, oral, rectal, oral, nasal), type (morphine,…) and the total 
dose during the past 24 hours
•	 Total	fluid	intake	during	the	week	preceding	the	recognition	of	the	dying	phase
 o Oral intake (1 cup is approximately 250 ml)
 o None
 o Sibs
 o Between 1-4 cups/ day
 o More than 4 cups/ day
•	 Intravenous	infusion
 o None
 o Less than 0,5 l/day
 o 0,5-1 l/day
 o 1-1,5 l/day
 o 1,5 l/day and more
•	 Feeding	tube
 o None
 o Less than 0,5 l/day
 o 0,5-1 l/day
 o 1-1,5 l/day
 o 1,5 l/day and more
•	 Total	fluid	intake	during	the	last	24	hours	preceding	the	recognition	of	the	dying	phase
 o Oral intake (1 cup is approximately 250 ml)
 o None
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 o Sibs
 o Between 1-4 cups/ day
 o More than 4 cups/ day
•	 Intravenous	infusion
 o None
 o Less than 0,5 l/day
 o 0,5-1 l/day
 o 1-1,5 l/day
 o 1,5 l/day and more
•	 Feeding	tube
 o None
 o Less than 0,5 l/day
 o 0,5-1 l/day
 o 1-1,5 l/day
 o 1,5 l/day and more
Part 2 of the CPD, reflecting the patient’s situation from the start of the dying phase until 
death
Questions added to part 2 of the CPD specifically for this study
•	 Total	fluid	intake,	per	four	hourly	intervals,	until	death
 o Oral intake (1 cup is approximately 250 ml)
  ► None
  ► Sibs
  ► 1 cup
  ► More than 1 cup
 o Intravenous infusion
  ► None
  ► Less than 0,5 l/day
  ► 0,5-1 l/day
  ► 1-1,5 l/day
  ► 1,5 l/day and more
 o Feeding tube
  ► None
  ► Less than 0,5 l/day
  ► 0,5-1 l/day
  ► 1-1,5 l/day
  ► 1,5 l/day and more
•	 Has	the	patient	used	opioids	in	the	last	4	hours?	(yes/no)
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 o  Indicate route (transdermal, oral, rectal, oral, nasal), type (morphine,…) and the total 
dose during the past 24 hours
•	 Has	the	patient	had	death	rattle	in	the	last	4	hours?	(yes/no)
 o 0, inaudible
 o 1, audible only very close to the patient
 o 2, clearly audible at the end of the bed, in a quiet room
 o 3, clearly audible at the door of the room (about 20 feet / 10 meter), in a quiet room.
•	 Please	 indicate	 to	what	 extend	 you	 agree	 (strongly	 agree,	 agree,	mildly	 agree,	mildly	
disagree, disagree, strongly disagree) with the following statements
 o 1, patient appears calm
 o 2, patient appears restless
 o 3, patient appears distressed
 o 4, patient is moving around uneasily in bed
 o 5, patient is pulling at lines/tubes.
Part 3 of the CPD, reflecting the situation after death
•	 Date	and	time	of	death




Awareness of dying: it needs words
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AbstrAct
Purpose. The purpose of this research is to study to what extent dying patients are aware of 
the imminence of death, whether such awareness is associated with patient characteristics, 
symptoms and acceptance of dying, and whether medical records and nurses’ and family 
caregivers’ views on patients’ awareness of dying agree.
Methods. Nurses and family caregivers of 475 deceased patients from three different care 
settings in the southwest Netherlands were requested to fill out questionnaires. The two 
groups were asked whether a patient had been aware of the imminence of death. Also, 
medical records were screened for statements indicating that the patient had been informed 
of the imminence of death.
results. Nurses completed questionnaires about 472 patients, family caregivers about 280 
patients (response 59%). According to the medical records, 51% of patients had been aware 
of the imminence of death; according to nurses, 58%; according to family caregivers, 62%. 
Patients who, according to their family caregiver, had been aware of the imminence of 
death were significantly more often in peace with dying and felt more often that life had 
been worth living. Inter-rater agreement on patients’ awareness of dying was fair (Cohen’s 
Kappa= 0,23-0,31).
conclusions. Being aware of dying is associated with acceptance of dying, which supports 
the idea that open communication in the dying phase can contribute to the quality of the 
dying process. However, views on whether or not patients are aware of the imminence of 
death diverge between different caregivers. This suggests that communication in the dying 
phase of patients is open for improvement.
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introduction
Being aware that death is imminent is often seen as one of the features of a good death 
in modern Western culture1-4. However, until the early 1970’s the issue of death was rarely 
open for discussion in healthcare3 5. Not confronting terminally ill patients openly with their 
upcoming death was a generally accepted code of conduct for physicians. Physicians were 
encouraged to give patients hope on a serious chance of recovery. The belief within the 
medical world was that dashing someone’s hope for recovery implied heavy emotional bur-
den and therefore could lead to an unbearable end. Nowadays, in modern Western society 
this view is no longer commonly present. In accordance with currently often mentioned 
attributes of a good death6, communication and openness about the situation of a patient 
who is approaching death is increasingly seen as preferable3. But even in this age, which is 
characterized by an emphasis on “informed consent” and “open communication”, the course 
of a disease and its fatal conclusion are not always communicated explicitly by physicians7. 
Furthermore, there seems to be a relation between hope and the extent to which people are 
aware of the prognosis that they are going to die soon. McGrath suggests that the challenge 
of accepting the reality of a terminal diagnosis is so emotionally difficult that patients often 
oscillate between acceptance and hopeful denial8. It can be questioned to what extent this 
also holds for the dying phase, when death is expected within hours or days.
Awareness that a patient’s death is imminent allows healthcare professionals to appropri-
ately reset the goals of care to prevent possible harmful decisions. A prerequisite for such a 
reset is adequate communication. When there is shared agreement among members of the 
healthcare team that a patient is dying, the process of decision making can be better coordi-
nated9. This is confirmed by a study on whether recognition of the dying phase had impact 
on the number of medical interventions. That study showed that patients with a recognized 
dying phase received significantly less diagnostic interventions as compared to patients in 
whom the dying phase was not recognized10. Several instruments to support and promote 
clear communication around the dying and death of the patient have been developed, such 
as the Liverpool Care Pathway for the dying patient (LCP) 11-13. Open awareness of the onset 
of the dying phase among physicians, nurses, and patients and their family caregivers is an 
important element of the LCP10 14 15.
In this study we define the concept of awareness of dying as knowing that death is immi-
nent within hours or days. This definition is in concordance with the definition of the dying 
phase by Ellershaw and Ward12 which states that the dying phase means having only hours 
or days to live. We studied to what extent dying patients are aware of the imminence of 
death and whether such awareness is associated with patient characteristics, use of the LCP, 
symptoms and acceptance of dying (also defined as a central element of a good death3). In 
addition we investigated the level of agreement on patients’ awareness of dying between 




We performed a secondary analysis of data that were collected in the context of an interven-
tion study that investigated the effect of using the LCP on the care and quality of life during 
the last 3 days of life of 475 patients16-19. Data collection took place between November 2003 
and February 2006. Halfway this period, the LCP was introduced and subsequently used for 
each patient for whom the multidisciplinary team agreed that the dying phase had started.
For this study, patients were recruited from hospitals, nursing homes and home care ser-
vices in the southwest of the Netherlands19. Patients aged 18 years or older were included 
when they had died during the study period in either one of these institutions. The Medical 
Ethical Research Committee of the Erasmus MC approved the study.
About 2 months after the death of a patient, a relative, who had been ‘contact person’ 
for the patient, received a letter from the institution that had provided terminal care. In 
this letter, he/she was asked for consent to be approached by the research team to fill 
in a written questionnaire. A reminder was sent to nonresponding relatives after 2 and 6 
weeks, respectively. Only relatives who gave their consent were mailed a questionnaire. 
Within 1 week after the death of an eligible patient, a nurse who had been closely involved 
with caring for the patient during the last 3 days of life completed a questionnaire. In total, 
472 nurses (response 99%) participated. Of the relatives, 280 consented and completed a 
questionnaire (response 59%).
Data collection
Within each institution, a member of the care team (mostly a nurse) collected data on age, 
gender, diagnosis, use of LCP and place of dying, from the medical and nursing records. 
A question related to whether a patient had been aware of the imminence of death was 
included in the nurses’ and family caregivers’ questionnaires. Nurses were asked whether 
the patient had been informed about the onset of the dying phase (‘yes’, ‘more or less’, ‘no’). 
Family caregivers were asked whether, during the last 3 days of life, it had been clear to the 
patient that he/she would die within a couple of days (‘yes’, ‘more or less’, ‘no’, ‘unknown’). 
For the purpose of this study, ’yes’ and ‘more or less’ were combined to represent ‘yes’. 
In addition, medical records were screened for information indicating whether or not the 
patient was aware of the dying phase (‘yes’, ‘no’).
From the family caregivers’ questionnaires, we also used a question concerning the con-
sciousness of the patient 72 hours before death, a question about whether the patient was 
in peace with dying and a question about the relationship of the family caregiver with the 
patient. Nurses were asked if they had the impression that patients during the last 3 days of 
their lives had felt that life had been worth living. Nurses were also asked to assess the pres-
ence of 28 symptoms during the last 3 days of life. Questions about 16 symptoms (shortness 
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of breath, pain, fatigue, lack of appetite, need of rest, trouble sleeping, weakness, nausea, 
vomiting, constipation, diarrhoea, difficulty concentrating, tenseness, worrying, depressed 
mood and difficulty remembering) originated from the EORTC QLQ-C30 questionnaire20. 
Questions about the remaining 12 symptoms were added to the questionnaire (mouth prob-
lems/dysphagia, coughing, agitation, troublesome mucus production, poor vision, restless-
ness, involuntary movements, itching, incontinence, pressure ulcers, confusion and anxiety), 
because these symptoms are common in the last phase of life14 21-24. All questions concerning 
symptoms were scored on a 4-point Likert scale. Answer options were: ‘not at all’, ‘a little’, 
quite a bit’ or ‘very much’. For the purpose of this study, these answers were recoded: ‘quite 
a bit’ and ‘very much’ were added up to represent ‘symptom present’, ‘not at all’ and ‘a little’ 
were added up to represent ‘symptom not present’.
Analysis and statistics
Associations between awareness of dying and 4 patient characteristics (diagnosis, age, 
gender, place of dying), use of LCP, 2 aspects of acceptance of dying (peace with dying, life 
worth living) and the 28 symptoms were statistically tested, using Chi-square tests. Family 
caregivers’ rating whether a patient was aware of the imminence of death was used as refer-
ence in these analyses. Patients were excluded from these analyses when they had been 
unconscious during the last 72 h before dying. The agreement on patients’ awareness of 
dying between medical record, nurse and family caregiver was determined for each pair (i.e. 
medical record-nurse, medical record-family caregiver, nurse-family caregiver) by calculating 
Cohen’s Kappa’s. These scores were interpreted using the Landis and Koch criteria where 
kappa values are associated with the following levels of agreement: <0.00 = poor, 0.00 to 
0.20 = slight; 0.21 to 0.40 = fair; 0.41 to 0.60 = moderate; 0.61 to 0.80 = substantial; 0.81 to 
1.00 = almost perfect25. The significance level was set at 5%. For the analysis of the data, we 
used SPSS version 17.0.
results
Patients were on average 76 years old (range 34-100) at the time of death (Table 1). The 
majority (71%) had cancer as their primary diagnosis. A small majority of the patients were 
female. Of all patients 42% died in hospital, 24% in a nursing home and 29% at home. Ac-
cording to the medical records, 52% of all patients had been aware of the imminence of 
death, according to nurses 58% and according to family caregivers 62%. The LCP, introduced 
halfway during the study period, was used in a third of all patients. Patients were reported to 
have had an average of 8 different symptoms (interval, 0-20). Symptoms most prevalent dur-
ing the last three days of life were related to lack of energy (need of rest, fatigue, weakness 
74-85%), lack of appetite (73%), difficulty concentrating (47%) and shortness of breath (44%).
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table 1. characteristics of patients (N=280)
Characteristic
Age category N %
≤75 years 128 46








At home 82 29




According to the medical record patient was aware 145 52
According to nurse patient was aware 163 58
According to family-caregiver patient was aware 173 62




Other family 28 10




Symptom prevalence during the last 3 days of life N1/ N2 %
In need of rest 224 / 265 85
Fatigue 215 / 264 81
Weakness 195 / 263 74
Lack of appetite 191 / 263 73
Difficulty concentrating 118 / 251 47
Shortness of breath 116 / 266 44
Incontinence 110 / 266 41
Pain 106 / 271 39
Mouth problems / dysphagia 77 / 207 37
Restlessness 100 / 269 37
Worrying 86 / 250 34
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Different variables were assessed on their association with awareness of dying. Of four 
patient characteristics tested, only place of dying was significantly associated with aware-
ness of dying (p= 0.012) (Table 2). Of patients dying at home, 83% were aware of the im-
minence of death, compared to 68% of patients dying in a hospital and 62% of patients dying 
in a nursing home.
Patients who were aware of the imminence of death were more often in peace with 
dying (p= 0.000) and felt more often that life had been worth living (p= 0.009), compared to 
patients who were not aware (Table 3). No clear association between symptoms and aware-
ness was found, except for two symptoms. Patients aware of dying more often experienced 
a lack of appetite (p= 0.049) and less often experienced tenseness (p= 0.014) compared to 
patients not aware of dying (not in table).
The percentage of patients that, according to the family caregivers, had been aware of 
the imminence of death was stable before and after introduction of the LCP (63% before, 
62% after, p = 0.474). For nurses, the percentage of patients that they thought had been 
aware of the imminence of death was 54% before and 62% after introduction (p =0.143). The 
percentage of patients for whom a statement was found in the medical record indicating 
that he or she was aware of the dying phase was 38% before and 64% after the introduction 
of the LCP (p = 0.000) (not in table). The level of agreement, as assessed by Cohen’s kappa, 
table 1. characteristics of patients (N=280) (continued)
Characteristic
Difficulty remembering 83 / 253 33
Tenseness 68 / 252 27
Troublesome mucus 73 / 271 27
Confusion 68 / 263 26
Anxiety 67 / 260 26
Trouble sleeping 64 / 266 24
Depressed mood 58 / 247 23
Poor vision 45 / 252 18
Coughing 37 / 214 17
Involuntary movements 43 / 268 16
Nausea 41 / 266 15
Constipation 38 / 261 15
Pressure ulcers 36 / 270 13
Vomiting 29 / 267 11
Agitation 25 / 256 10
Diarrhoea 23 / 261 9
Itching 12 / 265 5
N1 number of patients in whom the symptom was present, N2 number of patients for whom the nurse an-
swered the item
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on whether or not the patient had been aware of the imminence of death, was 0.23 for 
the medical records and family caregivers, 0.28 for nurses and caregivers, and 0.31 for the 
medical records and nurses (table 4). The inter-rater agreement was not related to patient 
characteristics, such as age, gender, diagnosis, use of the LCP or place of death (not in table).
discussion
According to the medical records, nurses and caregivers, 51% to 62% of patients had been 
aware of the imminence of death in the last days of life. Patients dying at home were more 
often aware of the imminence of death compared to patients who died in a hospital or in a 
nursing home. Whether a patient was aware of dying was not clearly associated with symp-
toms. Finally, awareness turned out to be associated with acceptance of dying; patients who 
were aware of the imminence of death were more often in peace with dying and felt more 
often that life had been worth living than patients who were not aware.
In 1965, Glaser and Strauss described four categories of ‘awareness of dying’, used for 
deaths expected within hours, days, weeks or months of a patient’s life. These categories 
table 2. Patients’ characteristics and awareness of the imminence of death (n=213a)
Patient aware of the imminence of death b P-value c
Yes No
Diagnosis
Cancer (n=134) 72% 28% 0.477
Non-cancer (n=43) 70% 30%
Age
≤75 years (n=82) 72% 28% 0.560
>75 years (n=103) 72% 28%
Gender
Male (n=87) 69% 31% 0.328
Female (n=100) 73% 27%
Place of dying
At home (n=53) 83% 17% 0.012
Nursing home (n=87) 62% 38%
Hospital (n=38) 68% 32%
Elsewhere (n=9) 100% 0%
a Excluding unconscious patients (n=67)
b Excluding patients for whom awareness was unknown (N=25)/ missing (n=1)
c Chi square test
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ranged from closed awareness (the patient does not recognize his impending death even 
though everyone else does) through suspicion awareness (the patient suspects what the oth-
ers know and therefore attempts to confirm of invalidate his suspicion) and mutual pretence 
(each party defines the patient as dying, but each pretends that the other has not done so’) 
to open awareness (caregivers and patient both are aware that the patient is dying, and act 
on this awareness relatively openly)26. In 1997 Seale et al.27 argued that ‘a preference for 
open awareness of dying is now well established in terminal care settings and amongst the 
general population in the UK, USA and other Anglophone countries’. It is plausible that this 
is also true for the Netherlands. However, the percentage of cases in our study in which 
dying patients were openly aware of the imminence of death within days was only 51-62%, 
depending on whether it was assessed through the medical record, the nurse or a family 
member.
Studies on awareness of dying and its determinants are scarce2 7 27. The fact that over 
one third of patients was not considered being aware of the imminence of death probably 
reflects, at least partly, the difficulty of diagnosing dying, even in settings where death is a 
relatively common event. The natural course of a lethal disease is typically not a straightfor-
ward matter of steady or stepwise decline from diagnosis to death. Consequently it can be 
difficult to distinguish a decline in the patient’s condition due to an acute reversible problem, 
from a decline due to the progression of a life-limiting illness towards death9. This seems 
to be even more complex for non-malignant diseases, because these often have ‘entry–re-
entry’ death trajectories, involving episodic, acute exacerbations, frequent hospitalisation, 
stabilisation and subsequent further decline, making determination of the end of life phase 
more problematic28 29. Our analyses however did not reveal a relation between awareness of 
dying and malignant or non-malignant diseases. Previous research has also shown that prog-
nostication at the end of life is difficult, although predictions become more accurate when 
table 3. Awareness of the imminence of death and acceptance of dying (n=213a)
Patient aware of the imminence of death b
P-value c
Yes No
N % N %
118 36
Patient in peace with dying Yes 85 56 0.000
No 15 44
120 44
During the last 3 days,
patient felt that life had been 
worth living
Yes 72 50 0.009
No 28 50
a Excluding unconscious patients (n=67)
b Excluding patients for whom awareness was unknown (N=25)/ missing (n=1)
c Chi square test
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patients are closer to death, a finding which has been referred to as the ‘horizon effect’30-32. 
The finding that age and gender were not associated with awareness of dying is in agree-
ment with a study by Seale et al27. In Seale’s study awareness of dying was more common 
among younger family caregivers and among patients who died from non-cancer diseases. 
Comparisons were however limited to patients in ‘full open awareness’ (where there is not 
only knowledge of dying, but also a value commitment towards openness) and patients in 
‘closed awareness’, leaving all possible other types of awareness and a large proportion of 
patients in more limited types of open awareness, out of the analyses. This could perhaps 
explain why in our study we did not find this same association. Our finding that patients 
dying at home were more often aware of the imminence of death than patients dying in a 
hospital or nursing home is probably related to the selection of patients who die in these 
settings. Severely ill patients in the Netherlands are often admitted to the hospital with the 
aim of addressing complications or relieving complex symptoms, in the expectation that 
they will be discharged to go home. Additionally, in the nursing home, a higher percentage 
of patients with dementia probably resulted in a lower percentage of patients being aware 
of dying. Our finding is consistent with previous research by Seale et al.27 who also found 
higher frequencies of awareness of dying among patients dying at home. They hypothesise 
that patients who are aware of their imminent death have a greater tendency to control the 
circumstances of death, including their place of death. Patients who were aware of the im-
minence of death were, compared to patients who were not aware, significantly more often 
in peace with dying and felt more often that life had been worth living. Whether awareness 
of dying leads to acceptance of dying or acceptance leads to awareness remains unclear.
table 4. Patients’ awareness of the imminence of death: Inter-rater agreement between medical records, 
nurses and family caregivers (n=250a)
Medical record Nurse Caregiver
rating of awareness
Was the patient aware that he 
was going to die?
Yes No Missing Yes No Missing Yes No Missing Unknown
51% 21% 28% 58% 33% 9% 62% 25% 1% 12%
inter-rater agreement
Medical record and Nurse K = 0.31b
Medical record and Caregiver K = 0.23c
Nurse and Caregiver K = 0.28b
Interpretation of Cohen’s Kappa; Poor agreement ≤0,00, Slight agreement 0,00-0,20, Fair agreement 0,21-
0,40,
Moderate agreement 0,41-0,60, Substantial agreement 0,61-0,80, Almost perfect agreement 0,81-1,025
a Excluding patients for where not all three sources answered this question (n=30)
b p=0,000
c p=0,003
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The medical record and nurses’ and family caregivers’ perspectives on whether or not 
patients had been aware of the imminence of death differed in a substantial number of 
cases. Deviating perspectives on awareness of dying were also found by Rich et al.33 in a 
study concerning the experiences of medical staff and family of deceased patients. These 
authors also found only fair agreement between medical staff and family on the question 
‘did you know that death was imminent’? Apparently, communication between physician, 
nurses and family in the dying phase is not optimal in a substantial number of cases. The 
percentage of cases in which, according to the medical record, the patient had been aware 
increased significantly after the introduction of the LCP. However, the agreement between 
the three groups did not increase accordingly. Although use of the LCP seems to improve 
the knowledge of physicians and nurses about patients’ awareness of dying, the alignment 
between all parties involved is not optimal. The use of the LCP in this study was limited 
to a particular period and physicians and nurses were new in using this instrument. More 
extended use of the instrument may lead to more communication and mutual knowledge 
about patients in the dying phase.
Our study had some limitations. Firstly, all data were collected after the death of a 
patient. It was therefore not possible to obtain information from the patient. In addition, 
family caregivers and nurses provided information retrospectively and a certain degree 
of recall bias can therefore not be precluded. Secondly, the cross-sectional design of the 
study makes inferences about causality not possible. Finally, our study population is not 
completely representative for the Dutch population. In our study the mean age of death was 
lower (76) than in the Dutch population (80)34 and the proportion of cancer patients (71%) 
was higher than the proportion of cancer deaths in the Dutch population (30%)35. Moreover, 
the place of dying of the patients in this study was not fully comparable with the distribution 
in the Netherlands. In our study the distribution was, 29% of patients dying at home, 24% in 
a nursing home and 42% in a hospital, compared to the distribution in the Dutch population 
which is 38%, 23% and 33%36.
In conclusion, our finding that being aware of the imminence of death is associated with 
acceptance of dying supports the idea that open communication in the dying phase between 
physicians, nurses, patients and family caregivers can contribute to the quality of the dying 
process. Communication about all potentially relevant aspects of the situation of a patient 
in the dying phase is a requirement for adequate patient-centred care and also an important 
focus of the LCP. Findings of the current study suggest that the communication in the dying 
phase of patients is not yet optimal and open for improvement. The most suitable time and 
strategy to enhance open communication about the dying phase cannot be concluded from 
our data, and should be a topic in future research.
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AbstrAct
Background. Clinical nursing practice may involve moral distress, which has been reported 
to occur frequently when nurses care for dying patients. Palliative sedation is a practice that 
is used to alleviate unbearable and refractory suffering in the last phase of life and has been 
linked to distress in nurses.
Aim. The aim of this study was to explore nurses’ reports on the practice of palliative sedation 
focusing on their experiences with pressure, dilemmas and morally distressing situations.
Methods. In-depth interviews with 36 nurses working in hospital, nursing home or primary 
care.
results. Several nurses described situations in which they felt that administration of pal-
liative sedation was in the patient’s best interest, but where they were constrained from 
taking action. Nurses also reported on situations where they experienced pressure to be 
actively involved in the provision of palliative sedation, while they felt this was not in the 
patient’s best interest. The latter situation related to (1) starting palliative sedation when the 
nurse felt not all options to relieve suffering had been explored yet; (2) family requesting an 
increase of the sedation level where the nurse felt that this may involve unjustified hasten-
ing of death; (3) a decision by the physician to start palliative sedation where the patient had 
previously expressed an explicit wish for euthanasia.
conclusions. Nurses experienced moral distress in situations where they were not able to 
act in what they believed is the patient’s best interest. Situations involving moral distress 
require nurses to be well informed and able to adequately communicate with suffering 
patients, distressed family and physicians.
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introduction
When being confronted with challenges in clinical practice, nurses and other healthcare 
professionals can experience moral distress1. Moral distress is defined as ‘‘the pain or anguish 
affecting the mind, body or relationships in response to a situation in which the person 
is aware of a moral problem, acknowledges moral responsibility, and makes a moral judg-
ment about the correct action; yet, as a result of real or perceived constraints, participates, 
either by act or omission, in a manner he or she perceives to be morally wrong’’2 3. Morally 
distressed nurses experience burnout and have a high tendency to leaving the profession3-6. 
A growing number of studies have reported on moral distress among nurses, but until now 
these are mainly restricted to intensive and acute care7-9.
Moral distress has been reported to occur frequently when nurses care for dying patients. 
In a survey study of 47 critical care nurses, 79% reported that they had experienced moral 
distress1. Nurses play an important role in care at the end of life, as they are often the 
frontline caregivers for patients nearing the end of life10. Care at the end of life is often 
complex, nurses working in this field have to deal on a daily basis with difficult symptoms 
of terminal illnesses, distressed patients and families, suffering and death11. Moral distress 
among nurses working in end-of-life care seems to be inextricably bonded to the distress 
that is experienced by patients1 12 13. A study focusing on end-of-life care among 222 geriatric 
nurses showed that 8% of the nurses actually left their job and 12% considered quitting their 
job because of discomfort with the way patient care was handled14.
A common practice at the end of life, which has been described as something nurses 
struggle with, is palliative sedation15. Patients who are nearing death sometimes experi-
ence symptoms that cannot be relieved with conventional therapeutic interventions, such 
as intractable pain, dyspnoea, and delirium16 17. Palliative sedation is a medical interven-
tion used to alleviate unbearable and refractory suffering in the last phase of life by the 
deliberate lowering of a patient’s level of consciousness to induce decreased awareness of 
symptoms18-20. Palliative sedation includes several subtypes: intermittent and continuous 
sedation, as well as deep and superficial sedation. Continuous deep sedation until death is 
the most far-reaching subtype20. In the Netherlands, the Royal Dutch Medical Association 
has issued a guideline on palliative sedation that states that continuous deep sedation until 
death can only be considered for patients who have a life expectancy of one to two weeks 
at most20. Palliative sedation is frequently used in end-of-life care, most often in hospitals 
and for patients with cancer21-23. Studies have indicated that palliative sedation was used in 
12%-18% of dying patients in the UK, Belgium (Flanders), and the Netherlands24-26.
Palliative sedation is a practice of last resort and is therefore often used in complicated 
cases, under stressful conditions and with time constraints19 27 28 29. In addition, a number of 
studies reported on experiences of physicians with pressure related to palliative sedation. 
Blanker performed a study among general practitioners (GP’s) and found that one in six GPs 
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had experienced pressure during a decision making process on the use of palliative sedation, 
from patients, relatives or other persons30. Also, pressure to increase the level of sedation 
as a means to hasten death has been described in other studies focusing on physicians31. 
Palliative sedation has been linked to (emotional) burden for nurses5 32. A study among 2607 
nurses in Japan showed that 12% of nurses experienced emotional burden related to pallia-
tive sedation5. A qualitative study among 26 home care nurses and 25 (GPs) focusing on their 
collaboration, roles, and responsibilities during the process of palliative sedation showed 
that some nurses found performing sedation “burdensome”32.
The aim of this study was to explore nurses’ reports on the practice of palliative sedation 
focusing on their experiences of pressure, dilemmas and morally distressing situations by 
performing a secondary data analysis of an interview study among nurses.
method
Participants
In this study we analysed data from qualitative interviews with nurses that were collected 
as part of a larger project about the practice of palliative sedation in the Netherlands after 
the introduction of a national guideline on palliative sedation33. The project focused on 
physicians’ and nurses’ experiences with continuous palliative sedation. The first part of the 
project was a questionnaire study; 185 nurses working in general practice, nursing homes, 
hospices and hospitals completed a questionnaire about their most recent case of continuous 
palliative sedation. Details of the study have been described elsewhere33-35. In the question-
naire, respondents were asked if they were willing to participate in an additional qualitative 
interview. In total, 36 nurses indicated willingness and were subsequently interviewed.
Procedures
A semi structured interview scheme was developed with open-ended questions that were 
based on themes from the questionnaire: refractory symptoms, decision-making and com-
munication, the practice of palliative sedation, and experiences with the palliative seda-
tion guideline from the Royal Dutch Medical Association20. Questions partly pertained to 
the case that respondents had described in the questionnaire, but also concerned other 
experiences with the practice of palliative sedation. Nurses who had stated willingness to 
participate in an interview were approached via telephone and the study aims and meth-
ods were explained to them. An interview was arranged and they were interviewed at a 
location of their choice. Participants consented to the audiotaping of their interview. The 
interviews were conducted during a 7-month period (October 2008 - April 2009) by four 
interviewers with a medical or health science background. Consistency among interviewers 
was ensured through the use of the interview scheme, a one-day training, and monthly 
meetings to discuss findings and interim analyses. The interviews lasted between 30 and 65 
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minutes. Information about the nurses’ age, gender and work setting was obtained from the 
questionnaire. This study was exempt from review by a research ethics committee under 
Dutch law.
Analysis
The recordings were transcribed verbatim by a professional agency and anonymized. Analy-
ses were performed with the constant comparative method36. Themes and subthemes were 
independently derived from a subset of five interviews by MEL and SJS. These (sub)themes 
were compared and organized in an initial coding tree which was discussed in depth by 
MEL, SJS and AvdH on several occasions after which the coding tree was adjusted. The final 
version was used for coding all interviews. Another five interviews were coded by MEL and 
SJS independently and differences in coding were discussed until consensus was reached. 
The final version was used for coding all interviews. The remaining interviews were coded 
by MEL, interview fragments that raised questions while coding were discussed in depth 
between MEL and SJS. The codes used in the interviews were connected to the main theme 
´pressure´, with several subthemes. The coded fragments were discussed in depth by MEL, 
SJS and AvdH. Quotes were selected by MEL and AvdH to illustrate the arguments.
results
Table 1 shows the characteristics of the 36 interviewed nurses.
In the interviews, several nurses described that interacting with physicians and family 
members is an important part of their work in palliative care. Whether or not a patient is 
experiencing unbearable suffering can be judged differently by the family, the physician or 
the nurse. Nurses described situations in which they felt that providing palliative sedation 
was in the patient’s best interest, but experienced (real 
or perceived) constraints that prevented them from tak-
ing action. They also described situations in which they 
experienced pressure to be involved in the administra-
tion of palliative sedation, but felt that their action was 
not in the patient’s best interest.
Experiencing constraints preventing action.
Several nurses described situations in which they felt 
that starting palliative sedation was necessary to al-
leviate the patient’s suffering, whereas the physician 
thought that it was too early to start. These situations 
related to differences in the assessment of the patient’s 
situation leading to a discrepancy in opinion about the 
table 1 Nurses’ characteristics (n=36)
Age








General practice/ home care 11
Nursing home/ Hospice 10
Hospital 15
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severity of the patient’s suffering. The hierarchical difference between physicians and nurses 
in situations where such disagreement is present was also mentioned as distressing.
“A young person still, and it was clear that he couldn’t go on like that any longer. It had already 
been discussed that when the situation would become unbearable sedation could be started. And 
the physician just refused. He thought it was not yet necessary… Clearly a case of “you’re just a 
nurse, I’m the physician and I decide what ‘s going to happen”. Not listening to your observations 
and your experience. Well that’s it, you have to accept that. And that’s really awful.” R931 hospital
Nurses are often the caregivers that spend the most time with the patient and his fam-
ily, usually more than physicians. Explaining or justifying on behalf of the physician to the 
patient why it was not yet time to start palliative sedation when nurses themselves thought 
it was, was experienced as very troublesome.
“Talking, talking, talking, and of course you try to explain [to the patient and his relatives] why 
the physician isn’t willing to start [the sedation]. Of course the need should be there, but I had the 
feeling that the physician’s reluctance was not right; that it was perfectly okay to start with [the 
sedation].” R822 nursing home
Differences in opinions between nurses and physicians seemed to occur relatively often 
during out of office hours or in the absence of a pro-active care plan.
“It happened during the night shift (….) it was obvious that the situation couldn’t go on like that, 
and it had been agreed upon already that when the situation would not be under control anymore 
that sedation could be initiated. And the physician just refused. He did not find it necessary.” R931 
hospital
Experiencing pressure to act
Feeling pressured to act but not being convinced that this act is in the best interest of 
the patient was a frequently reported theme in the interviews. Feeling pressure to act was 
described as occurring at two points in time, i.e. before the start of sedation and during the 
sedation process, and coming from different sources, i.e. the physician and the family.
Pressure before the start of palliative sedation
Several nurses reported on situations where they felt that the family was requesting action, 
i.e. the initiation of palliative sedation, but where the nurse did not feel that it was indicated 
or appropriate yet. Watching a close relative nearing the end of life can be a heavy burden 
for family members, sometimes an even greater burden than it seems to be for the patient 
himself.
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“Sometimes the relatives say: “we can’t bear the sight [of our suffering relative] anymore” or “when 
will it end?” While you don’t observe this feeling in the patient. Sometimes you do, but not always. 
Sometimes I get the feeling that the relatives suffer most, more than the patient.” R869 nursing 
home
Nurses indicated that intensive and careful communication with the family is needed to 
explain why their request may come too early. The Dutch guideline states that a life expec-
tancy of one to two weeks at most is a necessary condition for starting palliative sedation. 
Nurses however seem to have a narrower view: they seem to consider the start of the dying 
phase, that is the moment at which it is recognized that the patient will very likely die within 
hours or days, as the only appropriate moment to start palliative sedation.
“(…) What we always try to do, if possible, together with the GP is to keep the situation as stable 
as possible until we can establish someone has entered the dying phase. (...) I have rarely seen… I 
can’t remember I’ve ever seen that a GP failed to resist the pressure [of family to start sedation]. 
But still a lot of communication with the relatives is needed. “R712 home care
A decision by the physician to start palliative sedation can also be experienced by nurses 
as coming too early. Sometimes nurses felt that not all options to relieve the patient’s suf-
fering had been discussed or explored yet and that therefore not all requirements to start 
palliative sedation had been met.
“Sometimes you doubt if the physician has done enough to address the symptoms. And if he has 
adequately judged whether or not the patient is in the dying phase” A863 home care
Dealing with this situation required a lot of deliberation and the nurse sometimes felt a 
need to provide the physician with alternative options to relieve the patient’s symptoms. 
To be able to engage fully in these discussions, nurses require adequate knowledge about 
clinical and ethical aspects of palliative sedation. When the physician was receptive to the 
arguments of the nurse the decision to start palliative sedation was sometimes postponed, 
but this was not always the case.
“When he [the physician] wants to start continuous sedation, while you yourself aren’t convinced 
yet that that is necessary or useful at that moment, this sometimes led to the whole thing not 
taking place. (.....)  [If you want to have an impact as a nurse,] you have to have alternatives 
available. When I don’t have an alternative, I can’t start the conversation.” R878 nursing home
Several nurses stressed the difference between palliative sedation and euthanasia. Some 
of them described a situation in which a patient had expressed an explicit wish for euthana-
sia (i.e. active ending of life, a legal practice in the Netherlands as long as it is performed by a 
physician who acts in accordance with the legal criteria of due care), but where the physician 
decided to provide palliative sedation, either because the euthanasia procedure was judged 
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as too time consuming or because of a conscientious objection of the physician to perform 
euthanasia. Nurses indicated that they felt distressed by the disregard of the patient’s wish 
in such a situation.
“We’ve had a case of a man who had been ill for a long time, he had expressed a clear wish for 
euthanasia but his GP didn’t want to cooperate. In the end these people were somewhat pressured 
into the direction of palliative sedation. Eventually he was sedated, but it took several days, and 
he even regained consciousness and was distressed. Afterwards, when I went there for a house 
call, his wife told me “this wasn’t how he had wanted it”. I feel bad about that.” R706 home care
Pressure during the sedation process
Nurses described experiencing distress when family members, after the goodbyes had been 
said and palliative sedation had been started, explicit or implicitly requested for expediting 
the patient’s dying trajectory because it was taking longer than they had expected.
“Well sometimes the relatives are tired of waiting and they think: how long will this go on? Do we 
really have to sit here for another three days? We don’t want that. That’s when you sometimes 
feel pressured.” A773 hospital
About continuous sedation, I think about the phase when a patient is sedated and relatives fairly 
soon start to ask if the pump can be turned up some more, they’ve had enough of it, they’re all 
there now, so they think if the pump is turned up, their relative will die sooner, and that would suit 
them.” A863 home care
Nurses and family members may disagree upon whether a patient is comfortable while 
being sedated. Family members were reported to sometimes having a preference for a deep 
level of sedation and requesting an increase of the sedative drug dosage to suppress moves 
or noises from the patient, such as death rattle, while nurses indicated that these phenom-
ena are part of the normal dying process.
“With every little movement or sound a patient makes, they want the pump to be turned up. And 
just after it has been turned up a little, they want it to be turned up some more. You can try to 
explain that the effect should be awaited, but then they may manage to pressure you in a way that 
makes you feel very ill at ease in the end. That’s when you think, “I’m now doing something I don’t 
feel comfortable with” R990 hospital
discussion
Nurses described two distinct situations involving distress while working together with 
physicians in caring for patients in the last phase of life for whom palliative sedation is 
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considered: (1) the nurse felt that palliative sedation was needed to alleviate the suffering 
of a patient, whereas the physician thought that it was not (yet) indicated; 2) the physician 
decided to start palliative sedation whereas the nurse viewed this as not indicated because 
not all requirements to start palliative sedation had been met (yet). Nurses’ feelings of dis-
tress in both these situations can be characterized as feelings of powerlessness. The feeling 
of powerlessness as a cause of moral distress was also identified by Oberle et al13 who 
studied acute care nurses’ and doctors’ perceptions of ethical dilemmas in end of life care 
decisions. In that study, moral distress as experienced by nurses was related to their ‘lower’ 
hierarchical position: not being listened to by doctors; being expected to remain silent even 
when witnessing choices they consider wrong; being unable to have an impact on decisions 
despite their professional assessment and detailed understanding of the patient’s condition. 
In our interviews nurses described difficult situations when having to deal with physicians 
who are on duty and do not know the patient, physicians who are inexperienced in end-
of-life care or in providing palliative sedation and situations in which a pro-active care plan 
was absent. Preferably the decision to start palliative sedation does not come as a ‘surprise’ 
to the involved healthcare professionals; instead, it should be the anticipated potential 
outcome of a process of efforts to control symptoms near the end of life.
It is obvious that nurses and physicians can have different interpretations of what the 
appropriate indication and time to start palliative sedation are. Nurses experienced their 
inability to alleviate the patient’s suffering in situations where the physician disagrees with 
providing palliative sedation as evoking stress. Such stress can in turn result in suffering 
for themselves13. On the other hand, nurses judged recognition that the dying phase has 
started as an important prerequisite to start palliative sedation. Recognizing the start of the 
dying phase most often occurs hours or days before death. The Dutch guideline on palliative 
sedation states that continuous sedation can only be administered when a patient’s ‘life 
expectancy is less than one to two weeks20. This prerequisite is included to make clear that 
continuous sedation can only be used when there is no or a very limited possibility that it 
hastens death. There seems to be a discrepancy between the criterion on life expectancy 
in the guideline and nurses’ views, where nurses appear to prefer a more limited life expec-
tancy than the guideline. This may be related to nurses’ concerns that sedation might hasten 
death, a concern previous reported by Anquinet et al. in a qualitative study of home care 
nurses and their experiences with palliative sedation32. In addition, adequately predicting 
patients’ remaining life expectancy remains difficult, although such predictions have been 
shown to become more accurate when patients are closer to death37-39.
Nurses may also feel uncomfortable when the course of sedation is not in line with 
expectations or preferences of patients. Especially waking up during continuous sedation 
can cause distress40. A protracted and seemingly disquiet dying process can also be very 
burdening for family. This may lead to implicit or explicit requests to increase the level of the 
sedation, either or not with the purpose of hastening the patient’s death. A decision of the 
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physician to grant such requests may evoke the feeling that the patient receives unnecessary 
or arguable treatment. Providing medical treatment and care that is perceived as not serving 
the patient’s best interest has been described before as evoking moral distress41-44.
Feelings of powerlessness and the experience of patients receiving unnecessary treatment 
have also been described as causes of moral distress by Hamric et al42. They distinguished 
different root causes of moral distress, including internal worker factors, such as perceived 
powerlessness, and factors related to the immediate clinical situation, such as the experi-
ence of patients receiving unnecessary treatment. Nurses seem to feel that they are very 
capable of estimating dying patients’ needs, because of their experience and nearness to 
the patient, without having the authority to make decisions on care and treatment. In our 
study, we did not find other causes of moral distress as suggested by Hamric et al., such as 
lacking situational knowledge (an internal worker factor); a lack of truth-telling; a lack of 
patient consent to be treated (factors related to the immediate clinical situation); or external 
factors, such as inadequate staffing and lack of administrative support.
According to Epstein and Hamric45 addressing moral distress is not a matter of analysing 
single cases. Instead, multidisciplinary interventions aimed at the organization of care are 
needed. Based on our interviews we feel that several actions may be needed to support 
nurses in dealing with stressful situations that may result from the use of palliative sedation. 
These actions may be focused on nurses as individuals or on a group-level. The first action 
would be education about the guideline and decision making process that precedes pallia-
tive sedation. When nurses are well educated they will better understand the procedure and 
considerations of the physician and more adequately discuss their concerns or feelings with 
physicians. A second action would be to focus on the communication between nurses and 
physicians. Epstein suggests to design and use forums for interdisciplinary problem solving 
such as interdisciplinary rounds45. When both physicians and nurses are included in discus-
sions about the use of palliative sedation this could lead to a better understanding of each 
other’s roles, thoughts and reasoning. A third action is related to the content of the Dutch 
guideline for palliative sedation. This guideline20 describes the different steps in the deci-
sion making process and acknowledges dilemma’s that can arise when palliative sedation 
is prescribed. However the guideline is not very specific about the roles and tasks of the 
physician and the nurse and could benefit from more explicit guidance in that area. A fourth 
action would be to investigate to what extent physicians experience moral distress related 
to the provision of palliative sedation. Insights from physicians could further substantiate 
strategies to support nurses in dealing with stressful situations related to palliative sedation.
Using interviews from a rather large group of nurses increased the validity of this qualita-
tive interview study. However, our study also has some limitations. Due to the fact that the 
original data collection was not aimed at achieving saturation of information on the topics 
studied here, we cannot be sure that we have not missed any relevant information. Further, 
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due to the retrospective design of the study we cannot preclude recall bias, which was 
however limited by asking about specific and recent cases.
To conclude, the nurses in this study described various situations in which they experi-
enced moral distress when being involved in the practice of palliative sedation. Their main 
concern was that they felt that they were not able to act in the patient’s best interest. To 
deal with these situations, nurses need to be able to adequately communicate with suffering 
patients, distressed family members and physicians and to have adequate knowledge about 
clinical and ethical aspects of palliative sedation. Empowering nurses in up taking their 
professional role seems to serve the best interest of both patients and nurses themselves.
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The studies described in this thesis concern various aspects of symptoms and symptom 
relief during the last phase of life of patients with advanced diseases. This chapter presents 
the key findings of the studies, followed by methodological considerations and a general 
discussion focusing on two important emerging themes in these studies, i.e. acknowledging 
different perspectives and communication. Finally some implications and recommendations 
for clinical practice and future research will be discussed.
Key findings
In order to deliver good healthcare, it is important to know which symptoms occur during 
a specific disease or disease phase, as well as their impact on patients’ daily functioning 
and quality of life. We studied the prevalence and impact of symptoms in two understud-
ied patient groups (chapter 2 & 3). First, we focused on patients with incurable head and 
neck cancer (chapter 2) and found that these patients reported an average of 14 different 
symptoms (interval 0–26), of which 10 somatic symptoms and 4 psychosocial symptoms. 
The most frequently reported somatic symptoms were ‘fatigue’, ‘pain’ and ‘weakness’. In the 
psychosocial area, these were ‘worrying’, ‘sadness’ and ‘tenseness’. The symptom with the 
greatest impact on daily functioning, was ‘dyspnoea’. We compared the reporting of patients 
and family members and found that in two thirds of cases, although not always significant, 
the occurrence rates and impact scores of physical symptom as estimated by family members 
were higher than those estimated by patients. For about 50% of the psychosocial symptoms 
we found a reverse trend. Second, we studied patients with advanced heart failure in South 
Africa (chapter 3). We found that patients, of whom 14% had completed high school and 
26% had no income, reported a mean of 19 symptoms. Physical symptoms with the high-
est occurrence were ‘shortness of breath’, ‘feeling drowsy/tired’ and ‘pain’ . Psychological 
symptoms with the highest occurrence were ‘worrying’, ‘feeling irritable’ and ‘feeling sad’. 
Symptoms with the highest burden were ‘shortness of breath’, ‘numbness/ tingling in hands 
or feet’ and ‘I do not look like myself’. Higher symptom burden was associated with a higher 
age, having no income and fewer hospital admissions within the previous 12 months.
As death comes nearer, patients with advanced illness have been reported to experience 
many symptoms in their last week or days of life1-11. However, until now, research on the 
occurrence and impact of several symptoms in the dying phase has been scarce. This also 
holds for death rattle. We performed a systematic search of scientific literature concerning 
the prevalence of death rattle, its impact on patients, relatives and professional caregivers, 
and the effectiveness of interventions (chapter 4). We found that death rattle is a com-
mon symptom in dying patients. Approximately a third of patients will present with this 
symptom during the dying process. Death rattle leads to distress in both family members 
and professional caregivers, but it is doubtful if patients suffer from this symptom. Different 
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medication regimes for the treatment of death rattle have been studied. Current evidence 
does not support the use of antimuscarinic drugs in the treatment of death rattle.
At the end of life, oral fluid intake is often reduced. Whether it is beneficial for patients to 
substitute decreasing oral intake with artificial hydration has been debated frequently12-14. 
This debate has mostly focused on two distinct symptoms: death rattle, which has been 
linked to over-hydration, and terminal restlessness, which has been linked to under-hydra-
tion. To investigate whether the amount of fluid intake, preceding and during the dying 
phase, is related to the occurrence of death rattle and terminal restlessness, we performed 
a multicentre prospective observational study in patients who were, according to their 
multidisciplinary care team, likely to die within a few days (chapter 5). We found that death 
rattle was reported at least once in 40% of patients during the dying phase, and in 35% 
of patients during the last 24 hours of life. The occurrence of death rattle increased with 
death coming nearer. Terminal restlessness was reported in 26% of patients during the dying 
phase and in 13% of patients during the last 24 hours of life. Terminal restlessness occurred 
almost evenly throughout the dying phase. We found no association between fluid intake 
and the occurrence of death rattle. Terminal restlessness during the last 24 hours of life was 
associated with a higher intake of fluid during the period 48-25 hours before death.
Being aware that death is imminent is often seen as one of the features of a good death 
in modern Western culture15-19. We studied to what extent patients are aware of the im-
minence of their death by performing a secondary analysis of data from questionnaires filled 
in by nurses and bereaved family members, and data from patients’ medical record (chapter 
6). We found varying reports on whether patients were aware of the imminence of their 
death. According to the medical records, 51% of patients had been aware of the imminence 
of death, according to nurses this was true for 58% and according to family members for 
62% of patients. Inter-rater agreement on patients’ awareness of dying was fair. Whether 
a patient was aware of the imminence of dying was not clearly associated with the occur-
rence of symptoms that are common in the last days of life, such as fatigue, shortness of 
breath, pain, dysphagia or restlessness. Patients dying at home were more often aware of 
the imminence of death than patients who died in a hospital or in a nursing home. We also 
found that awareness of imminent death was associated with acceptance of dying: patients 
who were aware of the imminence of death were more often in peace with dying and more 
often felt that life had been worth living, than patients who had not been aware according 
to the family member.
Sometimes the symptoms which patients who are nearing death experience cannot be 
relieved with conventional therapeutic interventions. Palliative sedation is used to alleviate 
unbearable and refractory suffering in the last phase of life and has been linked to distress 
in nurses20 21. To explore the extent to which nurses experience distress when being in-
volved in the practice of palliative sedation, we performed a secondary analysis of data from 
qualitative interviews with nurses (chapter 7). We found that whether or not a patient is 
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experiencing unbearable suffering can be judged differently by the family, the physician or 
the nurse. Nurses described morally distressing situations in which they felt that providing 
palliative sedation was in the patient’s best interest, but experienced (real or perceived) 
constraints from physicians that prevented them from taking action. In these situations 
nurses felt that starting palliative sedation was necessary to alleviate the patient’s suffering, 
whereas the physician thought that it was too early. Nurses also described situations in 
which they experienced pressure from physicians or family members to be actively involved 
in the provision of palliative sedation, but felt that this was not in the patient’s best interest. 
The latter situation was related to (1) starting palliative sedation when the nurse felt not 
all options to relieve suffering had been explored; (2) family requesting an increase of the 
sedation level where the nurse felt that this may involve hastening of death; (3) a decision 
by the physician to start palliative sedation where the patient had previously expressed an 
explicit wish for euthanasia.
methodologicAl And other considerAtions
We used different methods in the studies described in this thesis: cross-sectional surveys 
among patients and family members; a systematic literature review; a prospective observa-
tional study; secondary analyses of (1) cross-sectional data collected through questionnaires 
and from the medical record, and (2) data from qualitative interviews. Methodological and 
other considerations will be discussed per study.
cross-sectional surveys - Prevalence & impact of symptoms in 2 understudied 
patient groups
A cross-sectional study is an observational study that provides a snapshot of a certain 
population. For the data collection in the head and neck-study (chapter 2) we used instru-
ments (i.e. Pal-C and Pal-SI) that were judged by the healthcare professionals as practical for 
gathering information on symptom prevalence in the least possible intrusive way. However, 
these instruments did not undergo a formal psychometric evaluation. In this study, data 
were provided by two separate groups: the first group consisted of 124 patients who pro-
vided information on symptom presence, the second group consisted of 24 patient and 
family member couples who both provided information on the impact of symptoms. The 
44% non-response within the group that provided information on symptom prevalence is a 
limitation. Non-responding patients had a significantly shorter life expectancy and seemed 
to have a much worse condition than responding patients. The large nonresponse (more 
specifically, patients who did not respond because of their weak condition) within this group 
confirms how vulnerable this specific cancer population is. The number of patients and fam-
ily members in the group that provided information on the impact of symptoms was small 
which limits the possibility to generalize results.
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In the heart failure study (chapter 3), we used the Memorial Symptom Assessment Scale 
(MSAS), a widely used and well validated instrument. Patients were recruited over the course 
of a month at multiple wards of the hospital and the questionnaire was available in different 
languages. Although we had a high response rate, most patients who were included in the 
study were diagnosed with stage III heart failure. It is therefore possible that our results are 
not generalizable to patients with stage IV heart failure.
systematic review - Death rattle prevalence, impact and interventions
We conducted a systematic review to synthesize current evidence concerning the symptom 
death rattle (chapter 4). We found that the reported death rattle prevalence varied widely 
between studies. This variation might be explained by several factors. First, there is a wide 
variety of labels used to describe death rattle, and whether various labels all refer to the 
exact same phenomenon is not clear. Second, different study designs were used. 34% were 
prospective studies and the weighted mean occurrence of death rattle in these studies was 
45%. Sixty-four percent of the studies were retrospective studies and the weighted mean 
occurrence of death rattle in these studies was 30%. Third, methods to determine the preva-
lence of death rattle varied between the studies. Few studies used validated instruments, 
such as the death rattle scoring scale22.
The most optimal study design to evaluate the effectiveness of medical therapy and other 
interventions for death rattle is a controlled study. We found no studies that included a 
placebo group. Further, randomized controlled trials among patients who are in the dying 
phase are rare, mainly because of ethical and practical considerations related to randomiza-
tion, informed consent, use of placebo and follow-up1-5.
Prospective observational study - Hydration and symptoms in the last days of life
A randomized controlled trial would also be the most optimal design to study the effects 
of fluid intake on the occurrence of symptoms, but would pose ethical challenges. In the 
Netherlands, healthcare professionals tend to be reserved about prescribing artificial hydra-
tion at the end of life.23 In daily practice, fluid intake and administration of hydration vary. 
Therefore, we conducted a prospective observational study, to explore whether there is a 
relation between fluid intake in daily practice and the occurrence of death rattle and termi-
nal restlessness (chapter 5). We prospectively collected information on fluid intake at three 
moments in time: the week before the start of the Care Program for the Dying (CPD), the 
day before the start of the CPD and 4 hourly during the dying phase, i.e. after the CPD was 
started. The occurrence of symptoms was also measured 4 hourly during the dying phase. To 
avoid mixing cause and effect, we calculated the total amount of fluid intake during the time 
period 48-25 hours before death and related this to occurrence of death rattle and terminal 
restlessness during the last 24 hours of life. Whereas terminal restlessness occurred almost 
evenly throughout the dying phase and often only once, it is possible that patients who were 
Discussion 143
classified as having no terminal restlessness during the last 24 hours of life actually presented 
with terminal restlessness before the last 24 hours of life but were successfully treated, e.g. 
by providing them with palliative sedation. However, we found no evidence that patients 
with terminal restlessness were more often sedated than patients without terminal restless-
ness. At the start of this study no instrument to measure terminal restlessness was available. 
We therefore decided to use the calmness scale of the Vancouver Interaction and Calmness 
Scale. Whereas the value of this instrument to measure terminal restlessness has not been 
assessed, it is possible that patients were misclassified. The prevalence found in our study is 
however in line with other studies on restlessness in the terminal phase of life. Occurrence 
of death rattle was measured using the validated Death rattle scoring scale by Back et al22.
secondary analyses – Awareness of dying & Palliative sedation and moral distress
An advantage of secondary analyses of research data is that it is a form of efficient use of 
research data. Especially for research in palliative care with its potentially fragile patients it 
is an advantage when data can be used as efficient as possible. However, when using data 
from qualitative studies, (chapter 7) it is unclear if the number of interviews was sufficient 
to achieve saturation of information on the researched topic. It is possible that relevant 
information is missed. In both secondary analyses, (chapter 6 & 7) data were used that were 
collected after the death of a patient. A certain degree of recall bias can therefore not be 
precluded. For the qualitative interviews, we tried to limit this bias by focusing on specific 
and recent cases.
interpretAtion of the findings
Acknowledging different perspectives
The studies in this thesis cover various aspects of the burden and management of symptoms 
during the last phase of life of patients with an advanced illness. A recurrent theme in the 
studies in this thesis is the presence of different perspectives. A specific situation can be 
viewed upon differently by different observers. Also, ‘what you see is not always all there 
is to see’. In palliative care, this was already suggested when Dame Cicely Saunders in 1964 
introduced the concept of ‘total pain’, which includes the physical, emotional, social, and 
spiritual dimensions of distress and thus encompasses more than might be expected when 
discussing pain24.
In several specific situations studied in this thesis different perspectives appeared to be 
present: symptom prevalence and burden in patients with head and neck cancer may vary 
according to patients and family members (chapter 2), awareness of dying of a patient may 
vary according to healthcare professionals and family members (chapter 6) and what is in 
the best interest of a patient may vary according to nurses, physicians and family members 
in our study on palliative sedation (chapter 7).
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A patient’s assessment is often seen as the gold standard source to collect information 
about their health status. But even a patient’s rating may not always be in accordance with 
reality, because patients may e.g. underreport symptoms because they do not want to be 
a burden, or prefer not to worry their family members25-29. At the end of life and especially 
in after-death research, so called proxy-ratings are often used, i.e. a healthcare professional 
or a family member is asked to provide information on the patient’s situation. Studies have 
shown that patients’ ratings of e.g. symptoms may differ from proxy ratings25 30. It does 
not seem to matter in this respect who the proxy is (i.e. healthcare professional or family 
member)25. Proxies have been shown to reliably report on the more objectively observable 
symptoms. Agreement is poorer when the reporting is about more subjective symptoms, 
such as pain, feelings and thoughts, anxiety and depression30. This is in line with the results 
in our study in patients with head and neck cancer, in which we saw overreporting by family 
members of dyspnoea and underreporting of powerlessness and anxiety (chapter 2). The 
level of patient-proxy agreement appears to be dependent, to a certain degree, on the health 
status of the patient. Several studies have suggested a U-shaped relationship, meaning that 
agreement is better when the patient’s health status is either very good or very poor25. 
However, views on whether or not patients are aware of the imminence of death diverged 
between different caregivers (chapter 6). In our study on palliative sedation, the nurse, the 
physician and the family members appeared to potentially have different views on whether 
or not a patient was experiencing unbearable suffering (chapter 7). Nurses, physicians and 
family members usually differ on their level of knowledge and they have different roles and 
responsibilities when it comes to end of life care and decision making. We found in our study 
that nurses feel that they are very capable of estimating dying patients’ needs, because of 
their experience and nearness to the patient. They however do not have the authority to 
make decisions on medical care and treatment, only physicians are legally responsible for 
making such decisions31 32.
In our study on symptoms in patients with advanced heart failure, we found that patients 
reported more symptoms than expected (chapter 3). Many of the reported symptoms are not 
generally thought of as being caused by heart failure33 34. These symptoms might be related 
to treatment, but the causes of symptoms such as pain remain unclear. Two reviews have fo-
cused on symptoms in the last year of life and compared patients with cancer to those with 
other diagnoses35 36. They found that irrespective of the primary diagnosis, commonalities in 
the prevalence of symptoms were evident. The recommendation following that conclusion 
is that healthcare professionals should be aware that patients with life-limiting illnesses may 
exhibit problems and needs that are not strictly associated with their specific diagnosis. This 
suggests that there is a need for broad symptom screening, also because multimorbidity is 
currently becoming the norm at the end of life37.
It is evident that different perspectives exist in the last phase of life. These different 
perspectives may result from a different appreciation of a phenomenon, a lack of evidence 
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on what the most beneficial intervention would be, or from a lack of communication among 
those involved. Evidence and communication are to a certain extent within our reach to 
tackle, but some causes of different perspectives will remain. It is important to be aware of 
the potential presence of these different perspectives, to acknowledge them and to make 
them part of the continuous communication about the patients’ health status, with patients, 
family members and within the healthcare team.
‘Acknowledging different perspectives: it needs words.’
communication
Honest and sensitive communication has been identified by patients and family members as 
one of the most important elements of care during the last phase of life38-40. Care during the 
last phase of life is often delivered by a multidisciplinary team, which requires continuous 
communication and shared insights within the team and regular conversations between 
team members, patients, and family members41.
A systematic review on the preferences for end-of-life communication of patients with 
advanced diseases and their family members showed their need for clear information at 
all stages of the illness trajectory, about the illness itself, prognosis and symptom man-
agement40. It is important to inform the patient and family members about what can be 
expected during the last phase of life. This information should be repeated regularly and 
tailored to existing or expected symptoms. Also, discussions about what is experienced by 
the patient and family members are important. Being a family member of someone who 
is in the last phase of life is often an intense and difficult experience. It can be the family 
member’s first actual encounter with dying and death42. Even if family members are aware 
of the imminence of death, this does not mean that they are prepared for it43. A death 
from a chronic illness that is expected by healthcare professionals may be experienced as 
unexpected and traumatic by family members who are focusing on caregiving rather than 
on preparing themselves for bereavement44-47. In our study on palliative sedation (chapter 
7) nurses described requests from family members to start palliative sedation or to expedite 
the patient’s dying trajectory after palliative sedation had been started, which were from 
the perspective of the nurse not indicated or appropriate yet. Watching how a close relative 
is dying can be a heavy burden for family members, sometimes an even greater burden 
than for the patient him- or herself, which may result in such requests. It is important for 
healthcare professionals to listen to the family members, acknowledge their experiences 
and to communicate with the distressed family members to explain why their request may 
not be appropriate yet.
When focusing on two distinct symptoms of the dying phase, death rattle and terminal 
restlessness (chapter 4 and 5), there are different perspectives on how these symptoms 
should be addressed. For death rattle, this seems to be related to whether this symptom is 
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seen as a normal phenomenon at the end of life. When death rattle is seen as a distressing 
symptom which should be managed, communication and actions are most likely different 
from situations where the symptom is seen as a normal and non-burdening phenomenon of 
the dying phase48 49.
When healthcare professionals communicate within the healthcare team, and with pa-
tients and their family members during the last phase of life, it is important to be sensitive 
about what is said and about how and when and by whom it is said. In addition, they need to 
listen to what patients and family members say, but also ‘hear’ what they do not (explicitly) 
say. Being sensitive to non-verbal cues and ‘reading between the lines’ is sometimes neces-
sary to ‘hear’ what worries patients, family, or other healthcare professionals have, and what 
questions or fears for the near future.
implicAtions And recommendAtions
For clinical practice
Systematic screening of common symptoms is needed for patients with advanced illness, 
to be able to address the symptoms that are most distressing or burdensome for a pa-
tient. Screening of symptoms should not be limited to their presence, but should include 
a measure of the extent to which they cause distress or impact on daily functioning. For 
this screening, many (generic) symptom assessment instruments are available50 51. Bearing 
in mind the deteriorating condition of the patient, the length of such screening instruments 
should be kept to a minimum. Digital tools like computerized adaptive testing should be 
considered where possible. For care during the dying phase, the Care Program for the Dying 
can be used as a clinical instrument, because it includes systematic screening of the most 
common symptoms during the dying phase.
Care during the last phase of life should include continuous communication about the 
patients’ health status, with patients and family members to identify potential differences 
in perspectives and appreciations of the patient’s situation. The expected course of the ill-
ness, which symptoms could occur and the available treatment options should be discussed 
regularly. Palliative care is interdisciplinary care in which the complementary competences 
from different healthcare professionals are combined52. Ongoing communication within the 
healthcare team should be an integral part of palliative care. By doing so, physicians and 
nurses should be better able to understand each other’s viewpoints and argumentation.
Proactive care planning and anticipatory prescription of medication are of the essence. 
Decisions to start palliative sedation for patients with refractory and unbearable suffering 
should not come as a ‘surprise’ to the involved health care professionals; instead, it should 
be the anticipated potential follow-up of efforts to control symptoms near the end of life.
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For research
The number of studies focusing on symptoms in patients with advanced diseases has in-
creased during the last decades. Future research should focus on understudied non-cancer 
groups and effectiveness of interventions for certain understudied symptoms during the 
last phase of life, such as death rattle. Our systematic review showed that death rattle leads 
to distress in both family members and professional caregivers, and that there is a lack of 
evidence for the effectiveness of any antimuscarinic medication in the treatment of death 
rattle (chapter 4). From a pharmacological perspective, antimuscarinic medications are 
unable to reduce existing secretions53. There are however indications that antimuscarinic 
medication might have a prophylactic effect53-55. Studies on the effectiveness of prophylactic 
prescription of antimuscarinic medication on the development of death rattle are therefore 
needed. Studies are also needed on the effectiveness of nursing interventions to address 
death rattle, such as repositioning of the patient and suctioning of secretions. The effective-
ness of nursing interventions also needs to be investigated for many other symptoms, as the 
medical interventions often have limited results in the last phase of life56-58.
Our findings on awareness of dying suggest that communication during patients’ dying 
phase is not yet optimal (chapter 6). The optimal time and strategy to enhance open com-
munication about the dying phase cannot be concluded from our data and should be a topic 
in future research.
In this thesis, various aspects of symptoms and symptom relief during the last phase of 
life of patients with advanced diseases have been discussed. To be able to provide good 
quality of care during the last phase of life, we need to systematically screen for common 
symptoms, acknowledge different perspectives, communicate continually and tailor our 
care to the needs of the individual patient and their family members.
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In the introduction (chapter 1), the background and aim of this thesis are described.
In order to deliver good palliative care it is important to know which symptoms may oc-
cur during a specific disease trajectory or disease phase and what their impact on daily 
functioning is. The last 25 years, the number of studies focusing on symptoms in patients 
with advanced diseases has increased steadily, however evidence remains scarce or lacking 
for some subgroups, such as patients with a specific type of cancer, non-cancer diseases and 
patients in developing parts of the world.
The aim of this thesis was to providing insight into various aspects of symptoms and 
symptom relief during the last phase of life.
chapter 2 describes the results of a cross-sectional descriptive study into prevalence and 
impact of symptoms in patients with incurable head and neck cancer. Patients were included 
from the department of Otorhinolaryngology and Head and Neck Surgery. This study con-
sisted of two parts, first data from questionnaires that were gathered between October 2006 
and October 2008 as part of normal care was used to establish symptom prevalence for 30 
symptoms, of which 9 psychosocial. For the second part, data were prospectively gathered 
from patients and family members between February 2009 up to May 2009 to establish the 
impact of those 30 symptoms and discrepancies between the ratings from patients and their 
family caregivers. We found that patients with incurable head and neck cancer reported 
an average of 14 different symptoms (interval 0–26), of which 10 somatic symptoms and 4 
psychosocial symptoms. The most frequently reported somatic symptoms by the patients 
were ‘fatigue’, ‘pain’ and ‘weakness’. In the psychosocial area, these were ‘worrying’, ‘sadness’ 
and ‘tenseness’. The symptom with the greatest impact on daily functioning is ‘dyspnoea’. 
We compared the reporting of patients and family members and found that in two thirds of 
cases, although not always significant, the occurrence rates and the impact score of somatic 
symptoms were systematically estimated higher by the family members compared to the 
patients. However, when it comes to psychosocial symptoms, we found a reverse trend. 
About 50% of the symptom prevalence and the symptom impact score are indicated higher 
by the patients compared with family members.
chapter 3 describes the results of a cross-sectional descriptive study into prevalence and bur-
den of symptoms in patients with advanced heart failure at Groote Schuur Hospital in Cape 
Town South Africa. Patients were recruited for this study between August and November 
2012 from several inpatient facilities (i.e., emergency unit, emergency ward, cardiology ward, 
general medicine wards) and the outpatient cardiology clinic. Patients provided information 
on symptom prevalence of 28 physical and 4 psychological symptoms and the associated 
burden for each symptom recorded as prevalent. We found that the patients in our study, of 
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which 14% completed high school and 26% reported having no income, reported a mean of 
19 symptoms of which 18 symptoms were reported by more than 50% of all patients. Physical 
symptoms with highest occurrence were ‘shortness of breath’, ‘feeling drowsy/tired’ and 
‘pain’. Psychological symptoms with highest occurrence were ‘worrying’, ‘feeling irritable’ 
and ‘feeling sad’. Most symptoms were associated with high burden, symptoms with the 
highest burden were ‘shortness of breath’, ‘numbness/ tingling in hands or feet’ and ‘I do not 
look like myself’. Higher symptom burden is associated with a higher age, having no income 
and fewer hospital admissions within the past 12 months.
In chapter 4 the results of a systematic literature review on the prevalence of death rattle 
in dying patients, its impact on patients, relatives, and professional caregivers, and the ef-
fectiveness of interventions are presented. Several databases were searched for empirical 
studies in 2012. We investigated various labels and definitions of death rattle, the prevalence 
of death rattle, the impact of death rattle on patients, relatives, and professional caregiv-
ers, and effects of medical and nonmedical interventions. We found that death rattle is 
a common symptom in dying patients. Approximately a third of the patients will present 
with this symptom during the dying process. Death rattle leads to distress in both relatives 
and professional caregivers, but it is doubtful if patients suffer from this symptom. Differ-
ent medication-regimes for the treatment of death rattle have been studied. There is no 
evidence that the use of any antimuscarinic drug is superior to no treatment.
chapter 5 describes a multicentre prospective observational study we performed to study 
whether the amount of fluid intake, preceding and during the dying phase, is related to the 
occurrence of death rattle and terminal restlessness. Data were collected in 8 hospitals (one 
to three wards per hospital) and five hospices, including three palliative care units in nursing 
homes (PCUs), in the Netherlands. Data collection took place between November 2012 and 
November 2013 in patients who were, according to the multidisciplinary care team, likely 
to die within a few days. Data were collected using a digital version of the Care Program 
for the Dying (CPD), a Dutch instrument for multidisciplinary care for patients in the dy-
ing phase. For this study, the CPD was supplemented with questions about death rattle, 
terminal restlessness, use of opioids and patients’ fluid intake. We found that death rattle 
was reported at least once in 40% of patients during the dying phase, and in 35% of patients 
during the last 24 hours of life. The prevalence of death rattle increased with death coming 
nearer. Terminal restlessness was reported in 26% of patients during the dying phase and in 
13% of patients during the last 24 hours of life. Terminal restlessness occurred almost evenly 
throughout the dying phase. We found no association between fluid intake and prevalence 
of death rattle. We also did not find an association between low fluid intake and terminal 
restlessness. Terminal restlessness during the last 24 hours of life was associated with a 
higher intake of fluid during the period 48-25 hours before death.
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chapter 6 reports on the results of a secondary analysis of data from questionnaires filled 
in by nurses and bereaved family members, and data from the medical record we performed 
to investigate to what extent patients are aware of the imminence of their death. For the 
original study, patients were recruited from hospitals, nursing homes and home care services 
in the southwest of the Netherlands. Data collection took place between November 2003 
and February 2006. Halfway this period, the LCP was introduced and subsequently used for 
each patient for whom the multidisciplinary team agreed that the dying phase had started. 
Within 1 week after the death of an eligible patient, a nurse who had been closely involved 
with caring for the patient during the last 3 days of life completed a questionnaire. About 
2 months after the death of a patient, a relative, who had been ‘contact person’ for the 
patient, received a letter from the institution that had provided terminal care. In this letter, 
he/she was asked for consent to be approached by the research team to fill in a written 
questionnaire. A reminder was sent to nonresponding relatives after 2 and 6 weeks, respec-
tively. Only relatives who gave their consent were mailed a questionnaire. We found varying 
reports whether patients were, according to the nurse, family member or reporting in the 
medical record, aware of the imminence of their death. According to the medical records 
51% of patients had been aware of the imminence of death, according to nurses 58% and 
according to family members this was the case for 62% of patients. Inter-rater agreement on 
patients’ awareness of dying was fair. Whether a patient was aware of dying was not clearly 
associated with common symptoms in the last days of life. Patients dying at home were 
more often aware of the imminence of death compared to patients who died in a hospital 
or in a nursing home. We also found that awareness was associated with acceptance of 
dying; patients who were aware of the imminence of death were more often in peace with 
dying and felt more often that life had been worth living than patients who were not aware 
according to the family member.
To explore nurses’ reports on the practice of palliative sedation focusing on their experiences 
with pressure, dilemmas and morally distressing situations we performed a secondary data 
analysis of an interview study among nurses which we presented in chapter 7. Qualitative 
interviews with nurses were collected as part of a larger project about the practice of pallia-
tive sedation in the Netherlands after the introduction of a national guideline on palliative 
sedation. The project focused on physicians’ and nurses’ experiences with continuous pal-
liative sedation. The first part of the project was a questionnaire study; nurses working in 
general practice, nursing homes, hospices and hospitals completed a questionnaire about 
their most recent case of continuous palliative sedation. In the questionnaire, respondents 
were asked if they were willing to participate in an additional qualitative interview. In total, 
36 nurses indicated willingness and were subsequently interviewed between October 2008 
and April 2009. Analyses were performed with the constant comparative method. The 
codes used in the interviews were connected to the main theme ´pressure´, with several 
157Summary
subthemes. Subthemes related to pressure were: (1) the nurse pressuring the physician, (2) 
the physician pressuring the nurse, (3) the family pressuring the nurse/physician. We found 
that whether or not a patient is experiencing unbearable suffering can be judged differently 
by the family, the physician or the nurse. Nurses described morally distressing situations 
in which they felt that providing palliative sedation was in the patient’s best interest, but 
experienced (real or perceived) constraints from physicians that prevented them from taking 
action. These situations related to nurses feeling that starting palliative sedation was neces-
sary to alleviate the patient’s suffering, whereas the physician thought that it was too early 
to start. They also described situations in which they experienced pressure from physicians 
or family members to be actively involved in the provision of palliative sedation, but felt that 
their action was not in the patient’s best interest. The latter situation related to (1) starting 
palliative sedation when the nurse felt not all options to relieve suffering had been explored 
yet; (2) family requesting an increase of the sedation level where the nurse felt that this 
may involve unjustified hastening of death; (3) a decision by the physician to start palliative 
sedation where the patient had previously expressed an explicit wish for euthanasia.
Finally, in chapter 8 (general discussion) the key findings of the studies are summarizes 
and integrated. We concluded that it is important to acknowledge the presence of differ-
ent perspectives concerning symptoms and symptom relief during the last phase of life. To 
establish this, improvement of communication within the healthcare team and with patients 
and family members is needed. Communication related to symptoms should preferably be 
a continuous process. The chapter concludes with implications for clinical practice and 
recommendations for future research.
158 Chapter 9
sAmenvAtting
In de introductie (hoofdstuk 1), worden de achtergrond en doelstelling van dit proefschrift 
beschreven. Om goede palliatieve zorg te kunnen leveren is het belangrijk te weten welke 
symptomen tijdens een ziektetraject of ziektefase kunnen optreden en wat de impact van 
die symptomen is op het dagelijks functioneren. De laatste 25 jaar is het aantal studies 
naar symptomen bij patiënten met een vergevorderde ziekte gestaag toegenomen, maar 
bepaalde groepen zijn nog onderbelicht, zoals patiënten met bepaalde vormen van kanker, 
andere diagnoses dan kanker en patiënten in ontwikkelingsgebieden.
Het doel van dit proefschrift is om inzicht te geven in het voorkomen, de impact en de 
behandeling van symptomen tijdens de laatste levensfase.
Hoofstuk 2 beschrijft de resultaten van een cross-sectioneel beschrijvend onderzoek naar de 
prevalentie en impact van symptomen bij patiënten met een ongeneeslijke vorm van hoofd-
hals kanker. Patiënten werden geïncludeerd op de afdeling keel-, neus- en oorheelkunde. 
Het onderzoek bestond uit twee delen. In het eerste deel werd de prevalentie vastgesteld 
van 30 symptomen, waarvan 9 psychosociaal, gebaseerd op vragenlijsten die tussen oktober 
2006 en oktober 2008 onder patiënten werden afgenomen als onderdeel van de reguliere 
zorgverlening. In het tweede deel werd de impact van deze 30 symptomen bestudeerd en 
werden eventuele discrepanties tussen de antwoorden van patiënten en familieleden on-
derzocht in vragenlijsten die tussen februari 2009 en mei 2009, specifiek voor dit onderzoek, 
waren verzameld onder patiënten met een ongeneeslijke vorm van hoofd-hals kanker en 
hun familieleden. Wij vonden dat patiënten met een ongeneeslijke vorm van hoofd-hals 
kanker gemiddeld 14 symptomen rapporteerden (range 0–26), waarvan 10 somatisch en 4 
psychosociale symptomen. Somatische symptomen die het vaakst gerapporteerd werden 
waren vermoeidheid, pijn en zwakte. Vaak voorkomende psychosociale symptomen waren 
‘zich zorgen maken’, bedroefdheid en gespannenheid. Het symptoom met de grootste 
impact op het dagelijks functioneren was benauwdheid. We vergeleken de antwoorden van 
patiënten en familieleden en vonden dat in tweederde van de gevallen, hoewel niet altijd 
significant, familieleden de prevalentie en impact voor somatische symptomen systematisch 
hoger hadden gescoord dan de patiënten zelf. Ten aanzien van de psychosociale symptomen 
zagen we een tegengestelde trend: in ongeveer 50% van gevallen hadden de patiënten de 
prevalentie en de impact van de betreffende psychosociale scores hoger beoordeeld dan de 
familieleden.
Hoofdstuk 3 beschrijft de resultaten van een cross-sectioneel beschrijvend onderzoek naar 
symptoomprevalentie en symptoomlast bij patiënten met hartfalen in een vergevorderd 
stadium in het Groote Schuur Ziekenhuis in Kaapstad, Zuid-Afrika. Patiënten werden geïn-
cludeerd voor dit onderzoek tussen augustus en november 2012 op verschillende klinische 
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afdelingen in het ziekenhuis (spoedeisende hulp, spoedeisende zorgafdeling, cardiologie 
afdeling, interne geneeskunde afdeling) en de polikliniek cardiologie. Patiënten gaven 
informatie over het voorkomen van 28 fysieke en 4 psychologische symptomen en de bijbe-
horende symptoomlast. De patiënten, van wie 14% de middelbare school had doorlopen en 
26% geen inkomen had, rapporteerden gemiddeld 19 symptomen; 18 symptomen werden 
door meer dan 50% van alle patiënten gerapporteerd. Fysieke symptomen die het vaakst 
voorkwamen waren benauwdheid, slaperigheid/vermoeidheid, en pijn. Veel voorkomende 
psychologische symptomen waren ‘zich zorgen maken’, geïrriteerdheid, en bedroefdheid. 
Bijna alle aanwezige symptomen gingen gepaard met een grote symptoomlast; symptomen 
met de grootste symptoomlast waren benauwdheid, gevoelloosheid/tintelingen in handen 
of voeten, en ‘ik lijk niet op mezelf’. Een hogere symptoomlast was geassocieerd met een 
hogere leeftijd, geen inkomen en minder ziekenhuisopnames gedurende de 12 maanden 
voorafgaande aan het onderzoek.
In hoofdstuk 4 zijn de resultaten beschreven van een systematische literatuurreview naar 
het voorkomen van reutelen in de stervensfase, de impact ervan op patiënten, familieleden 
en professionele zorgverleners, en de effectiviteit van interventies. Verschillende databases 
zijn in 2012 doorzocht op empirische studies. Reutelen komt veel voor. Bij ongeveer eenderde 
van alle patiënten wordt dit symptoom gerapporteerd tijdens de stervensfase. Reutelen 
wordt door zowel familieleden als professionele zorgverleners ervaren als hinderlijk, maar 
in hoeverre patiënten last ervaren van reutelen is onduidelijk. Er zijn verschillende klinische 
studies uitgevoerd naar het effect van anti-cholinerge medicatie op de ernst van reutelen. 
Daarin is geen bewijs gevonden voor de effectiviteit van anti-cholinerge middelen.
Hoofdstuk 5 beschrijft een multicenter prospectief observationeel onderzoek waarin be-
studeerd is of de hoeveelheid vocht die voorafgaand aan en tijdens de stervensfase werd 
gebruikt gerelateerd is aan het optreden van reutelen en terminale onrust. Gegevens zijn 
verzameld in acht ziekenhuizen (een tot drie afdelingen per ziekenhuis) en vijf hospices, 
inclusief drie palliatieve zorg units in verpleeghuizen (PCU’s). Dataverzameling vond plaats 
tussen november 2012 en november 2013 onder patiënten van wie, volgens het multidiscipli-
naire zorgteam, verwacht werd dat zij binnen een aantal dagen zouden overlijden. Data wer-
den verzameld met een digitale versie van het Zorgpad Stervensfase (ZS), een Nederlands 
instrument voor multidisciplinaire zorg voor patiënten in de stervensfase. Specifiek voor 
dit onderzoek werd het ZS aangevuld met vragen over reutelen, terminale onrust, gebruik 
van opioïden en vochtgebruik. Reutelen werd minimaal eenmaal gerapporteerd bij 40% van 
de patiënten gedurende de stervensfase; voor de laatste 24 uur van het leven was dit bij 
35% van de patiënten het geval. De prevalentie van reutelen nam toe naarmate het sterven 
dichterbij kwam. Terminale onrust werd tijdens de stervensfase bij 26% van de patiënten 
gerapporteerd; gedurende de laatste 24 uur van het leven trad dit bij 13% van de stervenden 
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op. Het voorkomen van terminale onrust was over het algemeen gelijk verdeeld over de hele 
periode van de stervensfase. We vonden geen associatie tussen de mate van vochtgebruik 
en het voorkomen van reutelen. We vonden ook geen associatie tussen een laag vochtge-
bruik (≤ 500 ml) en het voorkomen van terminale onrust. Terminale onrust gedurende de 
laatste 24 uur van het leven was wel geassocieerd met een hoger vochtgebruik gedurende 
de periode 48-25 uur voor het overlijden.
Hoofdstuk 6 beschrijft een onderzoek waarin bestudeerd is of patiënten zich bewust waren 
van hun naderend overlijden. Voor dit onderzoek is een secundaire analyse uitgevoerd van 
gegevens van een vragenlijstonderzoek onder verpleegkundigen en nabestaanden en gege-
vens vanuit de respectievelijke medisch dossiers. Dit onderzoek betrof patiënten die overle-
den waren in ziekenhuizen, verpleeghuizen en thuiszorgorganisaties in zuidwest-Nederland. 
Gegevens werden tussen november 2003 en februari 2006 verzameld. Halverwege deze 
periode werd het Zorgpad Stervensfase geïntroduceerd. Binnen een week na het overlijden 
werd door een verpleegkundige die nauw betrokken was geweest bij de zorg gedurende 
de laatste drie dagen van het leven van de patiënt een vragenlijst ingevuld. Ongeveer twee 
maanden na het overlijden ontving het familielid dat de ‘contactpersoon’ voor de patiënt 
was geweest een brief met de vraag of hij/zij toestemming wilde geven om benaderd te 
worden door het onderzoeksteam om een vragenlijst in te vullen. Een reminder werd ver-
stuurd als na twee en zes weken nog geen reactie was ontvangen. Volgens de rapportage 
in het medisch dossier was 51% van de patiënten zich bewust geweest van hun naderend 
overlijden, volgens verpleegkundigen gold dit voor 58% en volgens nabestaanden voor 62% 
van de patiënten. De interbeoordelaarsbetrouwbaarheid was redelijk. Of een patiënt zich 
bewust was geweest van het naderend overlijden was niet geassocieerd met veel voorko-
mende symptomen in de stervensfase. Patiënten die thuis stierven waren zich vaker bewust 
van het naderend overlijden dan patiënten die in het ziekenhuis of verpleeghuis overleden. 
Patiënten die zich bewust waren van hun naderende overlijden hadden vaker vrede met 
het sterven en gaven vaker aan dat hun leven de moeite waard was geweest dan patiënten 
die zich volgens de nabestaanden niet bewust waren geweest van het naderend overlijden.
Om de ervaringen van verpleegkundigen met de praktijk van palliatieve sedatie en situaties 
waarin druk, dilemma’s en gewetensnood voorkwamen te exploreren werd een secundaire 
analyse uitgevoerd op data vanuit een kwalitatief onderzoek onder verpleegkundigen; de 
resultaten zijn beschreven in hoofdstuk 7. Het onderzoek betrof 36 verpleegkundigen werk-
zaam in de eerste lijn, verpleeghuis, hospice of ziekenhuis Analyses werden uitgevoerd met 
behulp van de constant vergelijkende methode. De gebruikte coderingen waren gerelateerd 
aan het hoofdonderwerp ‘ het uitoefenen van druk’, met verschillende sub-thema’s: (1) de 
verpleegkundige oefent druk uit op de arts, (2) de arts oefent druk uit op de verpleegkundige, 
(3) de familie oefent druk uit op de verpleegkundige/arts. Verpleegkundigen gaven aan dat 
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de mate waarin een patiënt ondraaglijk lijdt verschillend wordt ingeschat door familieleden, 
de arts of de verpleegkundige. Verpleegkundigen beschreven situaties waarin ze morele last 
ervoeren omdat zij vonden dat op basis van de situatie van de patiënt palliatieve sedatie 
gestart zou moeten worden, maar de arts het daarvoor nog te vroeg achtte. Aan de andere 
kant beschreven verpleegkundigen situaties voorafgaand aan en tijdens sedatie waarbij zij 
druk ervoeren van de arts of familie om mee te werken aan palliatieve sedatie terwijl zij dit 
te vroeg of niet nodig achtten. Deze laatste situaties betroffen (1) het starten van palliatieve 
sedatie op een moment dat de verpleegkundige het gevoel had dat nog niet alle opties 
om het lijden te verlichten waren geëxploreerd; (2) familieleden die een ophoging van de 
sedatie verzochten terwijl de verpleegkundige vond dat daarmee het overlijden zou worden 
bespoedigd; (3) een besluit van de arts om met palliatieve sedatie te starten bij een patiënt 
die eerder een verzoek om euthanasie had gedaan.
In hoofdstuk 8 worden de belangrijkste bevindingen van de in het proefschrift beschreven 
onderzoeken samengevat en geïntegreerd. We concluderen dat het belangrijk is om te 
onderkennen dat er verschillende perspectieven ten aanzien van symptomen en symptoom-
verlichting gedurende de laatste levensfase bestaan en van belang zijn. Bij de communicatie 
binnen het behandelteam en met de patiënt en zijn familieleden dient daar rekening mee 
gehouden te worden. Communicatie over symptomen is bij voorkeur een continu proces. 




Een proefschrift staat gelijk aan vele uren alleen achter je computer zitten en dat red je 
alleen als je regelmatig begeleiding, steun en soms ook wat broodnodige afleiding krijgt. Ik 
ben dankbaar dat ik dat van velen heb mogen ontvangen. 
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